chloroquine has been researched along with hydroxychloroquine in 814 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 179 (21.99) | 18.7374 |
| 1990's | 55 (6.76) | 18.2507 |
| 2000's | 61 (7.49) | 29.6817 |
| 2010's | 93 (11.43) | 24.3611 |
| 2020's | 426 (52.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Aranda, E; Maisonet, J; Nordstrøm, LU; Perez-Soler, R; Schwartz, EL; Sironi, J; Wu, P | 1 |
| Behnam, MA; Boldescu, V; Klein, CD; Nitsche, C | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cheong, SL; Ng, CH; Tibon, NS | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X | 1 |
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Meyer, W; Weyerbrock, W | 1 |
| Evens, RP | 1 |
| Mikkelsen, J | 1 |
| Good, MI; Shader, RI | 1 |
| Brinkley, JR; Dubois, EL; Ryan, SJ | 1 |
| Nagy, E; Szakály, I | 1 |
| Isomäki, H; Martio, J | 1 |
| Milazzo, S | 1 |
| Bellows, AR; Bienfang, DC; Chylack, LT; Stillman, JS | 1 |
| Ablonczy, E; Gyarmati, L; Morzsányi, E; Nagy, E; Soós, G; Stampf, G | 1 |
| Easterbrook, M | 12 |
| Mazanec, DJ; Sayers, ME | 1 |
| Dighe, S; Gurbarg, M; Noory, A; Shah, VP; Skelly, JP | 1 |
| Iredale, J; Wainer, IW | 1 |
| Khalil, SK; Miller, DR; Nygard, GA | 1 |
| Ruiz, RS; Saatci, OA | 1 |
| Cutler, DJ; Ferrari, V | 1 |
| Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB | 1 |
| Ochsendorf, FR; Runne, U | 2 |
| Cutler, D; Day, R; Tett, S | 1 |
| Hanno, PM; Wein, AJ | 1 |
| Früh, B; Niemeyer, G | 1 |
| Friedlaender, MH; Lozier, JR | 1 |
| Bhargava, SK; Raines, MF; Rosen, ES | 1 |
| Betts, WH; French, JK; Gorjatschko, L; Hurst, NP | 2 |
| Lanciani, P | 1 |
| Muirden, KD | 1 |
| Bird, HA; Dixon, JS; Greenwood, M | 1 |
| Bell, AL; Betts, WH; Cleland, LG; French, JK; Hurst, NP; Nuki, G; O'Donnell, ML | 1 |
| Brown, KF; Cutler, DJ; Day, RO; Tett, SE | 1 |
| Cutler, DJ; MacIntyre, AC; Tett, SE | 1 |
| Parke, AL | 1 |
| Dugowson, CE; Gilliland, BC | 1 |
| Maksymowych, W; Russell, AS | 1 |
| Bolsen, K; Goerz, G; Lissner, R; Merk, H; Schmitter, H; Seuwen, P | 1 |
| Tulzer, W | 1 |
| Jayson, MI; Kay, EA; Rees, JA | 1 |
| Sharma, OP; Verdegem, TD | 1 |
| Malina, L | 1 |
| Benziger, DP; Brown, RR; Stroshane, RM | 1 |
| Chou, BR; Cullen, AP | 1 |
| Bellamy, N; Brooks, PM | 1 |
| Estes, ML; McMahon, JT; Myles, JL; Ratliff, NB; Shirey, EK | 1 |
| Betts, WH; French, JK; Hurst, NP; O'Donnell, ML | 1 |
| Chou, SM; Estes, ML; Ewing-Wilson, D; Hanson, M; Mitsumoto, H; Ratliff, NB; Shirey, E | 1 |
| Clark, SK | 1 |
| Sammartino, JP; Soll, DB | 1 |
| Sugar, J | 1 |
| Rynes, RI | 3 |
| Finbloom, DS; Gunkel, R; Newsome, DA; Silver, K | 1 |
| Gold, DH; Henkind, P | 1 |
| Achurra, A; Klinefelter, HF | 1 |
| Boström, H; Whitehouse, MW | 1 |
| Zvaifler, NJ | 2 |
| Holtz, G; Mantel, W | 1 |
| Cowey, FK; Whitehouse, MW | 1 |
| Alvarez Sotolongo, M; Krácmar, J; Krácmarová, J | 1 |
| Brown, RK | 1 |
| Cambie, E; de Laey, JJ; de Rouck, A; François, J | 1 |
| Juva, K; Koskiahde, V; Laaksonen, AL | 2 |
| Gonasun, LM; Potts, AM | 1 |
| Smukler, NM | 1 |
| Petrohelos, MA | 1 |
| Nylander, U | 1 |
| Burnham, TK; Fine, G; Neblett, TR | 1 |
| Kitridou, RC; Solomon, SD | 1 |
| Banks, WF; Conway, WD; McChesney, EW; Rogers, JE; Shekosky, JM | 1 |
| Dodson, WH; Holley, HL | 1 |
| Ignarro, LJ | 2 |
| Peter, JB | 1 |
| David-Chaussé, F; David-Chaussé, J; Dehais, J; Lagoarde, J; Laporte, G; Picot, C | 1 |
| Sanders, HJ | 1 |
| Burnham, TK; Fine, G; Lester, RS; Murray, K | 1 |
| Crews, SJ | 1 |
| Alfieri, R; Sole, P | 1 |
| Ball, EG; Markus, HB | 1 |
| Gagnon, FT; Jobin, F | 1 |
| Pinckers, A | 1 |
| Drewnowska-Sochańska, A; Kuprianowicz, W; Petrus, B | 1 |
| Juva, K; Laaksonen, AL; Sunell, JE | 1 |
| Hirvonen, L; Juva, K; Laaksonen, AL; Länsimies, E | 1 |
| Dodge, BG; Freeman, RG; Knox, JM | 1 |
| Kajander, A; Sarmela, T | 1 |
| Bertrand, JJ; Debeyre, N; Kahn, MF; Ryckewaert, A | 1 |
| Carr, RE; Henkind, P; Rothfield, N; Siegel, IM | 1 |
| Bailey, DM | 1 |
| Banks, WF; McChesney, EW; Sullivan, DJ | 1 |
| Bonnichsen, R; Maehly, AC | 1 |
| Arden, GB; Kolb, H | 1 |
| Cloud, RS; Ward, JR | 1 |
| Schuppli, R | 1 |
| Bertrand, JJ | 1 |
| Ashurst, PJ | 1 |
| Banks, WF; Fabian, RJ; McChesney, EW | 1 |
| Koranda, FC | 1 |
| Grundmann, M; Lukásová, D; Ríhová, D; Vrublovský, P | 1 |
| Simpson, LL | 1 |
| Scherbel, AL | 1 |
| Callen, JP; Portnoy, JZ | 1 |
| Mackenzie, AH | 3 |
| Gall, EP | 1 |
| Lipsky, PE; Salmeron, G | 1 |
| Broekhuyse, RM; Pinckers, A | 1 |
| Bechetoille, A; Douche, C; Ebran, JM | 1 |
| Burde, RM; Drews, RC; Hart, WM; Johnston, GP | 1 |
| Hughes, GR; Lanham, JG | 1 |
| Elgart, M; Isaacson, D; Turner, ML | 1 |
| Bunch, TW; O'Duffy, JD | 1 |
| Bernstein, HN | 1 |
| Tanenbaum, L; Tuffanelli, DL | 1 |
| Olansky, AJ | 1 |
| Paulus, HE | 1 |
| Volin, P | 1 |
| Breedveld, FC; Dijkmans, BA; Goeei The, SG; Landewé, RB; Van Rijthoven, AW; Vergouwen, MS | 1 |
| Feldmann, R; Salomon, D; Saurat, JH | 1 |
| Tett, SE | 1 |
| Simon, M; von den Driesch, P | 1 |
| Croes, K; Flanagan, RJ; McCarthy, PT | 1 |
| Magaña-García, M | 1 |
| Aylward, JM | 1 |
| Wallace, DJ | 2 |
| Fieger, H; Iredale, J; Wainer, IW | 2 |
| Fox, RI | 1 |
| Goerz, G; Ochsendorf, FR; Runne, U; Zrenner, E | 1 |
| Cutler, DJ; MacIntyre, AC | 1 |
| Cutler, DJ; McLachlan, AJ; Tett, SE | 1 |
| Cutler, DJ | 1 |
| Esterly, NB; Rabinowitz, LG; Ziering, CL | 1 |
| Fox, R | 1 |
| Furst, DE | 1 |
| Khraishi, MM; Singh, G | 1 |
| Parke, AL; Rothfield, NF | 1 |
| Spalton, DJ | 1 |
| Bader, S; Nelson, D; Schultz, KR | 1 |
| de Rooij, HH; Dijkmans, BA; le Cessie, S; van den Borne, BE; Verweij, CL | 1 |
| Callen, JP | 1 |
| Gilman, AL; Schultz, KR | 1 |
| Sharma, OP | 2 |
| Bader, S; HayGlass, KT; Nelson, D; Schultz, KR; Wang, MD | 1 |
| García-Lora, E; Jáimez, L; Jiménez-Alonso, J; Tercedor, J | 1 |
| Marvisi, M | 1 |
| Anderson, SF; Ferrucci, S; Townsend, JC | 1 |
| Aviña-Zubieta, JA; Galindo-Rodriguez, G; Newman, S; Russell, AS; Suarez-Almazor, ME | 1 |
| Bruce, IN; Gladman, DD; Hallett, D; Rahman, P; Urowitz, MB; Yuen, K | 1 |
| Houpt, JB | 1 |
| Bharadwaj, P; Sharma, OP; Wilcox, A | 1 |
| Alarcón, R; Brethauer, U; Jiménez, M; Martínez, A; Morales, R | 1 |
| Boelaert, JR; Gennero, L; Savarino, A; Sperber, K | 1 |
| Lewis, RA; Lupski, JR; Shroyer, NF | 1 |
| Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA | 1 |
| Kumamoto, T | 1 |
| Browning, DJ | 1 |
| Cabana Vázquez, M; Graña Gil, J; Sánchez Meizoso, MO; Vázquez González, A | 1 |
| Carr, RE; Easterbrook, M; Farjo, AA; Marmor, MF; Mieler, WF | 1 |
| Baethge, BA; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Gibbs, JP; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Munster, T; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Shen, D; Weisman, M; Welch, KE; Yocum, D | 1 |
| Sundelin, SP; Terman, A | 1 |
| Kellner, H; Schiemann, U | 1 |
| Gross, WL; Schnabel, A | 1 |
| Marmor, MF | 3 |
| Adagu, IS; Craig, JC; Cullander, C; Steele, JC; Warhurst, DC | 1 |
| Bernatsky, S; Clarke, A; Joseph, L; Pineau, C | 1 |
| HOEKENGA, MT | 2 |
| CORNBLEET, T | 1 |
| FRUMESS, GM; LEWIS, HM | 1 |
| MULLINS, JF; WATTS, FL; WILSON, CJ | 1 |
| BENNETT, JH; REES, RB | 1 |
| HARRISON, JW; SCHERBEL, AL; SCHUCHTER, SL | 1 |
| ANSELL, HB; APPEL, B; SCHIFF, B; TYE, MJ; WOLF, M | 1 |
| GOODE, P | 1 |
| BURRELL, ZL; MARTINEZ, AC | 1 |
| ANSELL, HB; APPEL, B; TYE, MJ; WHITE, H | 1 |
| FRAGA, S | 1 |
| BUTTERWORTH, RF | 1 |
| GALLA, F | 1 |
| MURPHY, JC; PETTY, S | 1 |
| QUEEN, HO | 1 |
| LOFFERER, O; PLASUN, R | 1 |
| YOUNG, MD | 1 |
| BRODTHAGEN, H | 1 |
| GRAHAM, JD | 1 |
| SYLVEST, B | 1 |
| GROTH, CG; RYBECK, B | 1 |
| HAMILTON, EB; SCOTT, JT | 1 |
| SCULL, E | 1 |
| NOVA, F | 1 |
| ELISEO, V; GIULIANI, V; ORTOLANI, G | 1 |
| FREDRIKSSON, T; LODIN, A; ROSENGREN, S | 1 |
| RYCKEWAERT, A | 1 |
| COSTE, F | 1 |
| ABRAHAM, RK; DUBOIS, EI; TUFFANELLI, D | 1 |
| MANDEL, EH | 1 |
| JEFFREY, MR | 1 |
| DUTHIE, JJ | 1 |
| ATDJIAN, M; MACKENZIE, AH; SCHERBEL, AL | 1 |
| NEWBOULD, BB | 1 |
| CAHN, MM; LEVY, EJ; SHAFFER, B | 1 |
| ARORA, RB; LAL, A | 1 |
| RUGGIERO, HA | 1 |
| PERELMAN, R | 1 |
| BORC, K | 1 |
| BOUMA, HG; DEVRIES, K; JANSZ, A; NIEWEG, HO | 1 |
| SULLI, G; VARRONE, F | 1 |
| BOTTIROLI, JA; ROSENBERG, FJ | 1 |
| ALVING, AS; BREWER, GJ; MILLAR, JW; POWELL, RD | 1 |
| MASON, RM | 1 |
| GREENWALD, ES | 1 |
| BELL, HE; LITTLE, AS | 1 |
| BERESDEVIN, M | 1 |
| BETTLEY, FR | 1 |
| KERSLEY, GD | 1 |
| BOUVIER, M; LEJEUNE, E; MAITREPIERRE, J | 1 |
| GAUCHER, A; JEANBLANC, J; LOUYOT, P; MONTET, Y | 1 |
| ANSEL, M; THIBAUT, M | 1 |
| FRANCHIMONT, P; LAMBERT, PH; LAPIERE, CM; LEFEBVRE, P; LISIN, N; SALMON, J; VANCAUWENBERGE, H | 1 |
| DILLAHA, CJ; HONEYCUTT, WM; JANSEN, GT | 1 |
| KERSLEY, GD; PALIN, AG | 1 |
| COSTE, F; DELBARRE, F; KERUZORE, A | 1 |
| BERBERIAN, DA; DENNIS, EW; RIZK, E | 1 |
| KIMURA, I; MATSUURA, Y; MORIYA, K; TIODA, J | 1 |
| Bara, A; Dean, T; Dewey, A; Lasserson, TJ; Walters, EH | 1 |
| Rivett, K | 1 |
| Albuisson, E; Anquetil, D; Crochet, M; Ingster-Moati, I; Jacob, A; Le Brun, D; Lestrade, C; Manchon, E | 1 |
| Hoven, AD; Romanelli, F; Smith, KM | 1 |
| Cuny, JF; Lardet, D; Martin, S; Schmutz, JL; Truchetet, F; Virion, JM | 1 |
| Tutor-Ureta, P; Yebra-Bango, M | 1 |
| McCauliffe, DP; Wozniacka, A | 1 |
| Jessop, S; Whitelaw, D | 1 |
| Klein-Schwartz, W; Smith, ER | 1 |
| Bodaghi, B; Bui Quoc, E; Chosidow, O; Ingster-Moati, I; Rigolet, MH | 1 |
| Amini, H; Razeghinejad, MR; Torkaman, F | 1 |
| Ariza, A; Casado, E; Gratacós, J; Larrosa, M; Martínez, JM; Ojanguren, I; Real, J; Sanjuán, A; Tolosa, C | 1 |
| Tzekov, R | 1 |
| Cassone, A; Cauda, R; Di Trani, L; Donatelli, I; Savarino, A | 1 |
| Esteban, MJ; Giner Galvañ, V; Oltra, MR; Redón, J; Rueda, D | 1 |
| Abdelmaksoud, W; Bouassida, S; Hachicha, M; Marrekchi, S; Masmoudi, A; Mseddi, M; Turki, H; Zahaf, A | 1 |
| Gol'dshteĭn, VD; Ivantsova, LN | 1 |
| Kellner, U; Renner, AB; Tillack, H | 1 |
| Bui Quoc, E; Crochet, M; Dufier, JL; Ingster-Moati, I; Orssaud, C; Roche, O | 1 |
| Ghaffarpour, G; Jalali, MH; Mazloomi, S; Soltani-Arabshahi, R; Yaghmaii, B | 1 |
| Colson, P; Raoult, D; Rolain, JM | 1 |
| Berndt, S; Foerster, J; Rüther, K; Schroeter, J | 1 |
| Vanheesbeke, A | 1 |
| Moraes de Oliveira, AR; Sueli Bonato, P | 1 |
| Keegan, BM; Mateen, FJ | 1 |
| Amoura, Z; Aymard, G; Costedoat-Chalumeau, N; Francès, C; Hulot, JS; Lechat, P; Leroux, G; Piette, JC | 1 |
| MANSON-BAHR, P | 1 |
| WALLACE, RB | 1 |
| Balme, B; Dalle, S; Debarbieux, S; Durupt, F; Ronger, S; Thomas, L | 1 |
| Bové, A; Brito-Zerón, P; Coca, A; Muñoz, S; Plaza, J; Ramos-Casals, M; Sentís, J; Sisó, A; Soria, N; Testi, A | 1 |
| Flach, AJ | 1 |
| Collins, GB; McAllister, MS | 1 |
| Basque, J; Cantin, AM; Leduc, R; Martel, M | 1 |
| BERLINER, RW; EARLE, DP | 1 |
| BAZ, I; HALAWANI, A; MORKOS, F | 1 |
| Iyamu, E; Perdew, H; Woods, G | 1 |
| Chiffoleau, A; Guillet, A; Jolliet, P; Zanlonghi, X | 1 |
| Namazi, MR | 1 |
| Garralda Luquin, A | 1 |
| Jun, G; Kim, ES; Kim, TH; Lee, KS; Lim, HS; Park, JW; Yeom, JS | 1 |
| Dongre, VG; Ghugare, PD; Jadhav, A; Karmuse, P; Kumar, A; Singh, D | 1 |
| Altmeyer, P; Gaifullina, R; Gambichler, T; Kirschke, J; Kreuter, A; Tigges, C | 1 |
| Grenga, R; Karavitis, P; Nebbioso, M | 1 |
| Fishman, GA; Pasadhika, S | 1 |
| Rahim, R; Strobl, JS | 1 |
| Green, MD; Kim, C; Kim, H; Kim, HC; Kim, JY; Kim, YJ; Klein, TA; Ko, DH; Lee, DD; Lee, M; Lee, SW; Nettey, H; Park, I | 1 |
| Pluta, JP; Rüther, K | 1 |
| Baughman, R; Decker, C; Meyer, KC | 1 |
| Deveci, H; Kobak, S | 1 |
| Dosková, H; Karkanová, M; Matusková, V; Uhmannová, R; Vlková, E | 1 |
| Bergholz, R; Rüther, K; Schroeter, J | 1 |
| Francis, PJ; Michaelides, M; Stover, NB; Weleber, RG | 1 |
| Kellner, U; Lai, TY; Lyons, JS; Marmor, MF; Mieler, WF | 1 |
| Katz, SJ; Russell, AS | 1 |
| Choi, JY; Kim, C; Kim, HY; Kim, JM; Kim, YK; Park, I | 1 |
| Madhok, R; Wu, O | 1 |
| Koren, G; Osadchy, A; Ratnapalan, T | 1 |
| Al-Maskari, A; Hickley, NM; McKibbin, M | 1 |
| Bozzo, P; Einarson, A; Irvine, MH | 1 |
| Kimmelman, AC; Mancias, JD | 1 |
| Kellner, U; Missner, S | 1 |
| Heinrich, EL; Hsin, LY; Kim, J; Labarge, S; Lee, W; Li, H; Lu, J; Shen, X; Vaidehi, N; Yip, ML | 1 |
| Godfrey, T; Nikpour, M; Stawell, R; Tang, C | 1 |
| Hughson, LR; Lum, JJ; Poon, VI; Schlie, K; Townsend, KN; Westerback, A | 1 |
| Atkinson, JB; Azimian, M; Ely, KA; Fuchs, HA; Gultekin, SH; Hata, JL; Mobley, BC | 1 |
| Akcakaya, AA; Ekinci, A; Erbil, H; Sadigov, F; Yaylali, SA | 1 |
| Daniels, BH; Gultekin, SH; Lee, HS; Margeta, M; McComb, RD; Mobley, BC | 1 |
| Beltrán-Catalán, E; Epifanio, I; Marco-Ventura, P; Martínez-Costa, L; Murcia-Bello, C; Verdejo-Gimeno, C; Victoria Ibañez, M | 1 |
| Asara, JM; Choi, AM; Coloff, JL; Finkel, T; Henske, EP; Kwiatkowski, DJ; Locasale, JW; Malinowska, IA; Mizumura, K; Parkhitko, AA; Priolo, C; Wu, JJ; Xu, W; Yu, J; Yun, J | 1 |
| Bienkowski, P; Bogaczewicz, A; Bogaczewicz, J; Robak, E; Sobów, T; Sysa-Jedrzejowska, A; Wozniacka, A | 1 |
| JOSEPH, AA; LOUGHLIN, EH; RAPPAPORT, I; RICE, JB; WELLS, HS | 1 |
| Beltrán-Catalán, E; Epifanio, I; Ibañez, MV; Marco-Ventura, P; Martínez-Costa, L; Murcia-Bello, C; Trentini, FJ; Verdejo-Gimeno, C | 1 |
| Blachley, TS; Edwards, P; Lee, PP; Nika, M; Stein, JD | 1 |
| Jančinová, V; Kassab, RB; Lojek, A; Pekarová, M; Perečko, T; Vašíček, O | 1 |
| Amoura, Z; Arnaud, L; Barete, S; Chasset, F; Francès, C | 1 |
| Brézin, AP; Costedoat-Chalumeau, N; Dunogué, B; Jallouli, M; Le Guern, V; Leroux, G; Marmor, MF; Melles, RB; Morel, N; Piette, JC | 1 |
| Al-Bari, MA | 1 |
| Marmor, MF; Melles, RB | 1 |
| Bastiaans, J; Dik, WA; Korthagen, NM; van Bilsen, K; van Hagen, PM; van Meurs, JC | 1 |
| Ahmadi Pirshahid, S; Coupland, SG; Gottlieb, CC; Hamilton, J; Tsang, AC; Virgili, G | 1 |
| Savarino, A; Shytaj, IL | 1 |
| Kwatra, SG | 1 |
| Arnaud, L; Chasset, F; Francès, C | 1 |
| Clifford-Rashotte, M; Kean, WF; Parke, AL; Rainsford, KD | 1 |
| Chan, T; Gillies, MC; Lu, X; Madigan, MC; Shen, W; Xu, C; Zhou, F; Zhu, L | 1 |
| Amarger, S; Assier, H; Avenel-Audran, M; Barbaud, A; Francès, C; Girardin, P; Raison-Peyron, N; Soria, A; Tétart, F | 1 |
| Sanabria, MR; Toledo-Lucho, SC | 1 |
| Bodaghi, B; Le Hoang, P; Massamba, N; Sellam, A | 1 |
| Bakardzhiev, I; Chokoeva, AA; Krasnaliev, I; Lotti, T; Tana, C; Tchernev, G; Wollina, U | 1 |
| Kellner, U; Lai, TY; Marmor, MF; Melles, RB; Mieler, WF | 1 |
| Gaca-Wysocka, M; Grzybowski, A; Leszczyński, P; Pawlak-Buś, K | 1 |
| Marceau, F; Parks, A | 1 |
| Arnaud, L; Bouaziz, JD; Chasset, F; Costedoat-Chalumeau, N; Francès, C | 1 |
| Cardiel, MH; Codding, C; Garg, JP; Genovese, MC; Greenwald, M; Kivitz, AJ; Shay, K; Wang, A; Wang, X; Zubrzycka-Sienkiewicz, A | 1 |
| Barceló, B; Dastis, M; Fernández, J; Gomila, I; López-Corominas, V; Quesada, L; Sahuquillo, L; Servera, MÁ; Torrents, A | 1 |
| Lee, MS; Murray, JJ | 1 |
| Chen, HE; Chou, KY; Hwang, TI; Lin, JF; Lin, YC; Tsai, TF; Wen, SI; Yang, SC | 1 |
| Abouaf, L; Coury, F; Couturier, M; Guiot, A; Tebib, JG | 2 |
| Aldighieri, S; Horvath, H; Javelle, E; Martí-Carvajal, A; Ramon-Pardo, P; Reveiz, L; Rodriguez-Abreu, J; Simon, F | 1 |
| Charlier, B; Dal Piaz, F; Fasano, S; Filippelli, A; Iudici, M; Izzo, V; Pantano, I; Pierro, L; Pingeon, M | 1 |
| Levy, JMM; Thorburn, A; Towers, CG | 1 |
| Bobrowska-Snarska, D; Brzosko, M; Lubiński, W; Modrzejewska, M; Wiacek, MP | 1 |
| Amaravadi, RK; Brown, E; Buckley, M; Gimotty, PA; Ma, XH; Mcafee, Q; Nicastri, MC; Ojha, R; Piao, S; Rebecca, VW; Samanta, A; Winkler, JD | 1 |
| Feng, R; Mittal, L; Werth, VP; Zhang, L | 1 |
| Arnaud, L; Bagot, M; Barbaud, A; Bouaziz, JD; Chasset, F; Cordoliani, F; Francès, C; Jachiet, M; Monfort, JB | 1 |
| An, N; Chen, Y; Liu, HF; Pan, Q; Wang, C; Wang, S; Wu, ZH; Xue, J; Yang, C; Ye, L | 1 |
| Gladman, DD; Pakchotanon, R; Su, J; Urowitz, MB | 1 |
| Bartolini, D; Dallaglio, K; Galli, F; Piroddi, M; Torquato, P | 1 |
| Lotery, AJ; Yusuf, IH | 1 |
| Abdulaziz, N; McCune, WJ; Shah, AR | 1 |
| Galloway, J; Ledingham, JM; Lotery, AJ; MacPhie, E; Yusuf, IH | 1 |
| Audo, I; Barreau, E; Couturier, A; Giocanti-Aurégan, A; Girmens, JF; Le Mer, Y; Massamba, N | 1 |
| Koudriavtseva, T; Plantone, D | 1 |
| Chatre, C; Jorgensen, C; Pers, YM; Roubille, F; Vernhet, H | 1 |
| Ardern-Jones, MR; Bishop, PN; Burdon, MA; Foot, B; Galloway, J; Lotery, AJ; Watson, SL; Yelf, C; Yusuf, IH | 1 |
| Boone, BA; Doerfler, WR; Ellis, JT; Liang, X; Lotze, MT; Miller-Ocuin, J; Murthy, P; Neal, MD; Ross, MA; Sperry, JL; Wallace, CT; Zeh, HJ | 1 |
| Coppes, RP; Engedal, N; Hijlkema, KJ; Luhr, M; Mari, M; Mauthe, M; Orhon, I; Reggiori, F; Rocchi, C; Zhou, X | 1 |
| Alessandri, C; Ceccarelli, F; Conti, F; Garufi, C; Massaro, L; Miranda, F; Morello, F; Moscarelli, E; Perricone, C; Spinelli, FR; Truglia, S; Valesini, G | 1 |
| Fardet, L; Nazareth, I; Petersen, I | 2 |
| Borik, L; Heil, PM; Kinaciyan, T; Petzelbauer, P; Quint, T; Wöhrl, S | 1 |
| Li, J; Wei, B; Zhan, L | 1 |
| Berchem, G; Bosseler, M; Chevigne, A; Janji, B; Menard, L; Noman, MZ; Ollert, M; Szpakowska, M; Xiao, M | 1 |
| Lee, YH | 1 |
| Aizawa, T; Hirono, K; Imaizumi, T; Tanaka, H; Tsugawa, K; Watanabe, S | 1 |
| Gracner, T; Holc, I; Kosic Knez, N; Pahor, A; Pahor, D; Šiško, K | 1 |
| Bazzichi, L; Bianchino, L; Caporali, R; Nacci, F; Sinigaglia, L | 1 |
| Ji, Z; Xu, C; Xu, R; Zhu, J | 1 |
| Lavrijsen, APM; Nguyen, AL; Tan, AN | 1 |
| Femia, A; Riley, K; Schwager, Z; Stern, M; Vleugels, RA | 1 |
| Amoura, Z; Combarel, D; Funck-Brentano, C; Lori, L; Noé, G; Seycha, A; Tissot, N; Zahr, N | 1 |
| Cabral, RTS; Carneiro, S; Klumb, EM | 1 |
| Chen, T; Cheng, GY; Jiang, YM; Liu, D; Shang, J; Tao, CY; Xiao, J; Yu, D; Zhao, ZZ | 1 |
| Ahmadi, S; Coupland, SG; Gao, J; Gottlieb, CC; Hamilton, J; Tsang, AC; Virgili, G | 1 |
| Samson, CM; Schwartzman, S | 1 |
| Caminal-Montero, L; Suárez-Díaz, S | 1 |
| Bernatsky, S; Clarke, AE; Grenier, LP; Kalache, F; Mukwikwi, ER; Nashi, E; Pineau, CA; Vinet, E | 1 |
| Amiri, N; Baldwin, C; De Vera, MA; Rebić, N; Sayre, EC; Zusman, EZ | 1 |
| Akhtari, S; Alberdi, HV; Butany, J; Gladman, DD; Hanneman, K; Harvey, PJ; Karur, GR; Osuntokun, T; Thavendiranathan, P; Tselios, K; Urowitz, MB; Wald, RM | 1 |
| Chen, C; Ding, W; Du, Y; Feng, Z; Ma, M; Ma, X; Sun, X; Yu, T; Zhao, S | 1 |
| Dörner, T; Schrezenmeier, E | 1 |
| Brouqui, P; Colson, P; Lagier, JC; Raoult, D; Rolain, JM | 1 |
| de Lamballerie, X; Touret, F | 1 |
| Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L | 1 |
| Saffaei, A; Sahraei, Z; Shabani, M; Shokouhi, S | 1 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Frieman, M; Hu, TY; Wolfram, J | 1 |
| Guastalegname, M; Vallone, A | 1 |
| Chen, X | 1 |
| Cohen, J; Kupferschmidt, K | 1 |
| Li, T; Liu, Z; Qin, Y; Wang, J; Wang, Q; Yan, X; Zeng, X; Zhang, F; Zhang, S; Zhang, W; Zhang, X; Zhao, Y | 1 |
| Agrawal, S; Goel, AD; Gupta, N | 1 |
| Kim, AHJ; Yazdany, J | 1 |
| Mégarbane, B | 1 |
| Bavari, S; Keshtkar-Jahromi, M | 1 |
| Chen, X; Chen, Y; Guan, H; Guo, Y; He, X; Li, H; Li, Y; Pokharel, S; Xiao, H; Yang, H | 1 |
| Marotto, D; Sarzi-Puttini, P | 1 |
| Chahinian, H; Di Scala, C; Fantini, J; Yahi, N | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
| Juurlink, DN | 1 |
| Aronson, JK; Ferner, RE | 1 |
| Jakhar, D; Kaur, I | 1 |
| Kupferschmidt, K | 1 |
| Jaffe, S | 1 |
| Bottega, A; da Rosa, TF; Foletto, VS; Hörner, A; Hörner, R; Serafin, MB | 1 |
| Das, S; Jain, A; Misra, DP; Negi, VS; Shah, S | 1 |
| Gao, J; Hu, S | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Amato, AA; Guidon, AC | 1 |
| Bauman, JL; Tisdale, JE | 1 |
| Avorn, J; Rome, BN | 1 |
| Şimşek Yavuz, S; Ünal, S | 1 |
| Clerc, A; Gendrot, M; Javelle, E; Pradines, B; Savini, H | 1 |
| Aajal, A; Ait Brik, A; Ammour, O; Benajiba, C; El Boussadani, B; El Hangouch, J; Oussama, B; Oussama, O; Raissuni, Z; Tahiri, N | 1 |
| Zhao, M | 1 |
| Esposito, S; Principi, N | 1 |
| Ish, P; Kalantri, A; Kalantri, S; Rathi, S | 1 |
| Cavalluzzi, MM; Habtemariam, S; Lentini, G | 1 |
| Bartoloni, E; Bonifacio, AF; Bursi, R; Cafaro, G; Gerli, R; Perricone, C; Perricone, R; Triggianese, P | 1 |
| Avdeev, S; Brovko, M; Fomin, V; Moiseev, S; Novikov, P | 1 |
| Khunti, K; Khunti, N; Khunti, S; Seidu, S | 1 |
| Aryal, D; Beane, A; Dondorp, AM; Hayat, M; Schultz, MJ | 1 |
| Baldini, L; Caporali, R; Cimaz, R; Favalli, EG; Giani, T; Licciardi, F | 1 |
| Abena, PM; Adejumo, P; Bottieau, E; Decloedt, EH; Eholie, SP; Kallay, O; Mills, EJ; Muyembe TamFum, JJ; Nachega, JB; Sam-Agudu, NA; Seydi, M; Suleman, F; Zumla, A | 1 |
| Beard, T; Cowan, M; Manning, TJ; Thomas-Richardson, J | 1 |
| Brown, JD; Cicali, B; Henriksen, CH; Sarayani, A | 1 |
| Bradley, SM; Fihn, SD; Perencevich, E | 1 |
| Alexander, PE; Alhazzani, W; Aryal, K; Brocard, E; Debono, VB; Deng, D; Iorio, A; Mammen, MJ | 1 |
| Drici, MD; Funck-Brentano, C; Nguyen, LS; Roden, DM; Salem, JE | 1 |
| Hashimoto, K; Xie, B; Zhang, J | 1 |
| Cho, SG; Dayem, AA; Iyer, M; Jayaramayya, K; Lee, SB; Subramaniam, MD; Vellingiri, B | 1 |
| Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A | 1 |
| Askanase, AD; Buyon, JP; Khalili, L | 1 |
| Sargin, G; Yavasoglu, I; Yavaşoğlu, Sİ | 1 |
| Ceccarelli, F; Conti, F; Di Franco, M; Spinelli, FR | 1 |
| Beldner, S; Chang, D; Chinitz, J; Epstein, LM; Gabriels, J; Goldner, B; Ismail, H; John, R; Mahmood, E; Makker, P; Mansoor, A; Mitra, R; Mountantonakis, S; Saleh, M; Skipitaris, N; Soo Kim, B; Willner, J | 1 |
| Ayers, JW; Caputi, TL; Dredze, M; Kesselheim, AS; Liu, M | 1 |
| Jeevaratnam, K | 1 |
| Becker, G; El-Hage, W; Hingray, C; Javelot, H; Meyer, G; Michel, B | 1 |
| Chen, T; Chen, Y; Ferrari, V; Han, Y; Jagasia, D; Kang, Y; Mui, D; Scherrer-Crosbie, M | 1 |
| Barbuto, AF; Burns, MM; Chary, MA; Hayes, BD; Izadmehr, S | 1 |
| Genoni, G; Kozel, D; Monzani, A; Pistis, G; Scopinaro, A; Secco, GG | 1 |
| Chowdhury, MS; Gernsheimer, J; Rathod, J | 1 |
| Chacón-Dulcey, V; Frías, J; González, N; López-Labady, J; Pérez Alfonzo, R; Tirado, W; Villarroel-Dorrego, M | 1 |
| Shader, RI | 1 |
| Svensson, M | 1 |
| Seftel, MD | 1 |
| Nath, KA | 1 |
| Agranat, I; D'Acquarica, I | 1 |
| Lazar, S; Naksuk, N; Peeraphatdit, TB | 1 |
| Akram, J; Klonoff, DC; Meo, SA | 2 |
| Conti, F; Di Franco, M; Lucchino, B | 1 |
| Wong, A | 1 |
| Piszczatoski, CR; Powell, J | 1 |
| Annangi, S | 1 |
| Gadebusch Bondio, M; Marloth, M | 1 |
| Anastasiou, IA; Eleftheriadou, I; Tentolouris, A; Tentolouris, N; Tsilingiris, D | 1 |
| Costa, LB; Lanza, K; Palmeira, VA; Perez, LG; Ribeiro, VT; Silva, ACSE | 1 |
| Derwand, R; Scholz, M | 1 |
| Thai, TN; Vouri, SM; Winterstein, AG | 1 |
| Arnalich-Montiel, F; Cárceles, JA; Cordero-Coma, M; Garay-Aramburu, G; García-Delpech, S; Gegúndez-Fernández, JA; López-Alemany, A; Mendicute Del Barrio, J; Muñoz-Negrete, FJ; Pablo-Júlvez, L; Zarranz-Ventura, J | 1 |
| Acunzo, R; Asensio, E; Saad, EB; Sáenz, LC; Uribe, W | 1 |
| Masand, N; Patil, VM; Singhal, S | 1 |
| Abraham, GM; Andrews, R; Bledsoe, TA; Centor, RM; Etxeandia-Ikobaltzeta, I; Forciea, MA; Haeme, R; Humphrey, LL; Jokela, JA; Kansagara, DL; Marcucci, M; Miller, MC; Obley, AJ; Qaseem, A; Yost, J | 1 |
| Gevers, S; Kwa, MSG; van Nieuwkoop, C; Wijnans, E | 1 |
| Estella, Á; Garnacho-Montero, J | 1 |
| Marto, N; Monteiro, EC | 1 |
| Kucharz, EJ | 1 |
| Kesselheim, AS; Lye, CT; Zhai, MZ | 1 |
| Biasiotto, G; Magro, P; Quiros Roldan, E; Zanella, I | 1 |
| Blumenthal, RS; Gersh, BJ; Gluckman, TJ; Michos, ED; Oren, O; Yang, EH | 1 |
| Dong, Z; Edelstein, CL; Venkatachalam, MA | 1 |
| Chukwuma, J; Khawaja, S; Yahya, AS | 1 |
| Baranchuk, A; Barbosa, M; Márquez, MF; Mendoza, I; Nuñez, E; Sosa Liprandi, Á; Wyss Quintana, FS; Zaidel, EJ | 1 |
| Chabalala, H; Dassarma, B; Matsabisa, MG; Roy, S; Tripathy, S | 1 |
| Barboza, JJ; Hernandez, AV; Pasupuleti, V; Roman, YM; White, CM | 4 |
| Alpízar-Rodríguez, D; Bautista-Molano, W; Gcelu, A; Hodkinson, B; Pons-Estel, G; Singh, P | 1 |
| Hamdan, MH; January, CT; Kamp, TJ | 1 |
| Joseph, J; Mehra, MR; O'Donnell, CJ; Vaduganathan, M; van Meijgaard, J; Warraich, HJ | 1 |
| Fernando, SD; Rajapakse, S; Rodrigo, C | 1 |
| Hoepelman, AIM; Weehuizen, JM | 1 |
| Ge, W; Luo, X; Peng, Y | 1 |
| Ledford, H | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Ibáñez, S; Martínez, O; Silva, F; Valenzuela, F; Valenzuela, O | 1 |
| Chen, Y; Fan, X; Han, Q; Liu, Z; Sun, J; Wang, X | 1 |
| Bohula, EA; Lang, JP; Morrow, DA; Moura, FA; Siddiqi, HK; Wang, X | 1 |
| Mvumbi, DM | 1 |
| Campos, L; Gouveia, CC | 1 |
| da Mota, LMH; de Medeiros Pinheiro, M; Dos Reis Neto, ET; Dos Santos Paiva, E; Ferreira, GA; Kakehasi, AM; Marques, CDL; Pileggi, GCS; Provenza, JR; Reis, APMG; Sato, EI; Xavier, RM | 1 |
| Benzaquen, J; Brest, P; Hofman, P; Klionsky, DJ; Mograbi, B | 1 |
| Bayry, J; Bonam, SR; Klionsky, DJ; Muller, S | 1 |
| Berni-Betancourt, A; Carrasco, OF; Medeiros-Domingo, A | 1 |
| Hernandez, AV; White, CM | 1 |
| Medina, MT; Moncada, SS | 1 |
| Bravo-Jeria, R; Rada, G; Santillán-García, A; Verdugo-Paiva, F | 1 |
| Bosic, M; Stojkovic-Filipovic, J | 1 |
| Abraham, GM; Etxeandia-Ikobaltzeta, I; Forciea, MA; Humphrey, LL; Jokela, JA; Miller, MC; Obley, AJ; Qaseem, A; Yost, J | 1 |
| Al-Bari, AA | 1 |
| Fuhr, U; Höhl, R; Li, X; Sörgel, F | 1 |
| Bode-Böger, SM; Eden, G; Kielstein, JT; Martens-Lobenhoffer, J; Schmidt, JJ; Seffer, MT | 1 |
| Chee, YJ; Tan, SK; Yeoh, E | 1 |
| Houston, T; Pati, S | 1 |
| Fassihi, R; Fassihi, SC; Nabar, NR | 1 |
| Abrams-Downey, A; Saabiye, J; Vidaurrazaga, M | 1 |
| Civljak, M; Fidahic, M; Lovric Makaric, Z; Markotic, F; Nujic, D; Puljak, L; Runjic, R | 1 |
| Gafarova, AR; Gainullina, EN; Timerbulatov, SV; Timerbulatov, VM; Timerbulstov, MV | 1 |
| Baguley, DM; Kasbekar, AV; Prayuenyong, P | 1 |
| Devanathan, V; Nimgampalle, M; Saxena, A | 1 |
| Bi, Y; Motriuk-Smith, D; O'Kane, AM; Peng, H; Ren, J; Wu, L | 1 |
| Abbate, A; Aspromonte, N; Camilli, M; Crea, F; Del Buono, MG; Iannaccone, G; Lavie, CJ; Massetti, M; Ronco, C; Scacciavillani, R | 1 |
| Million, M; Raoult, D; Roussel, Y | 1 |
| Ahluwalia, A; Cirino, G | 1 |
| Barros, H; Chuchene, AG; Miguel, PTG; Polanski, JF; Skare, TL; Tanaka, EA | 1 |
| Thorburn, A | 1 |
| Guzman-Prado, Y | 1 |
| Budnitz, DS; Lovegrove, M; Shehab, N | 1 |
| Carvajal, A; Oscanoa, TJ; Romero-Ortuno, R; Savarino, A | 1 |
| Chen, X; Geiger, JD | 1 |
| Elyasi, S; Ghodousi, M; Naghipour, S; Rahsepar, S | 1 |
| Charris, JE; Di Giulio, C; Martinez, GP; Mijares, MR; Zabaleta, ME | 1 |
| Biguetti, C; Brotto, M; Marrelli, MT | 1 |
| Baud, FJ; Clemessy, JL; Hoglund, RM; Megarbane, B; Tarning, J; Watson, JA; White, NJ | 1 |
| Agostinis, P; Carafoli, E; Li, X; Melino, G; Rabson, A; Shi, Y; Sun, E; Wang, Y | 1 |
| Aza, A; Buitrago-Garcia, D; Cabrera, M; Rivero, W; Rojas-Villarraga, A; Santos-Moreno, P; Villarreal, L | 1 |
| Graef, ER; Kim, AH; Liew, JW; Sparks, JA | 1 |
| Daily, J; Di Biase, L; Ferrick, KJ; Fisher, JD; Greige, N; Hsia, BC; Khokhar, AS; Krumerman, A; Quiroz, JA | 1 |
| Abdelrahim, MEA; Abdelrahman, MA; Ali, AMA; Gomaa, D; Harb, HS; Madney, YM; Osama El-Gendy, A; Osama, H; Saeed, H; Zawbaa, HM | 1 |
| Allwood, B; Blockman, M; Decloedt, EH; Koegelenberg, CFN; Parker, A; Reuter, H; Taljaard, J | 1 |
| Abi Jaoude, J; El Alam, MB; Garcia Garcia, CJ; Kouzy, R; Ludmir, EB; Taniguchi, CM | 1 |
| Falcão, M; Falcão-Reis, F; Lima-Fontes, M; Torres-Costa, S | 1 |
| Barnard, AR; Chandler, LC; MacLaren, RE; McClements, ME; Xue, K; Yusuf, IH | 1 |
| Burmester, GR; Dörner, T; Eckardt, KU; Schrezenmeier, EV | 1 |
| Cortegiani, A; Einav, S; Giarratano, A; Ingoglia, G; Iozzo, P; Ippolito, M | 1 |
| Drozd, M; Duda-Sikuła, M; Jankowska, EA; Knysz, B; Ponikowski, P; Sierpiński, R; Simon, K; Szachniewicz, J; Szenborn, L; Tkaczyszyn, M | 1 |
| Cook, J; Joshi, A; Nicol, MR; Rizk, ML; Sabato, PE; Savic, RM; Wesche, D; Zheng, JH | 1 |
| Khuroo, MS | 1 |
| Alejandro, R; Caprio, M; Fabbri, A; Infante, M; Ricordi, C | 1 |
| Cardona, A; Paliani, U | 1 |
| Carvalho Junior, RN; J C Neto, AM; Martins, AY; Reis, AF; S Costa, JF; Silva Arouche, TD | 1 |
| Kang, R; Klionsky, DJ; Li, J; Tang, D; Zhang, R | 1 |
| Mauthe, M; Nirk, EL; Reggiori, F | 1 |
| Islam, M | 1 |
| Lebin, JA; LeSaint, KT | 2 |
| Etxeandia-Ikobaltzeta, I; Humphrey, LL; Qaseem, A; Yost, J | 1 |
| Braz, HLB; de Moraes, MEA; Jorge, RJB; Marinho, AD; Monteiro, HSA; Moraes Filho, MO; Silveira, JAM | 1 |
| Arriola-Bolado, P; Cervera Cano, M; Gallego-Arenas, A; Jurado-López, A; Mayayo-Vicente, S; Novella-Arribas, B; Rodriguez Salvanés, F; Ruiz-López, M; Sánchez-Gómez, LM; Sierra García, B | 1 |
| Dai, L; Zhang, X; Zhang, Z; Zou, L | 1 |
| Berenbaum, F; Chock, YPE; Coates, LC; Danila, MI; Duarte-García, A; Grainger, R; Jayatilleke, A; Johnson, SR; Kilian, A; Kim, AHJ; Korsten, P; Liew, J; Murad, MH; Palmerlee, C; Peirce, A; Prokop, LJ; Putman, M; Sanchez-Alvarez, C; Sattui, SE; Sparks, JA; Tam, H; Wallace, ZS | 1 |
| Beissert, S; Enk, A; Grabbe, S | 1 |
| de Boer, MGJ; Gieling, EM; Sinha, B; van der Linden, PD; Vollaard, A | 1 |
| Munic Kos, V; Norgren, K; Norinder, U; Tuck, A | 1 |
| Bajocchi, G; Boiardi, L; Carrozzi, G; Cassone, G; Costantini, M; Croci, S; Galli, E; Giorgi Rossi, P; Gradellini, F; Mancuso, P; Marata, AM; Muratore, F; Pandolfi, P; Pipitone, N; Reta, M; Salvarani, C; Sandri, G; Viani, N | 1 |
| Camci, ED; Davis, SN; Raible, DW; Rubel, EW; Simon, JA; Wu, P | 1 |
| Savarino, A; Tarek, M | 1 |
| Gupta, A; Malviya, A | 1 |
| Ahur, MH; Bagheri, M; Eidizadeh, M; Rashe, Z | 1 |
| Chicharro, P; De Argila, D; Llamas-Velasco, M; Muñoz-Aceituno, E; Muñoz-Hernández, P; Rodríguez-Jiménez, P | 1 |
| Costa, E; De Franceschi, L; Dima, F; Morandi, M; Olivieri, O | 1 |
| Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S | 1 |
| Coban, C | 1 |
| Fuochi, V; Furneri, PM; Gentile, D; Rescifina, A | 1 |
| Bancone, G; Schilling, WHK; White, NJ | 1 |
| Sanghai, N; Shafiq, K; Tranmer, GK | 1 |
| Halm, MA | 1 |
| Baricault, B; Botton, J; Dray-Spira, R; Drouin, J; Herlemont, P; Penso, L; Sbidian, E; Semenzato, L; Weill, A; Zureik, M | 1 |
| Fiolet, T; Guihur, A; Mahamat-Saleh, Y; Mulot, M; Peiffer-Smadja, N; Rebeaud, ME | 2 |
| Filipova, E; Pavlova, V; Uzunova, K; Vekov, T | 1 |
| Andreoli, MCC; Bastos, K; D'Avila, R; Kraychete, A; Misael, AM; Moura-Neto, JA; Nascimento, MMD; Silva, DRD | 1 |
| Fatima, S; Fatima, U; Hassan, MI; Rizvi, SSA | 1 |
| Brooks, JT; Budnitz, DS; Bull-Otterson, L; Courtney, J; García, MC; Gray, EB; Gundlapalli, AV; Mac Kenzie, WR; Schieber, LZ; Strosnider, HM | 1 |
| Chan, XHS; Cheah, PY; Hoglund, RM; Tarning, J; Watson, JA; White, NJ | 1 |
| Elavarasi, A; Garg, P; Madan, K; Maulik, SK; Nischal, N; Prasad, M; Sahoo, RK; Seth, T; Sharma, A; Soneja, M | 1 |
| Nessaibia, I; Siciliano, D; Tahraoui, A | 1 |
| Danjuma, MI; Fatima, H; Mohamed, MFH; Nathoe, H; Sinha, U | 1 |
| Antonijević Miljaković, E; Antonijević, B; Baralić, K; Buha Djordjevic, A; Ćurčić, M; Jorgovanović, D; Živančević, K; Đukić-Ćosić, D | 1 |
| Dai, B; Ding, Y; Fu, J; Gao, J; Ge, S; Han, S; He, H; He, L; Hou, Y; Hu, S; Hu, T; Jia, Q; Li, X; Liang, P; Liu, R; Lu, J; Lu, S; Lu, W; Lv, Y; Ma, W; Meng, L; Pan, X; Ta, W; Wang, C; Wang, J; Wang, N; Wang, S; Wang, X; Wang, Y; Zhan, Y; Zhang, J; Zhang, L; Zhang, Y; Zhou, H | 1 |
| Fu, X; Liu, Y; Xie, C | 1 |
| Prommer, E | 1 |
| Ach, T; Berlin, A; Hillenkamp, J; Kleefeldt, N; Radun, V; Reichel, C; Sloan, KR; Tarau, IS | 1 |
| Abad-Santos, F; Koller, D; Navares-Gómez, M; Saiz-Rodríguez, M; Zubiaur, P | 1 |
| Almeida, CAF; Boralli, VB; Costa, KCM; de Barros, CM; Diwan, S; Garcia, RCT; Maia, LDB; Pereira, B; Pinheiro, FA; Torres, LH; Trindade, CM | 1 |
| Bassetti, M; Ferro Desideri, L; Nicolò, M; Traverso, CE | 1 |
| Jones, CW; Platts-Mills, TF; Woodford, AL | 1 |
| Bonnier, A; Chong, W; Saha, BK | 1 |
| Belhassan, A; Bouachrine, M; En-Nahli, F; Lakhlifi, T; Zaki, H | 1 |
| Achutha, AS; Pushpa, VL; Suchitra, S | 1 |
| Alhatali, B; Berling, I; Ghannoum, M; Gosselin, S; Hoffman, RS; King, JD; Lavergne, V; Nolin, TD; Roberts, DM; Shepherd, G; Wilson, G | 1 |
| Bomze, D; Boursi, B; Dankner, R; Goldman, A; Hod, H; Maor, E; Meirson, T | 1 |
| Grundmark, B; Vidlin, SH; Watson, S; Zekarias, A | 1 |
| Shah, RR | 1 |
| Allam, MF; Andraous, F | 1 |
| Hadi, MA; Hasan, SS; Kow, CS; Marran, AMN; Mazhar, F; Merchant, HA | 1 |
| Bax, H; Bokhizzou, N; Brinkman, K; Brohet, RM; Dofferhoff, A; El Moussaoui, R; Ellerbroek, J; Groeneveld, PHP; Hassing, RJ; Hermanides, G; Koster, C; Lammers, AJJ; Postma, DF; Rood, R; Theunissen, REP; van den Berge, M; Verhagen, DWM; Visser, H | 2 |
| Carafoli, E | 1 |
| AlDosary, O; Garbati, MA; Gerberi, D; Kashour, T; Kashour, Z; Murad, MH; Riaz, M; Sohail, MR; Tlayjeh, H; Tleyjeh, IM | 1 |
| Baroutjian, A; Boneva, D; Elkbuli, A; McKenney, M; Sanchez, C | 1 |
| González-Cuevas, R; Ortega-Peña, M | 1 |
| Junqueira, DR; Rowe, BH | 1 |
| Cui, J; Huang, YY; Li, X; Li, Z; Lin, Y; Liu, H; Liu, R; Luo, HB; Wang, X; Wu, D; Wu, Y; Xu, X; Yu, K; Zhan, CG; Zhang, L; Zhang, Y; Zhou, L | 1 |
| Beudel, M; Bomers, MK; Buijs, J; Collard, D; De Haan, LR; De Ruijter, W; Douma, RA; Elbers, PW; Goorhuis, A; Gritters van den Oever, NC; Knarren, LG; Moeniralam, HS; Mostard, RL; Peters, EJ; Quanjel, MJ; Reidinga, AC; Renckens, R; Sikkens, JJ; Van Assen, S; Van Den Bergh, JP; Vlasveld, IN | 1 |
| Bornstein, K; Coye, A; Della Porta, A; Long, B; Montrief, T; Parris, MA | 1 |
| Ciorba, A; Hatzopoulos, S; Pelucchi, S; Skarżyński, PH | 1 |
| Ban, K; Choi, SW; Go, YY; Jung, E; Kim, SJ; Lee, J; Lee, JH; Moon, SH; Park, HJ; Park, SJ; Park, SM; Park, YG; Shin, JS | 1 |
| Da, Z; Ding, X; Feng, X; Hu, H; Jin, Z; Li, J; Liu, L; Pan, W; Qian, X; Sun, L; Tan, J; Tao, J; Wang, F; Wang, M; Wei, H; Wu, J; Wu, M; Zhang, M; Zou, Y | 1 |
| Ahmad, A; Alotaibi, NH; Butt, MH; Khan, YH; Mallhi, TH; Misbah, S | 1 |
| Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kastritis, E; Korompoki, E; Migkou, M; Ntanasis-Stathopoulos, I; Psaltopoulou, T; Terpos, E; Tzanninis, IG | 1 |
| Niburski, K; Niburski, O | 1 |
| Andersson, N; Pimentel, J | 1 |
| Abagyan, R; Cohen, IV; Issa, MA; Makunts, T; Moumedjian, T | 1 |
| Dragojevic Simic, V; Miljkovic, M; Rancic, N; Ratkovic, N; Simic, R; Stamenkovic, D; Vekic, B | 1 |
| Fearon, U; Molloy, E; Mongey, AB; Murray, K; O'Neill, L; O'Rourke, A; Quinn, S; Turk, M; Veale, DJ | 1 |
| Asaruddin, MR; Bhawani, SA; Law, WY; Mohamad, S | 1 |
| Fiolet, T; Guihur, A; Mahamat-Saleh, Y; Peiffer-Smadja, N; Rebeaud, ME | 1 |
| Athar, M; Jha, PC; Patel, D | 1 |
| Cassone, A; Cauda, R; Iacoviello, L | 1 |
| Berlivet, L; Löwy, I | 1 |
| Katyal, A; Kumar, M; Madan, J; Singh, SB; Sodhi, RK | 1 |
| Ahmed, AAQ; Bakadia, BM; Boni, BO; He, F; Lamboni, L; Mukole, BM; Souho, T; Ullah, MW; Yang, G | 1 |
| Andersen, JT; Andersson, NW; Skov, L | 1 |
| Mishra, SK; Tripathi, T | 1 |
| Alalbila, TM; Bangalee, V; Oosthuizen, F; Yamoah, P | 1 |
| Alkasir, A; Lippmann, S | 1 |
| Albreem, MA; Alomari, OA; Alsharif, MH; Alsharif, YH; Hossain, MS; Jahid, A; Solyman, AAA; Yahya, K | 1 |
| Czerw, A; Deptała, A; Kapala, P; Kiedrowska, M; Kiedrowski, M; Skoczynska, A | 1 |
| Guengerich, FP; Rendic, S | 1 |
| Govil, A; Luckett, K; Miller-Handley, H | 1 |
| Collard, D; Peters, EJG; Sikkens, JJ | 1 |
| Brüggemann, RJ; Burger, DM; de Mast, Q; Hassing, RJ; van Luin, M; Verheijen, S | 1 |
| Asselbergs, FW; Linschoten, M; Nab, L; Tieleman, R; van der Horst, ICC | 1 |
| Fu, J; Han, S; Jia, Q; Liang, P; Lv, Y; Wang, S; Zhang, L; Zhou, H | 1 |
| Kim, G; N Husain, A; Nadeem, U; Pytel, P; Raafey, M; Schulte, JJ; Treger, J | 1 |
| Barbagallo, M; Barnett, Y; Celotto, S; Demurtas, J; Ilie, PC; Kurotschka, PK; Lagolio, E; Ometto, F; Pardhan, S; Smith, L; Soysal, P; Tonelli, R; Veronese, N | 1 |
| Almaghraby, A; Beshir, H; Ghazy, RM; Kamal, A; Moursi, A; Ramadan, A; Shaaban, R; Taha, SHN | 1 |
| Bilgin, ZD; Binay, G; Caglar Andac, S; Evcil, I; Gulsen, B; Huseynova, A; Okuyucu Genc, C; Ozdemir, AZ; Ozmen, E; Usta, Y; Ustun, S; Yazgi, D | 1 |
| Kumar, D; Trivedi, N; Verma, A | 1 |
| Ilunga, CK; Kongo, RM; Limbole, EB; Massolo, JM; Matangila, JR; Muyembe, BM; Mvwala, RK; Ngoy, CD; Ntalaja, JM; Nyembu, RK; Sakobo, TM; Telo, GM | 1 |
| Dingding, Q; Jiangfang, L; Yujia, W; Zequn, Z | 1 |
| Albashir, AAD; Elawad, OAMA; Homeida, A; Hussein, MIH | 1 |
| Casimiro, F; da Mata, GF; Fernandes, DE; Gomes, CP; Mastroianni-Kirsztajn, G; Passos, MT; Pesquero, JB; Varela, P | 1 |
| Lee, H; Won, JH | 1 |
| Crist, RM; Stern, ST; Stevens, DM | 1 |
| Fong, W; To, KKW | 1 |
| Kepp, O; Kroemer, G; Leduc, M; Liu, P; Martins, I; Tian, AL; Wu, Q; Zhao, L | 1 |
| Bahadoram, M; Keikhaei, B; Mahmoudian-Sani, MR; Saeedi-Boroujeni, A | 1 |
| Foot, B; Lotery, AJ; Yusuf, IH | 1 |
| Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
| Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M | 1 |
| Chen, Y; Cui, C; Dong, J; Li, H; Li, N; Li, Q; Liu, D; Liu, N; Niu, X; Qiao, J; Shen, N; Song, C; Wang, T; Wang, X; Wei, Y; Xu, F; Xu, Y; Yao, X; Zhang, H; Zhao, J | 1 |
| Abi-Gerges, N; Dumotier, B; Ghetti, A; Jordaan, P; Miller, PE; Traebert, M; Urban, L | 1 |
| Cracowski, JL; Khouri, C; Lepelley, M; Perez, J; Revol, B; Roustit, M | 1 |
| Bjørklund, G; Gasmi Benahmed, A; Gasmi, A; Lysiuk, R; Menzel, A; Noor, S; Peana, M | 1 |
| Gómez-Valent, M; Moreno-Ariño, M; Ortonobes Roig, S; Soler-Blanco, N; Torrente Jiménez, I; Van den Eynde Otero, E | 1 |
| Adnan, M; Alreshidi, MM; Badraoui, R; Bardakci, F | 1 |
| Lee, SH; Sohn, JT | 1 |
| Brügel, M; Habler, K; Liebchen, U; Paal, M; Scharf, C; Schönermarck, U; Teupser, D; Vogeser, M | 1 |
| Ehrlich, H; Elkbuli, A | 1 |
| Danduga, RCSR; James, RA; Kandaswamy, DK; Raj, CTD; Rajasabapathy, R | 1 |
| Aquino, BM; Bignardi, PR; Cerci Neto, A; Vengrus, CS | 1 |
| Alzaghari, O; Aroke, E; Coleman, B; Giger, JN; Gordon, Y; Lewis Iii, H; Powell-Young, YM; Reyes-Miranda, C; Strickland, OL | 1 |
| Abernathy, M; Anderson, WD; Beattie, KA; Chaudhary, KW; Coulot, J; Delaunois, A; Gryshkova, V; Hebeisen, S; Holbrook, M; Kramer, J; Kuryshev, Y; Leishman, D; Lushbough, I; Passini, E; Redfern, WS; Rodriguez, B; Rossman, EI; Trovato, C; Valentin, JP; Wu, C | 1 |
| Chaplin, M; Fletcher, T; Kredo, T; Ryan, H; Singh, B | 2 |
| Costa, J; Duarte, GS; Ferreira, JJ; Gonçalves, N; Machado, T; Mainoli, B; Prada, L | 1 |
| Fibla, J; Martinez, E; Molina, I; Pontes, C; Roman-Viñas, R; Sánchez-Montalvá, A; Velasco Muñoz, C; Vivanco-Hidalgo, RM | 1 |
| Aweeka, F; Gingrich, D; Huang, L; Marzan, F; Sok, V | 1 |
| Guo, J; Li, W; Szendrey, M; Yang, T; Zhang, S | 1 |
| Jain, S; Kumar, J; Meena, J; Yadav, A | 2 |
| C Kapetanovic, M; Einarsson, JT; Geborek, P; Källmark, H; Nilsson, JÅ; Olofsson, T; Saxne, T | 1 |
| Araújo, AMM; Araújo, JV; Asato, MS; Buttenbender, SF; Carbonell, RCC; da Fonseca, AJ; Da Rocha, JG; de Andrade, SB; de Lima Moreira, A; de Sousa Resende, J; de Souza, RGS; Galan, LEB; Marques, FSS; Paiva, ADP; Portella, DGS; Santos, NMD; Santos, PL; Silva, GMA; Tizolim, MR | 1 |
| Bennett, C; Chen, S; Hannon, CW; Lima, HC; McCourt, C | 1 |
| Altulea, D; Baranov, MV; Maassen, S; van den Bogaart, G | 1 |
| Cooper, D; Couse, Z; Cui, X; Eichacker, PQ; Li, Y; Minkove, SJ; Sun, J; Torabi-Parizi, P | 1 |
| Alotaibi, NH; Bokharee, N; Khan, YH; Khokhar, A; Mallhi, TH; Rasheed, M | 1 |
| Joshi, G; Poduri, R; Thakur, S | 1 |
| Leblanc, K; Ng, TSB; Tsang, TSM; Yeung, DF | 1 |
| Gould, S; Norris, SL | 1 |
| Brañez-Condorena, A; Diaz-Arocutipa, C; Hernandez, AV | 1 |
| Grygiel-Górniak, B; Majewska, KA; Majewski, D; Naskręcka, M | 1 |
| Bezerra, DP; Ferreira, JRO; Ferreira, PMP; Militão, GCG; Sousa, RWR | 1 |
| Askanase, A; Chen, T; Gartshteyn, Y; Giles, J; Guo, C; Tang, W | 1 |
| Altemir-Gómez, I; Fambuena-Muedra, I; Hershko, S; Jiménez-García, M; Tobarra-López, A | 1 |
| Edington, FLB; Gadellha, SR; Santiago, MB | 1 |
| Adebiyi, A; Mbakwem, AC; Ogah, OS; Ojji, DB; Orimolade, OA; Sani, MU; Sliwa, K; Stewart, S; Umuerri, EM | 1 |
| Megarbane, B; Schicchi, A | 1 |
| da Rocha Pitta, I; da Rocha Pitta, MG; da Silva Moura, JA; da Silva, SEB; de Sousa Nunes, TR | 1 |
| Abd-Elsalam, S; Abdo, EF; Abella, BS; Akram, J; Amaravadi, RK; Angus, DC; Arabi, YM; Axfors, C; Azhar, S; Baden, LR; Baker, AW; Belkhir, L; Benfield, T; Berrevoets, MAH; Chen, CP; Chen, TC; Cheng, CY; Cheng, SH; Chung, WS; Cohen, YZ; Cowan, LN; Dalgard, O; de Almeida E Val, FF; de Lacerda, MVG; de Melo, GC; Derde, L; Dubee, V; Elfakir, A; Goodman, SN; Gordon, AC; Hemkens, LG; Hernandez-Cardenas, CM; Hills, T; Hoepelman, AIM; Huang, YW; Igau, B; Ioannidis, JPA; Janiaud, P; Jin, R; Jurado-Camacho, F; Khan, KS; Kremsner, PG; Kreuels, B; Kuo, CY; Le, T; Lin, TH; Lin, WP; Lin, YC; Lyngbakken, MN; McArthur, C; McVerry, BJ; Meza-Meneses, P; Moher, D; Monteiro, WM; Morpeth, SC; Mourad, A; Mulligan, MJ; Murthy, S; Naggie, S; Narayanasamy, S; Nichol, A; Novack, LA; O'Brien, SM; Okeke, NL; Perez, L; Perez-Padilla, R; Perrin, L; Remigio-Luna, A; Rivera-Martinez, NE; Rockhold, FW; Rodriguez-Llamazares, S; Rolfe, R; Rosa, R; Røsjø, H; Sampaio, VS; Schmitt, AM; Seto, TB; Shahzad, M; Soliman, S; Stout, JE; Thirion-Romero, I; Troxel, AB; Tseng, TY; Turner, NA; Ulrich, RJ; Van't Hooft, J; Velinova, M; Walsh, SR; Webb, SA; Weehuizen, JM; Wong, HL; Wrenn, R; Zampieri, FG; Zhong, W | 1 |
| Bailly, C; Vergoten, G | 1 |
| Gao, Z; Gong, H; Li, J; Li, W; Qiu, R; Wang, C; Weng, Y; Xiao, Y; Zhang, Q | 1 |
| Muller, R | 1 |
| Demiri, I; Dimkovski, A; Dimovski, A; Filipce, V; Grozdanova, A; Panovska-Stavridis, I; Ridova, N; Ristevska, T; Stevanovic, M; Stojanoska, T; Stojanovska, S | 1 |
| Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W | 1 |
| Elavarasi, A; Garg, P; Prasad, M | 1 |
| Aljadeed, R | 1 |
| Bernardelli, RS; Câmara, BMD; Oliveira, MC; Queiroga, MVO; Réa-Neto, Á; Reese, FB | 1 |
| Chen, Y; Li, MX; Lu, GD; Shen, HM; Zhou, J | 1 |
| Auth, J; Brysch, E; Businger, R; Fröba, M; Große, M; Hu, D; Layer, M; Rauch, P; Rheber, S; Ruetalo, N; Schindler, M; Schubert, U; Setz, C | 1 |
| Anedda, L; Bianchini, L; Cuzzolin, L; Fanos, V; Finco, G; Marcialis, MA | 1 |
| Saint-Gerons, DM; Tabarés-Seisdedos, R | 1 |
| Furue, M; Kato, T; Takai-Yumine, A; Tsuji, G | 1 |
| Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D | 1 |
| Adebisi, OA; Adetuyi, BO; Adetuyi, OA; Awoyelu, EH; Olajide, PA; Oloke, JK | 1 |
| Bianchi, B; Boglione, L; Borrè, S; Esposito, M; Moglia, R; Poletti, F; Rostagno, R | 1 |
| Bu, Y; Chen, C; Ding, Y; Jiang, P; Lun, B; Shi, X; Song, M; Syafiandini, AF; Zhang, P | 1 |
| Agho, KE; Charwe, D; Chundung, MA; Ekpenyong, B; Ishaya, T; Kwasi Abu, E; Langsi, R; Mashige, KP; Nwaeze, O; Oloruntoba, R; Osuagwu, UL; Ovenseri-Ogbomo, G; Timothy, C | 1 |
| De Jonghe, S; Do, NDT; Foo, SC; Jochmans, D; Leyssen, P; Neyts, J; Persoons, L; Schols, D; Vanderlinden, E; Vangeel, L; Wang, X | 1 |
| Ahmed, R; Bharate, SB; Chandra, A; Das, S; Godbole, R; Guha, A; Gulzar, SE; Jahnavi, S; Lingamallu, SM; Mahajan, B; Mayor, S; Najar, AH; Nuthakki, VK; Panikulam, P; Prabhakara, C; Puthiyapurayil, TP; Sheth, D; Shivaraj, A; Sil, P; Singh, PP; Subhash, N; Sundaramurthy, V; U, I; van Zanten, TS; Vemula, P; Vishwakarma, R | 1 |
| Bao, Y; Chen, Z; Ding, J; Feng, Y; Guan, H; Li, H; Liu, W; Wang, X; Zhou, Z | 1 |
| Chang, AC; Chen, HE; Chen, PC; Chou, KY; Ho, CY; Hwang, TI; Tsai, TF | 1 |
| Nugraha Putra, O | 1 |
| Adebamowo, C; Botha, G; Brandenburg, JT; Choudhury, A; da Rocha, JEB; Gamo, FJ; Hazelhurst, S; Masimirembwa, C; Matshaba, M; Othman, H; Ramsay, M; Simo, G; Tiemessen, CT | 1 |
| Chi, G; Fitzgerald, C; Gibson, CM; Kazmi, SHA; Lee, JJ; Memar Montazerin, S; Shojaei, F | 1 |
| Chen, Z; Cheng, Y; Gao, M; Huang, C; Huang, J; Liu, A; Ma, Y; Wang, X; Xu, X | 1 |
| Chilmi, S; Fauzi, YR; Ichikawa, T; Morishita, K; Nakahata, S; Nakamura, T; Nueangphuet, P; Shimoda, K; Yamaguchi, R | 1 |
| García-Carrasco, M; Méndez-Martínez, S; Mendoza-Pinto, C; Munguía Realpozo, P | 1 |
| Cepatyte, D; Egberts, T; Giannis, D; Papazisis, G; Siafis, S; Stamoula, E; Tzachanis, D | 1 |
| Chen, J; Han, F; Liu, Y; Mo, M; Wang, C; Wu, J; Yang, Y | 1 |
| Rein, T | 1 |
| Costenbader, KH; Desmarais, J; Fett, N; Ginzler, EM; Goodman, S; Kovacs, R; Link, MS; O'Dell, J; Pineau, CA; Rosenbaum, JT; Schmajuk, G; Werth, VP | 1 |
| Fu, J; Han, S; Jia, Q; Liang, P; Lv, Y; Wang, S; Wang, Y; Zhang, L; Zhang, X; Zhou, H | 1 |
| Fan, J; Guo, D; He, R; Liang, Z; Su, W; Zhang, W | 1 |
| Abbade, JF; Abbade, LPF; Banzato, LR; Bolfi, F; de Barros Almeida, RAM; Dos Santos Nunes-Nogueira, V; Leite, MSF; Leite, RGOF; Mangolim, AS; Olivatti, TOF; Oliveira, FRK; Simões Corrêa Galendi, J; Soares, LT; Souza Botelho, M; Thabane, L | 1 |
| Amuzescu, B; Knott, T; Mann, SA; Mubagwa, K; Radu, BM; Thomet, U | 1 |
| Cotzomi-Ortega, I; García-Miranda, A; Jimenez-Ignacio, EE; Maycotte, P; Montes-Alvarado, JB; Pazos-Salazar, NG; Ramírez-Ramírez, D; Reyes-Leyva, J; Rojas-Sanchez, G; Romo-Rodríguez, RE; Sarmiento-Salinas, FL; Vallejo-Ruiz, V | 1 |
| Heitmann, S; Hill, AP; Kerr, N; Mangala, M; McArthur, JR; Perry, MD; TeBay, C; Vandenberg, JI; Windley, MJ | 1 |
| Abayomi, A; Abdur-Razzaq, H; Anya, SE; Erinoso, OA; Ezechi, O; Kuyinu, Y; Ojo, O; Ola, B; Osibogun, A; Wright, K; Zamba, E | 1 |
| Akinfe, OA; Al-Garbee, AI; Al-Kuraishy, HM; Batiha, GE; Kabrah, SM; Shaheen, HM; Teibo, JO; Teibo, TKA | 1 |
| Demir, AU; Demir, C | 1 |
| Ahmad, B; E Nayab, D; Sehar, B; Siddiqui, FA; Ul Hassan, N; Zeb, F | 1 |
| Calvino-Martin, F; Hoeng, J; Kolli, AR | 1 |
| Afarideh, M; Sprow, G; Werth, VP | 1 |
| Barros Edington, FL; de Rezende, DF; Dos Santos, LFS; Gadelha, SR; Garcia, RV; Santiago, MB | 1 |
| Bhardwaj, M; Chiu, MN; Sah, SP | 1 |
| Bovard, D; Calvino-Martin, F; Frentzel, S; Guy, PA; Hoeng, J; Ivanov, NV; Kolli, AR; Kuczaj, A; Majeed, S; Mazurov, A; O'Mullane, J; Peitsch, MC; Scheuner, S; Semren, TZ; van der Toorn, M | 1 |
| Boretti, A | 1 |
| Barry, H; Boly, R; Diendéré, AE; Drabo, MK; Ouédraogo, AR; Ouedraogo, AS; Ouédraogo, E; Poda, A; Rouamba, T; Sondo, A; Tahita, MC; Tarnagda, Z; Tinto, H; Traoré, I; Valea, I; Yaméogo, NV; Zoungrana, J | 1 |
| Beeraka, NM; Bettadapura, ADS; Dallavalasa, S; Fan, R; Greeshma, MV; Liu, J; Madhunapantula, SV; Nataraj, SM; Tulimilli, SV; Xiao, W; Zhang, Y; Zhao, D | 1 |
| Al-Zeidaneen, SA; Algwaiz, GF; Karim, NA; Mohsen, S; Nasef, N; Sobash, PT | 1 |
| Blumenberg, C; Cardoso, SV; Franco, A; Oliveira, MB; Paranhos, LR; Silva, PUJ; Siqueira, WL; Vieira, W | 1 |
| Kapuy, O; Korcsmáros, T | 1 |
| Choi, MY; Costenbader, KH; Di Carli, M; Ellrodt, J; Guan, H; Oakes, E; Sauer, W; Stevens, E; Tedrow, U; Weber, B | 1 |
| Gao, X; Guo, D; Ji, H; Jiang, S; Jing, X; Peng, L; Qiu, Y; Wang, J; Wu, W; Zheng, Y | 1 |
| Fei, Y; Qin, C; Shen, M; Zeng, X; Zhang, S; Zhang, W; Zhang, Y; Zhou, Y | 1 |
| Askman, N; Brent, J; Chai, PR; Farrugia, LA; Griswold, MK; Wax, PM; Weiss, S | 1 |
| Bui, BV; He, Z; Heriot, W; Hoang, A; Lim, JK; Metha, AB; Nishimura, T; Wong, VH; Zhao, D | 1 |
| Barrientos, C; Largo, A; León, I; Martín, V; Redondo, P; Sanz-Novo, M | 1 |
| Batista, JAD; Bazoni, RF; Costa, EA; Gonçalves, AP; Rocha, MS; Santos, AA | 1 |
| Chotsiri, P; Hoglund, RM; Tarning, J; Watson, JA; White, NJ | 1 |
| Blanco, Z; Charris, J; De Sanctis, JB; Martínez, GP; Mijares, MR; Ramírez, H | 1 |
| Csekes, E; Račková, L | 1 |
| Fernando, D; Herath, T; Rajapakse, S; Rodrigo, C; Wickramarachchi, U | 1 |
| Akbal-Dagistan, O; Basarir, NS; Culha, M; Erturk, A; Sahin, G; Sancar, S; Yildiz-Pekoz, A | 1 |
| Kumar, J; Meena, J | 1 |
| Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F | 1 |
| Kim, L; Lu, M; Nagoshi, K; Namchuk, MN; Yoo, SH | 1 |
| Brosnan, M; Fairley, JL; Mack, HG; Nikpour, M; Pellegrini, M; Saracino, AM; Wicks, IP | 1 |
| Byun, N; Choi, M; Choi, SJ; Choi, YS; Hwang, JR; Kim, JS; Oh, SY; Roh, CR; Sung, JH | 1 |
| Campos-Blázquez, JP; Clark, AH; Contreras, RG; Garay, E; Missirlis, F; Nachtegaal, M; Quintanar, L; Schuth, N; Vogelsang, U | 1 |
| Gagnon, LR; Oudit, GY; Sadasivan, C; Yogasundaram, H | 1 |
| Arnon, R; Hilely, A | 1 |
| Baksh, SN; Bennani, Y; Bierer, BE; Brown, SM; Buckel, WR; Clark, MR; Clement, ME; Di Stefano, L; Freilich, D; Gildea, MR; Goldenberg, NA; Gruber, J; Hanley, DF; Khanal, P; Li, T; McBee, N; Mulligan, MJ; O'Halloran, JA; Ogburn, EL; Ram, M; Rauseo, AM; Scharfstein, DO; Self, WH; Semler, MW; Seto, T; Stout, JE; Ulrich, RJ; Victory, J | 1 |
| Abrams, SL; Cervello, M; Follo, MY; Manzoli, L; Martelli, AM; McCubrey, JA; Ratti, S | 1 |
| Cai, T; Jiang, Y; Yang, Y; Zhang, JA; Zhao, J | 1 |
| Bennett, RG; Ding, L; Kapoor, E; Khan, R; Oupický, D; Panja, S; Tang, S; Tang, W | 1 |
| Alarcon, GS; Almeida-Brasil, CC; Aranow, C; Askanase, AD; Bae, SC; Bernatsky, S; Bruce, IN; Clarke, AE; Dooley, MA; Fortin, PR; Ginzler, EM; Gladman, DD; Gordon, C; Hanly, JG; Inanc, M; Isenberg, D; Jacobsen, S; Jönsen, A; Kalunian, K; Kamen, DL; Khamashta, M; Lim, SS; Lukusa, L; Manzi, S; Merrill, JT; Nived, O; Peschken, C; Petri, MA; Rahman, A; Ramos-Casals, M; Ramsey-Goldman, R; Romero-Diaz, J; Ruiz-Irastorza, G; Sánchez-Guerrero, J; Steinsson, K; Urowitz, M; van Vollenhoven, R; Wallace, DJ; Zoma, A | 1 |
| Alonso, AS; Auge, E; Behar Cohen, F; Costedoat-Chalumean, N; Derrien, S; Guillaume, J; Jebrane, H; Lafolie, J; Laumonier, E; Le Guern, V; Mauget-Faÿsse, M; Sukkarieh, G; Thevenin, S; Vasseur, V | 1 |
| Boone, BA; Geldenhuys, WJ; Hazlehurst, LA; Ivey, AD; Lotze, MT; Matthew Fagan, B; Murthy, P; Zeh, HJ | 1 |
| Affolter, K; Gudipaty, S; Kinsey, C; McMahon, M; Rohweder, R; Schuman, S; Silva, D; Silvis, MR; Truong, A; Yap, J | 1 |
| Hu, LY; Hu, YJ; Hu, YY; Wen, ZX; Yin, MM; Yuan, Y | 1 |
| Islam, M; Kim, B; Parvez, MAK; Rahman, MA; Rahman, MS; Saikat, ASM | 1 |
| Afione, SA; Atsumi, T; Chiorini, JA; Ji, Y; Motta, ACF; Nakamura, H; Noguchi, M; Oliveira, FR; Rocha, EM; Tanaka, T; Warner, BM; Zheng, C | 1 |
| Burdzhiev, NT; Hu, H; Kandinska, MI; Li, J; Li, Y; Lozanova, VV; Wang, M; Wang, X | 1 |
| Bowering, V; Bruce, JP; Cabanero, M; Chen, EX; Colombo, I; Dhani, NC; Garg, S; Gill, S; Joshua, AM; Ketela, T; Koritzinsky, M; Lheureux, S; Li, X; Li, ZJ; Madariaga, A; Mandilaras, V; Marastoni, S; Nair, SN; Oza, AM; Pesic, A; Pintilie, M; Rottapel, R; Shalev, Z; Wang, L; Wouters, BG; Zhang, W | 1 |
| Avezum, Á; Azevedo, L; Berwanger, O; Cavalcanti, AB; Lopes, RD; Lucchetta, R; Matuoka, JY; Oliveira Junior, HA; Oliveira, G; Rosa, RG; Veiga, VC | 1 |
| Debnath, J; Phadatare, P | 1 |
| Giarolla, J; Parise-Filho, R; Polli, MC; Vassiliades, SV; Vaz, ES | 1 |
| Arjmand, A; Hassani, MK; Naderpour, S; Pourahmad, J; Seydi, E | 1 |
| Ahn, SH; Bae, SI; Hwang, Y; Kang, D; Lee, SH; Ok, SH; Park, JK; Park, KE; Sim, G; Sohn, JT | 1 |
| Aït Moussa, L; Alj, L; Khattabi, A; Meski, FZ; Sefiani, H; Soulaymani Bencheikh, R; Tebaa, A | 1 |
| Chen, J; Chen, X; Huang, H; Kang, M; Li, QJ; Liu, LQ; Shao, Y; Shi, WQ; Wang, YX; Wei, H; Xu, SH | 1 |
| Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA | 1 |
| Ach, T; Berlin, A; Hillenkamp, J; Holz, FG; Kleefeldt, N; Radun, V; Reichel, C; Saßmannshausen, M; Sloan, KR; Tarau, IS | 1 |
| Biswas, M; Sukasem, C | 1 |
| Aguiar, FC; Aguiar, RLO; Anschau, F; Bartolazzi, F; Batista, JDL; Bicalho, MAC; Costa, FR; Ferreira, MAP; Guimarães-Júnior, MH; Machado-Rugolo, J; Manenti, ERF; Marcolino, MS; Menezes, LSM; Nascimento, GF; Nogueira, MCA; Oliveira, LS; Pereira, DN; Pereira, EC; Pires, MC; Polanczyk, CA; Rios, DRA; Ruschel, KB; Schwarzbold, AV; Souza-Silva, MVR; Tofani, MGT; Vasconcelos, DH; Vasconcelos, IM; Vianna, HR; Ziegelmann, PK | 1 |
| Abiola, A; Adeyemo, WL; Agabi, OP; Aina, OO; Ajibaye, O; Akase, IE; Akinbode, GO; Akintan, PE; Amoo, OS; Audu, RA; Bamidele, TA; Bode, C; Busari, AA; David, AN; Esezobor, C; Ezechi, OC; Fadipe, B; Ima-Edomwonyi, E; James, AB; Musa, AZ; Nmadu, N; Okoyenta, CO; Okwuraiwe, AP; Oladele, DA; Olakiigbe, AK; Olopade, OB; Osuolale, KA; Otrofanowei, E; Raheem, TY; Salako, AO; Salako, BL; Tade, T | 1 |
256 review(s) available for chloroquine and hydroxychloroquine
| Article | Year |
|---|---|
The Medicinal Chemistry of Dengue Virus.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dengue; Dengue Virus; Humans; Molecular Conformation; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
Topics: Animals; Antimalarials; Artemisinins; Drug Discovery; Drug Resistance; Humans; Malaria; Molecular Structure; Paclitaxel; Quinolines | 2020 |
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries | 2020 |
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
[Problems of basic therapy of rheumatic diseases with chloroquine, gold and D-penicillamine].
Topics: Aurothioglucose; Chloroquine; Gold; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Penicillamine; Rheumatic Diseases | 1979 |
Behavioral toxicity and equivocal suicide associated with chloroquine and its derivatives.
Topics: Adult; Aged; Amodiaquine; Behavior; Chloroquine; Consciousness; Delirium; Depression; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Personality; Psychoses, Substance-Induced; Suicide; Suicide, Attempted | 1977 |
Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients.
Topics: Chloroquine; Follow-Up Studies; Fundus Oculi; Humans; Hydroxychloroquine; Photography; Retinal Diseases; Visual Fields | 1991 |
[Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs].
Topics: Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; Half-Life; Humans; Hydroxychloroquine; Retinal Diseases; Skin Diseases | 1991 |
Antimalarials in rheumatic diseases.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lysosomes; Rheumatic Diseases | 1990 |
Medical treatment of interstitial cystitis (other than Rimso-50/Elmiron).
Topics: Administration, Intravesical; Administration, Oral; Amitriptyline; Azathioprine; Benzenesulfonates; Benzydamine; Chloroquine; Cystitis; Heparin; Histamine H1 Antagonists; Humans; Hydroxychloroquine; Pentosan Sulfuric Polyester; Prednisolone; Silver Nitrate | 1987 |
[Examination strategies in the diagnosis of drug-induced retinal damage].
Topics: Chloroquine; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Risk Factors; Vision Tests | 1989 |
Complications of antimalarial therapy.
Topics: Antimalarials; Chemical Phenomena; Chemistry; Chloroquine; Ciliary Body; Color Perception; Corneal Diseases; Dark Adaptation; Electrooculography; Electroretinography; Eye; Fluorescein Angiography; Humans; Hydroxychloroquine; Retinal Diseases; Visual Field Tests; Visual Fields | 1989 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical Trials as Topic; Gastrointestinal Diseases; Glomerulonephritis; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Myasthenia Gravis; Myositis; Pemphigus; Penicillamine; Pyrithioxin; Sulfasalazine; Thrombocytopenia | 1986 |
Management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyclophosphamide; Drug Therapy, Combination; Felty Syndrome; Gold; Humans; Hydroxychloroquine; Immunosuppressive Agents; Leukapheresis; Lung Diseases; Lymphoid Tissue; Methotrexate; Penicillamine; Plasmapheresis; Radiotherapy; Rheumatic Diseases; Salicylates; Sjogren's Syndrome; Spinal Diseases; Vasculitis | 1986 |
Antimalarials in rheumatology: efficacy and safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Biomechanical Phenomena; Chloroquine; Clinical Trials as Topic; Drug Therapy, Combination; Eye Diseases; Humans; Hydroxychloroquine; Longitudinal Studies; Radiography; Retinitis; Rheumatic Diseases; Time Factors | 1987 |
Ocular manifestations of rheumatic disorders. Natural and iatrogenic.
Topics: Adrenal Cortex Hormones; Arteritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Chloroquine; Conjunctivitis; Dermatomyositis; Eye Diseases; Eye Manifestations; Glaucoma; Gold; Granulomatosis with Polyangiitis; Humans; Hydroxychloroquine; Iatrogenic Disease; Indomethacin; Keratitis; Lupus Erythematosus, Systemic; Polyarteritis Nodosa; Polymyalgia Rheumatica; Retinal Diseases; Rheumatic Diseases; Sclera; Scleroderma, Systemic; Sjogren's Syndrome; Spondylitis, Ankylosing; Uveitis | 1973 |
Antimalarials in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Drug Eruptions; Headache; Humans; Hydroxychloroquine; Placebos; Retinal Diseases; Retinal Pigments | 1971 |
Rheumatoid arthritis.
Topics: Antigen-Antibody Reactions; Arthritis, Juvenile; Arthritis, Rheumatoid; Aspirin; Biopsy; Chloroquine; Gold; Humans; Hydroxychloroquine; Immunoglobulins; Lysosomes; Prednisone; Rheumatic Nodule; Rheumatoid Factor; Synovial Membrane; Synovitis; Tenosynovitis; Vascular Diseases | 1973 |
The patient with rheumatoid arthritis.
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Bursitis; Chloroquine; Diagnosis, Differential; Finger Joint; Gold; Gout; Hot Temperature; Humans; Hydroxychloroquine; Methylprednisolone; Neuralgia; Osteoarthritis; Pain; Physical Examination; Physical Exertion; Physical Therapy Modalities; Prednisolone; Rest; Salicylates; Synovectomy; Triamcinolone; Wrist Joint | 1971 |
Antimalarials.
Topics: Antimalarials; Chloroquine; DNA; Eye Diseases; Humans; Hydroxychloroquine; Quinacrine; RNA; Skin Diseases | 1981 |
Ophthalmologic aspects of chloroquine and hydroxychloroquine therapy.
Topics: Chloroquine; Dose-Response Relationship, Drug; Electroretinography; Eye; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Vision Tests | 1983 |
Antimalarial therapy in SLE.
Topics: Antimalarials; Binding Sites; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Immune Tolerance; Inflammation; Kinetics; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Nucleoproteins; Photosensitivity Disorders; Pregnancy; Quinacrine; Retinal Diseases; Retinal Pigments; Skin Diseases; Virus Replication | 1982 |
Anti-malarials in dermatology.
Topics: Absorption; Amodiaquine; Antimalarials; Chemical Phenomena; Chemistry; Chloroquine; Female; Humans; Hydroxychloroquine; Quinacrine; Skin Diseases | 1982 |
Disease-modifying drugs for progressive rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Azathioprine; Chloroquine; Cyclophosphamide; Gold; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Penicillamine; Retinal Diseases | 1980 |
Antimalarial agents. Chloroquine, hydroxychloroquine, and quinacrine.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Chloroquine; DNA; Eye Diseases; Female; Hematologic Diseases; Humans; Hydroxychloroquine; Immunosuppressive Agents; Male; Melanins; Neuromuscular Diseases; Porphyrias; Pregnancy; Quinacrine; Skin; Sunscreening Agents | 1980 |
Antimalarials and ophthalmologic safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine; Retinal Diseases | 1982 |
Clinical pharmacokinetics of slow-acting antirheumatic drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Chloroquine; Delayed-Action Preparations; Humans; Hydroxychloroquine; Organogold Compounds; Penicillamine; Sulfasalazine | 1993 |
Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Diseases; Risk Factors | 1993 |
Antimalarial agents and lupus.
Topics: Antibodies, Antiphospholipid; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Kidney Diseases; Lupus Erythematosus, Systemic; Neuromuscular Diseases; Pregnancy; Quinacrine | 1994 |
[Chloroquine retinopathy: avoidable by individualized daily dosing].
Topics: Adult; Child; Chloroquine; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Retinal Diseases | 1993 |
Antimalarials for children: indications, toxicities, and guidelines.
Topics: Adolescent; Child; Chloroquine; Humans; Hydroxychloroquine; Skin Diseases | 1993 |
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development.
Topics: Antigen Presentation; Antimalarials; Autoantigens; Autoimmune Diseases; Chloroquine; Drug Design; Histocompatibility Antigens Class II; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Peptides; Rheumatic Diseases; T-Lymphocytes | 1996 |
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.
Topics: Antirheumatic Agents; Biological Availability; Chloroquine; Drug Interactions; Humans; Hydroxychloroquine; Intestinal Absorption; Rheumatic Diseases; Tissue Distribution | 1996 |
The role of anti-malarials in rheumatoid arthritis--the American experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Drug Therapy, Combination; Humans; Hydroxychloroquine; Liver; Methotrexate; United States | 1996 |
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.
Topics: Antimalarials; Antiphospholipid Syndrome; Autoimmune Diseases; Chloroquine; Controlled Clinical Trials as Topic; Diabetes Mellitus; Humans; Hydroxychloroquine; Hyperlipidemias; Porphyria Cutanea Tarda; Sarcoidosis; Skin Diseases; Thromboembolism | 1996 |
Antimalarial drugs in pregnancy--the North American experience.
Topics: Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Systemic; North America; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Safety | 1996 |
Retinopathy and antimalarial drugs--the British experience.
Topics: Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases; Time Factors; United Kingdom | 1996 |
Ophthalmologic considerations in using antimalarials in the United States.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases; Safety; United States; Vision Tests; Visual Fields | 1996 |
Management of antimalarial-refractory cutaneous lupus erythematosus.
Topics: Antimalarials; Chloroquine; Drug Resistance; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous | 1997 |
The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease.
Topics: Animals; Antigen Presentation; Bone Marrow Transplantation; Chloroquine; Clinical Trials as Topic; Cyclosporine; Drug Synergism; Graft vs Host Disease; H-2 Antigens; Histocompatibility Antigens Class II; HLA Antigens; Humans; Hydroxychloroquine; Immunosuppressive Agents; Isoantigens; Lysosomes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; T-Lymphocytes, Cytotoxic | 1997 |
Antimalarial drugs in the treatment of rheumatological diseases.
Topics: Antimalarials; Chloroquine; Contraindications; Female; Humans; Hydroxychloroquine; Male; Pregnancy; Pregnancy Complications; Quinacrine; Rheumatic Diseases; Skin | 1997 |
[Osteoarticular sarcoidosis].
Topics: Adrenal Cortex Hormones; Adult; Analgesics; Antirheumatic Agents; Biopsy; Bone Diseases; Child; Chloroquine; Clinical Enzyme Tests; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Joint Diseases; Magnetic Resonance Imaging; Male; Peptidyl-Dipeptidase A; Sarcoidosis; Tomography, X-Ray Computed | 1998 |
Detection and prevention of maculopathy associated with antimalarial agents.
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Macula Lutea; Retinal Diseases | 1999 |
A rheumatologist's verdict on the safety of chloroquine versus hydroxychloroquine. Liability in off-label prescribing.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Contraindications; Dose-Response Relationship, Drug; Drug Labeling; Drug Prescriptions; Eye Neoplasms; Female; Humans; Hydroxychloroquine; Liability, Legal; Male; Malpractice; Middle Aged; Ontario | 1999 |
Bone sarcoidosis.
Topics: Antimalarials; Bone Diseases; Chloroquine; Female; Glucocorticoids; Granuloma; Humans; Hydroxychloroquine; Male; Radiography; Sarcoidosis | 2000 |
The anti-HIV-1 activity of chloroquine.
Topics: Anti-HIV Agents; Chloroquine; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Hydroxychloroquine; Virus Replication | 2001 |
[Amphiphilic cationic drug myopathy, drug-induced lysosomal storage lipidosis].
Topics: Aminoquinolines; Amiodarone; Animals; Anti-Arrhythmia Agents; Antimalarials; Autophagy; Cations; Chloroquine; Diagnosis, Differential; Humans; Hydroxychloroquine; Lysosomes; Muscle, Skeletal; Muscular Diseases; Perhexiline; Prognosis; Vacuoles | 2001 |
Screening for antimalarial toxicity: current concepts.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases | 2002 |
[Gastrointestinal side effects in the therapy of rheumatologic diseases].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Etanercept; Gastrointestinal Diseases; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Rheumatic Diseases; Stomach Ulcer; Sulfasalazine; Tumor Necrosis Factor-alpha | 2002 |
[EXTRAMALARIAL THERAPUETIC APPLICATIONS OF ANTIMALARIAL DRUGS. 1. CLINICAL UTILIZATIONS].
Topics: Amodiaquine; Antimalarials; Chloroquine; Collagen Diseases; Dermatology; Drug Utilization; Epilepsy; Female; Heart Diseases; Hematology; Humans; Hydroxychloroquine; Hypersensitivity; Multiple Sclerosis; Muscular Diseases; Neurology; Parasitic Diseases; Pharmacology; Primaquine; Proguanil; Pyrimethamine; Quinacrine; Quinine; Toxicology; Uterus | 1963 |
Chloroquine as a steroid sparing agent for asthma.
Topics: Adrenal Cortex Hormones; Asthma; Chloroquine; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic | 2003 |
Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity.
Topics: Animals; Anti-HIV Agents; Antimalarials; Chloroquine; Clinical Trials as Topic; HIV-1; Humans; Hydroxychloroquine | 2004 |
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
Topics: Antimalarials; Chloroquine; Drug Interactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Smoking; Time Factors; Treatment Outcome; Vision Disorders | 2005 |
Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers.
Topics: Animals; Child, Preschool; Chloroquine; Drug Overdose; Emergency Treatment; Humans; Hydroxychloroquine | 2005 |
Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Risk Factors; Vision, Ocular | 2005 |
Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiviral Agents; Bacterial Infections; Chloroquine; Humans; Hydroxychloroquine; Mycoses; Virus Diseases | 2007 |
[Retinal pigment epithelium--the point about safety of antimalarial agents].
Topics: Aged; Animals; Antimalarials; Chloroquine; Cisplatin; Humans; Hydroxychloroquine; Macular Degeneration; Pigment Epithelium of Eye; Risk Factors; Vision Screening | 2007 |
[Ocular toxicity induced by medication].
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Estrogen Antagonists; Humans; Hydroxychloroquine; Tamoxifen | 2008 |
Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy.
Topics: Antimalarials; Chloroquine; Early Diagnosis; Electroretinography; Humans; Hydroxychloroquine; Malaria; Retinal Diseases | 2009 |
[Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up].
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Dose-Response Relationship, Drug; Follow-Up Studies; Hydroxychloroquine; Macular Degeneration; Mass Screening; Retinal Diseases; Risk Factors | 2009 |
Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimetabolites; Autoimmune Diseases; Benzamides; Chloroquine; Cytotoxins; Drug Interactions; Female; Humans; Hydroxychloroquine; Imatinib Mesylate; Immunosuppression Therapy; Immunosuppressive Agents; Male; Piperazines; Pregnancy; Pyrimidines; Tumor Necrosis Factor-alpha | 2010 |
Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action.
Topics: Annexin A5; Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Cardiovascular Diseases; Chloroquine; Glucose; Humans; Hydroxychloroquine; Rheumatic Diseases; Toll-Like Receptors | 2011 |
Systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis | 2009 |
Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Topics: Antimalarials; Child; Chloroquine; Databases, Factual; Eye; Eye Diseases; Female; Humans; Hydroxychloroquine; Malaria; Pregnancy; Pregnancy Complications, Parasitic; Prenatal Exposure Delayed Effects; Randomized Controlled Trials as Topic; Rheumatic Diseases | 2011 |
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; Cohort Studies; Double-Blind Method; Drug Eruptions; Drug Interactions; Female; Fetus; Gastrointestinal Diseases; Humans; Hydroxychloroquine; Immunologic Factors; Lactation; Lipid Metabolism; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Models, Biological; Pregnancy; Pregnancy Complications; Proton Pump Inhibitors; Retinal Diseases; Ultraviolet Rays | 2012 |
Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Energy Metabolism; Humans; Hydroxychloroquine; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplasms; Proteasome Inhibitors; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
Topics: Antimalarials; Causality; Chloroquine; Cicatrix; Comorbidity; Drug Resistance; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Observational Studies as Topic; Odds Ratio; Prospective Studies; Retrospective Studies; Severity of Illness Index; Smoking; Smoking Cessation | 2015 |
A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
Topics: Animals; Chloroquine; Drug Dosage Calculations; Eye Diseases; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retina | 2015 |
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.
Topics: Antimalarials; Antineoplastic Agents; Cardiovascular Agents; Chloroquine; Drug Repositioning; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Immunologic Factors | 2015 |
Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test.
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Fluorescein Angiography; Humans; Hydroxychloroquine; Retinal Diseases; Sensitivity and Specificity; Tomography, Optical Coherence; Vision Disorders; Vision Screening; Visual Fields | 2015 |
Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.
Topics: Antimalarials; Chloroquine; Drug Repositioning; HIV Infections; Humans; Hydroxychloroquine; Immunologic Factors; Treatment Outcome | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Treatment Outcome | 2015 |
[Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Diseases | 2016 |
Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Chloroquine; Dermatologic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Observational Studies as Topic; Off-Label Use; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: A systematic review.
Topics: Antirheumatic Agents; Chikungunya Fever; Chikungunya virus; Chloroquine; Humans; Hydroxychloroquine; Musculoskeletal Diseases; Quality of Life; Randomized Controlled Trials as Topic; Rheumatic Diseases | 2017 |
Targeting autophagy in cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Biomarkers, Tumor; Chloroquine; Clinical Trials as Topic; Humans; Hydroxychloroquine; Microtubule-Associated Proteins; Neoplasms; Sequestosome-1 Protein; Tumor Escape | 2017 |
What is new in recommendations on ophthalmological screening in patients treated with chloroquine and hydroxychloroquine? Update and literature review.
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Mass Screening; Ophthalmology; Practice Guidelines as Topic; Retinal Diseases; Risk Factors; United States | 2017 |
Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Chloroquine; Humans; Hydroxychloroquine; Liver Neoplasms; NF-E2-Related Factor 2; Oxidative Stress; RNA-Binding Proteins | 2018 |
Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Topics: Antirheumatic Agents; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Hydroxychloroquine; Mass Screening; Renal Insufficiency; Retinal Diseases; Retrospective Studies; Rheumatic Diseases; Risk Factors; Tamoxifen; Tomography, Optical Coherence | 2018 |
Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Clinical Trials as Topic; Communicable Diseases; Forecasting; Humans; Hydroxychloroquine; Immune System Diseases; Lupus Erythematosus, Systemic; Malaria; Mycoses; Neoplasms; Nervous System Diseases | 2018 |
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.
Topics: Antimalarials; Cardiotoxicity; Chloroquine; Dose-Response Relationship, Drug; Female; Heart Diseases; Humans; Hydroxychloroquine; Male; Research Design; Time Factors | 2018 |
The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary.
Topics: Chloroquine; Clinical Protocols; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Mass Screening; Retinal Diseases; United Kingdom | 2018 |
Autophagy therapeutics: preclinical basis and initial clinical studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Survival; Chloroquine; Clinical Trials as Topic; Humans; Hydroxychloroquine; Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the Shots.
Topics: Adipogenesis; Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Biomarkers; Chemokine CCL5; Chloroquine; Cytotoxicity, Immunologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxychloroquine; Immunity, Innate; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Melanoma; Molecular Targeted Therapy; Signal Transduction | 2018 |
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Hydroxychloroquine; Neoplasms; Risk; Temozolomide; Treatment Outcome | 2018 |
Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis.
Topics: Adult; Antimalarials; Chloroquine; Dyslipidemias; Female; Humans; Hydroxychloroquine; Lipids; Lupus Erythematosus, Systemic; Male; Middle Aged; Treatment Outcome | 2019 |
Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?
Topics: Antimalarials; Chloroquine; Eye Diseases; Humans; Hydroxychloroquine; Patient Care Management; Rheumatic Diseases; Risk Adjustment | 2019 |
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Rheumatology; Treatment Outcome | 2020 |
Of chloroquine and COVID-19.
Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Glucocorticoids; Humans; Hydroxychloroquine; Inflammation; Interleukin-6; Janus Kinases; Pandemics; Pneumonia, Viral; SARS-CoV-2; Thrombosis; Vasculitis | 2020 |
Emerging prophylaxis strategies against COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chemoprevention; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines | 2020 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Monitoring, Physiologic; Pandemics; Patient Selection; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Teicoplanin | 2020 |
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
Topics: Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Pandemics; Patient Safety; Pneumonia, Viral; Risk Assessment; SARS-CoV-2; Treatment Outcome; Virulence | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
COVID-19 and neuromuscular disorders.
Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Delivery of Health Care; Deprescriptions; Disease Progression; Drug Development; Enzyme Inhibitors; Guillain-Barre Syndrome; House Calls; Humans; Hydroxychloroquine; Immunologic Factors; Immunosuppressive Agents; Infusions, Subcutaneous; Macrolides; Muscular Diseases; Myasthenia Gravis; Neurology; Neuromuscular Diseases; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Research; Risk Reduction Behavior; Self Administration; Telemedicine; Viral Vaccines | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Thiazoles | 2020 |
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1
Topics: Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiomyopathies; Cardiovascular Diseases; Cerebrovascular Disorders; Chloroquine; Comorbidity; Coronary Disease; Coronavirus Infections; COVID-19; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Methylprednisolone; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2; Virus Internalization | 2020 |
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cytokines; Humans; Hydroxychloroquine; Immunomodulation; Immunosuppressive Agents; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Continuous Positive Airway Pressure; Coronavirus Infections; COVID-19; Developing Countries; Disease Management; Humans; Hydroxychloroquine; Lopinavir; Lung; Oxygen; Pandemics; Pneumonia, Viral; Respiration, Artificial; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Juvenile; Betacoronavirus; Child; Child, Preschool; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Hydroxychloroquine; Infant; Interleukin-6; Italy; Pandemics; Pediatricians; Pneumonia, Viral; Rheumatic Diseases; Rheumatologists; SARS-CoV-2 | 2020 |
COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.
Topics: Biomedical Research; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Research Design | 2020 |
Current status of potential therapeutic candidates for the COVID-19 crisis.
Topics: Adrenal Cortex Hormones; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antimalarials; Antiviral Agents; Betacoronavirus; Bevacizumab; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Interferons; Janus Kinase Inhibitors; Killer Cells, Natural; Medicine, Chinese Traditional; Mesenchymal Stem Cell Transplantation; Nitric Oxide; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Trace Elements; Viral Vaccines; Vitamins; Zinc | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Cardiovascular manifestations and treatment considerations in COVID-19.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Azithromycin; Betacoronavirus; Biomarkers; Cardiovascular Diseases; Chloroquine; Comorbidity; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Disseminated Intravascular Coagulation; Extracorporeal Membrane Oxygenation; Humans; Hydroxychloroquine; Immunosuppressive Agents; Influenza, Human; Lung; Myocardium; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Troponin; Venous Thromboembolism | 2020 |
COVID-19: Therapeutics and Their Toxicities.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States | 2020 |
A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.
Topics: Antimalarials; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Research Design; SARS-CoV-2; Treatment Outcome | 2020 |
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; Cardiomyopathies; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Drug Monitoring; Humans; Hydroxychloroquine; Off-Label Use; Pandemics; Pneumonia, Viral; SARS-CoV-2; Torsades de Pointes | 2020 |
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19.
Topics: Antimalarials; Asymptomatic Diseases; Betacoronavirus; Blood Safety; Chloroquine; Contact Lenses; Coronavirus Infections; COVID-19; Disease Progression; Eye Diseases; Humans; Hydroxychloroquine; Infectious Disease Transmission, Patient-to-Professional; Ophthalmologic Surgical Procedures; Ophthalmology; Pandemics; Pneumonia, Viral; Postoperative Complications; Risk Factors; SARS-CoV-2; Societies, Medical; Spain; Symptom Assessment; Withholding Treatment | 2020 |
Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
Topics: Adult; Aged; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Hydroxychloroquine; Incidence; Long QT Syndrome; Male; Middle Aged; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Prognosis; Risk Assessment | 2020 |
A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
Topics: Aminoquinolines; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Repositioning; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome | 2020 |
Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Investigational; Global Health; Humans; Hydroxychloroquine; Lopinavir; Off-Label Use; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Should coronavirus disease 2019 concern rheumatologists?
Topics: Antirheumatic Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Rheumatic Diseases; Rheumatologists | 2020 |
The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Homeostasis; Humans; Hydroxychloroquine; Iron; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
Topics: Antimalarials; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-19; Global Health; Humans; Hydroxychloroquine; Incidence; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2 | 2020 |
[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-19; Heart; Hemodynamics; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2 | 2020 |
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Repositioning; Humans; Hydroxychloroquine; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
Topics: Betacoronavirus; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Global Health; Heart Diseases; Humans; Hydroxychloroquine; Incidence; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
Topics: Adult; Antiviral Agents; Betacoronavirus; Child; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Repositioning; Humans; Hydroxychloroquine; Observational Studies as Topic; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome; Viral Load | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 229E, Human; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Glycosylation; Humans; Hydroxychloroquine; Immunity, Innate; In Vitro Techniques; Long QT Syndrome; Lymphocyte Activation; MAP Kinase Signaling System; Middle East Respiratory Syndrome Coronavirus; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Reactive Oxygen Species; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Signal Transduction; T-Lymphocytes; Toll-Like Receptors; Treatment Outcome; Virus Internalization | 2020 |
A current review of COVID-19 for the cardiovascular specialist.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Biomarkers; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Hypoxia; Pandemics; Plasma; Pneumonia, Viral; Receptor, Angiotensin, Type 2; Risk Factors; SARS-CoV-2; Takotsubo Cardiomyopathy; Virus Internalization | 2020 |
Coronavirus Disease 2019: Clinical Review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Blood Coagulation Disorders; China; Chiroptera; Chloroquine; Coronavirus Infections; COVID-19; Glucocorticoids; Humans; Hydroxychloroquine; Infectious Disease Incubation Period; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Prognosis; Pyrazines; Radiography, Thoracic; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Symptom Assessment | 2020 |
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Coronavirus Infections; COVID-19; Drug Eruptions; Drug Interactions; Female; Glucose; Heart Diseases; Humans; Hydroxychloroquine; Lipids; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Pandemics; Platelet Aggregation; Pneumonia, Viral; Pregnancy; Renal Insufficiency; Retinal Diseases; Sjogren's Syndrome | 2020 |
Treatment of COVID 19-Repurposing drugs commonly used in dermatology.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dermatology; Drug Repositioning; Humans; Hydroxychloroquine; SARS-CoV-2 | 2020 |
Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19.
Topics: Aminoquinolines; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; SARS-CoV-2; Treatment Outcome; Virulence; Virus Replication | 2020 |
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide-1 Receptor; Glycemic Control; Humans; Hydroxychloroquine; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Interferon Type I; Lopinavir; Lung; Metformin; Obesity; Pancreas; Ritonavir; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2020 |
Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Pandemics; Pneumonia, Viral; Receptors, Interleukin-6; SARS-CoV-2 | 2020 |
[Drug treatment of coronavirus disease COVID-19: evidence exists?]
Topics: Adenosine Monophosphate; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tissue Plasminogen Activator | 2020 |
Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.
Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Emergencies; Hearing Loss; Humans; Hydroxychloroquine; Ototoxicity; Public Health; SARS-CoV-2; Tinnitus | 2020 |
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2; Virus Internalization | 2020 |
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Betacoronavirus; CCR5 Receptor Antagonists; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Cytokine Release Syndrome; Enzyme Inhibitors; Extracorporeal Membrane Oxygenation; Hemoperfusion; HIV Antibodies; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Immunomodulation; Interleukin 1 Receptor Antagonist Protein; Janus Kinase Inhibitors; Lung Injury; Mesenchymal Stem Cell Transplantation; Multiple Organ Failure; Pandemics; Plasma Exchange; Plasmapheresis; Pneumonia, Viral; Receptors, Interleukin-6; Respiratory Distress Syndrome; SARS-CoV-2; Tumor Necrosis Factor Inhibitors | 2020 |
Crosstalk between autophagy and apoptosis: Mechanisms and therapeutic implications.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Proteins; Chloroquine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxychloroquine; Lysosomes; Microtubules; Neoplasm Proteins; Neoplasms; Phagocytosis; Therapeutic Index, Drug | 2020 |
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Autophagy; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Cytokines; Disseminated Intravascular Coagulation; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Immunologic Factors; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2; Virus Internalization; Virus Replication | 2020 |
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Repositioning; HIV Infections; HIV-1; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
Topics: Autoimmune Diseases; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Immune System; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Is hydroxychloroquine beneficial for COVID-19 patients?
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Risk; SARS-CoV-2 | 2020 |
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Biological Products; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Non-Randomized Controlled Trials as Topic; Pandemics; Pneumonia, Viral; Protease Inhibitors; Protein-Tyrosine Kinases; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Viral Load | 2020 |
SARS-COV-2 in Ophthalmology: Current Evidence and Standards for Clinical Practice.
Topics: Aged; Antiviral Agents; Betacoronavirus; Chloroquine; Conjunctiva; Conjunctivitis, Viral; Coronavirus Infections; COVID-19; Disinfection; Equipment Safety; Female; Humans; Hydroxychloroquine; Infectious Disease Transmission, Patient-to-Professional; Male; Masks; Middle Aged; Ophthalmology; Pandemics; Personal Protective Equipment; Pneumonia, Viral; Practice Guidelines as Topic; Receptor, Angiotensin, Type 2; RNA, Viral; SARS-CoV-2 | 2020 |
Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.
Topics: Animals; Betacoronavirus; Chloroquine; Dependovirus; Genetic Therapy; Humans; Hydroxychloroquine; Immunomodulation; Retinal Diseases; SARS-CoV-2; Virus Diseases | 2020 |
Role for antimalarials in the management of COVID-19.
Topics: Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Post-Exposure Prophylaxis; Prospective Studies; Retrospective Studies; SARS-CoV-2 | 2020 |
Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
Topics: Age Factors; Aging; Antiviral Agents; Chloroquine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; COVID-19 Drug Treatment; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxychloroquine; Liver Failure; Malaria; Prospective Studies; Renal Insufficiency; SARS-CoV-2 | 2020 |
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Cytokines; Drug Administration Schedule; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Immunologic Factors; Pandemics; Pneumonia, Viral; SARS-CoV-2; Survival Analysis; Virus Internalization; Virus Replication | 2020 |
Hydroxychloroquine in rheumatic autoimmune disorders and beyond.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2020 |
Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment].
Topics: Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Uncertainty | 2020 |
Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral | 2020 |
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Bias; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Progression; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Interleukin 1 Receptor Antagonist Protein; Janus Kinase Inhibitors; Proportional Hazards Models; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides | 2021 |
Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Doxycycline; Humans; Hydroxychloroquine; Immunosuppression Therapy | 2020 |
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chemical and Drug Induced Liver Injury; Chloroquine; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; Endosomes; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Intracellular Membranes; Lysosomes; Membrane Lipids; Models, Biological; Pandemics; Phospholipids; Pneumonia, Viral; SARS-CoV-2; Surface-Active Agents; Virus Internalization | 2020 |
Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19?
Topics: Animals; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pre-Exposure Prophylaxis; Toxic Optic Neuropathy | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arrhythmias, Cardiac; Chloroquine; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Electrocardiography; Heart Failure; Humans; Hydroxychloroquine; Hypoxia; Inflammation; Long QT Syndrome; Lopinavir; Myocarditis; Myocardium; Precipitating Factors; Receptors, Interleukin-6; Respiratory Distress Syndrome; Ribavirin; Ritonavir; SARS-CoV-2; Water-Electrolyte Imbalance | 2021 |
The host targeting effect of chloroquine in malaria.
Topics: Animals; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Malaria; Pandemics; SARS-CoV-2 | 2020 |
Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Drug Discovery; Drug Repositioning; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.
Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Heart Diseases; Hospital Mortality; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Azithromycin; Bayes Theorem; Bias; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Risk; SARS-CoV-2; Standard of Care; Survival Analysis | 2021 |
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Synergism; Humans; Hydroxychloroquine; Immunologic Factors; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.
Topics: Bias; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Research Design; SARS-CoV-2; Treatment Outcome | 2020 |
Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pharmacogenetics; SARS-CoV-2 | 2020 |
COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
Topics: Antimalarials; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Outbreaks; Humans; Hydroxychloroquine; Pandemics; Retina; SARS-CoV-2 | 2021 |
Antimalarials as Antivirals for COVID-19: Believe it or Not!
Topics: Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2; Vero Cells | 2020 |
Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Outcome Assessment, Health Care; Pandemics; Pneumonia, Viral; Poisoning; Practice Guidelines as Topic; Quinine; Renal Dialysis; Risk Assessment; United States | 2020 |
Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Drug Repositioning; Humans; Hydroxychloroquine; Long QT Syndrome; Treatment Outcome; Viral Load | 2021 |
Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2020 |
Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Primary Prevention | 2021 |
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hospitalization; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Combinations; Evidence-Based Medicine; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; Systematic Reviews as Topic | 2020 |
Familiar Dermatologic Drugs as Therapies for COVID-19.
Topics: Androgen Antagonists; Antimalarials; Antioxidants; Antiparasitic Agents; Chloroquine; Cinchona; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ivermectin; Melatonin; SARS-CoV-2; Virus Internalization | 2021 |
Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Databases, Factual; Endpoint Determination; Female; Humans; Hydroxychloroquine; Male; Randomized Controlled Trials as Topic; Research Design; Time Factors; Treatment Outcome | 2021 |
Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians.
Topics: Chloroquine; COVID-19 Drug Treatment; Drug Overdose; Emergency Service, Hospital; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2020 |
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Hydroxychloroquine; SARS-CoV-2; Treatment Outcome | 2021 |
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Emerging treatment strategies for COVID-19 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Humans; Hydroxychloroquine; Immunization, Passive; Palliative Care; Pyrazines; SARS-CoV-2; Treatment Outcome | 2021 |
Chloroquine and its derivatives in the management of COVID-19: A scoping review
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Compassionate Use Trials; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Repositioning; Humans; Hydroxychloroquine; Multicenter Studies as Topic; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Registries; SARS-CoV-2; Treatment Outcome; Virus Replication | 2020 |
An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2021 |
Decoding the silent walk of COVID-19: Halting its spread using old bullets.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Immunotherapy; SARS-CoV-2 | 2021 |
Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine; Interferons; Treatment Outcome | 2021 |
One year update on the COVID-19 pandemic: Where are we now?
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses | 2021 |
Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Artificial Intelligence; Ascorbic Acid; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Deep Learning; Drug Combinations; Drug Development; Drug Repositioning; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Machine Learning; Ribavirin; Ritonavir; Vitamins | 2020 |
Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.
Topics: Animals; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxychloroquine; Membrane Transport Proteins; Pharmaceutical Preparations | 2020 |
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.
Topics: Antimalarials; Antiviral Agents; Cardiomyopathies; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine | 2021 |
An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy.
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2; Treatment Outcome | 2020 |
Liquid Chromatographic Methods for COVID-19 Drugs, Hydroxychloroquine and Chloroquine.
Topics: Animals; Antiviral Agents; Chloroquine; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Reproducibility of Results; SARS-CoV-2 | 2021 |
Possible treatment and strategies for COVID-19: review and assessment.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiparasitic Agents; Antiviral Agents; Cannabinoids; Chloroquine; Complement Inactivating Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Pyrazines; Ritonavir; SARS-CoV-2; Teicoplanin; Tetracyclines; Thiazoles | 2020 |
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; ERG1 Potassium Channel; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Off-Label Use; Ritonavir | 2021 |
Malaria and COVID-19: unmasking their ties.
Topics: Age Factors; Angiotensin-Converting Enzyme 2; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Interferons; Malaria; Prevalence; SARS-CoV-2 | 2020 |
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics.
Topics: Acute Kidney Injury; Amantadine; Angiotensin-Converting Enzyme 2; Cathepsin L; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cysteine Proteinase Inhibitors; Genetic Predisposition to Disease; Heparin; Humans; Hydroxychloroquine; Lysosomes; Molecular Targeted Therapy; Pandemics; Receptors, Virus; Respiratory Distress Syndrome; SARS-CoV-2; Serine Endopeptidases; Spike Glycoprotein, Coronavirus; Teicoplanin; Virus Internalization | 2020 |
The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.
Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Drug Repositioning; Humans; Hydroxychloroquine; Nucleosides; Pandemics; Protease Inhibitors; Public Health; SARS-CoV-2 | 2020 |
Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine.
Topics: Animals; Antimalarials; Chloroquine; Communicable Diseases; Drug Compounding; Humans; Hydroxychloroquine; Nanomedicine | 2020 |
Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Chemotherapy, Adjuvant; Chloroquine; Drug Repositioning; Humans; Hydroxychloroquine; Neoplasms; Patents as Topic | 2021 |
Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
Topics: Anti-Inflammatory Agents; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Hydroxychloroquine; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein | 2021 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Factual; Humans; Hydroxychloroquine; Immunoglobulins; Lopinavir; Pandemics; Pyrazines; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2021 |
Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Serotherapy; Dexamethasone; Drug Repositioning; Evolution, Molecular; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Phylogeny; Prospective Studies; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2021 |
Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome | 2021 |
Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: Review and Appraisal of Current Evidence.
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine | 2020 |
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Topics: Adult; Aged; Antimalarials; Antiviral Agents; Bias; Cause of Death; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Humans; Hydroxychloroquine; Middle Aged; Pandemics; Prognosis; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Standard of Care; Treatment Outcome | 2021 |
Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2; Treatment Outcome | 2021 |
Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Treatment Outcome | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine; Dermatologic Agents; Exanthema; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Medicine, Chinese Traditional; Methotrexate; Placebos; Quality of Life; Randomized Controlled Trials as Topic; Skin Diseases; Symptom Flare Up | 2021 |
What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.
Topics: Antiviral Agents; Cell Proliferation; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.
Topics: Alphapapillomavirus; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dengue Virus; Hepacivirus; Hepatitis C, Chronic; Herpesvirus 4, Human; HIV; HIV Infections; Humans; Hydroxychloroquine; Infectious Mononucleosis; SARS-CoV-2; Severe Dengue; Treatment Outcome; Warts | 2021 |
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Intensive Care Units; Length of Stay; Lopinavir; Methylprednisolone; Observational Studies as Topic; Patient Admission; Pyrazines; Ritonavir; SARS-CoV-2; Survival Rate | 2021 |
Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.
Topics: Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics | 2021 |
Medication use during COVID-19: Review of recent evidence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hydroxychloroquine; Immunoglobulins | 2021 |
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Observational Studies as Topic; Ritonavir | 2021 |
Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms.
Topics: Antineoplastic Agents; Autophagy; Chloroquine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Hydroxychloroquine; Immunomodulating Agents; Neoplasms | 2021 |
What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects.
Topics: Antimalarials; Caregivers; Chloroquine; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Health Personnel; Humans; Hydroxychloroquine; Ophthalmologists; Retina; Retinal Diseases; SARS-CoV-2 | 2021 |
Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis.
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
Topics: Acute Coronary Syndrome; Africa; Antimalarials; Arrhythmias, Cardiac; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-19; Delivery of Health Care; Economic Factors; Economic Recession; Gross Domestic Product; Health Resources; Heart Failure; Humans; Hydroxychloroquine; Inflammation; Myocardial Ischemia; Myocarditis; SARS-CoV-2; Severe Acute Respiratory Syndrome; Socioeconomic Factors; Takotsubo Cardiomyopathy | 2021 |
New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review.
Topics: Antimalarials; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Quinolines | 2022 |
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
Topics: Adult; Child; Chloroquine; Combined Modality Therapy; Comorbidity; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; International Cooperation; Odds Ratio; Patient Participation; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2021 |
The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2; Treatment Outcome | 2021 |
Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Prognosis; Risk Factors | 2021 |
Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Dexamethasone; Drug Combinations; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Lopinavir; Ritonavir; SARS-CoV-2 | 2021 |
The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2022 |
Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.
Topics: Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Endocytosis; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
What if COVID-19 affects the child: which weapons and how to use them.
Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Carrier State; Child; Child, Preschool; Chloroquine; Continuous Renal Replacement Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Extracorporeal Membrane Oxygenation; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Oseltamivir; Receptors, Cell Surface; Respiration, Artificial; Ribavirin; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thrombosis | 2021 |
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inducers; Dexamethasone; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Epilepsy; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Ivermectin; Lopinavir; Pyrazines; Ritonavir; SARS-CoV-2 | 2021 |
Epidemiology and Treatment Options for COVID-19: A Review.
Topics: Antiviral Agents; Chloroquine; Communicable Disease Control; COVID-19; Disease Outbreaks; Humans; Hydroxychloroquine; Medicine, Chinese Traditional; SARS-CoV-2; World Health Organization | 2020 |
Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antiviral Agents; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Network Meta-Analysis; Randomized Controlled Trials as Topic; Respiration, Artificial | 2021 |
Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Combined Modality Therapy; COVID-19; COVID-19 Serotherapy; Cytokine Release Syndrome; Fibrinolytic Agents; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Plasma Exchange; Protein Kinase Inhibitors; Respiratory Therapy; Rheumatology; Severity of Illness Index; Thrombosis | 2021 |
Current treatment strategies for COVID‑19 (Review).
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Serotherapy; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Immunization, Passive; SARS-CoV-2 | 2021 |
Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts.
Topics: Antidepressive Agents; Antiviral Agents; Artesunate; Autophagy; Chloroquine; COVID-19 Drug Treatment; Drug Development; Drug Repositioning; Endoplasmic Reticulum; Endosomes; Humans; Hydroxychloroquine; Imatinib Mesylate; Infliximab; Intracellular Membranes; Ivermectin; Macrolides; Middle East Respiratory Syndrome Coronavirus; Niclosamide; Pandemics; RNA, Viral; SARS-CoV-2; Virus Replication | 2022 |
Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions.
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2021 |
Possible mechanistic insights into iron homeostasis role of the action of 4-aminoquinolines (chloroquine/hydroxychloroquine) on COVID-19 (SARS-CoV-2) infection.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Homeostasis; Humans; Hydroxychloroquine; Iron; SARS-CoV-2; Virus Attachment | 2021 |
Efficacy of hydroxychloroquine in the prevention of thromboembolic events: A systematic review and meta-analysis.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2022 |
Safety profile of COVID-19 drugs in a real clinical setting.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Reproducibility of Results; Ritonavir; SARS-CoV-2 | 2022 |
Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ivermectin; SARS-CoV-2; Treatment Outcome; Zinc | 2022 |
COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19.
Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Humans; Hydroxychloroquine; SARS-CoV-2; Vaccines | 2022 |
Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review.
Topics: Autophagy; Chloroquine; Humans; Hydroxychloroquine; Neoplasms; United States | 2022 |
Oral pigmentation as an adverse effect of chloroquine and hydroxychloroquine use: A scoping review.
Topics: Chloroquine; Cross-Sectional Studies; Humans; Hydroxychloroquine; Hyperpigmentation; Pigmentation | 2022 |
Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update.
Topics: Anti-Inflammatory Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2022 |
Treatment of chikungunya-associated joint pain: a systematic review of controlled clinical trials.
Topics: Anti-Inflammatory Agents; Arthralgia; Chikungunya Fever; Chloroquine; Humans; Hydroxychloroquine; Methotrexate; Observational Studies as Topic; Retrospective Studies; Ribavirin | 2022 |
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Heparin; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2022 |
Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Topics: Anxiety; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Mental Disorders | 2023 |
A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemics.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome | 2022 |
How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
Topics: Antirheumatic Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Friends; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2023 |
Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
Topics: Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Heart Failure; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2022 |
Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis.
Topics: Chloroquine; COVID-19 Drug Treatment; Data Analysis; Humans; Hydroxychloroquine | 2022 |
Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies.
Topics: Antirheumatic Agents; Chloroquine; Cohort Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2022 |
Recent Update and Drug Target in Molecular and Pharmacological Insights into Autophagy Modulation in Cancer Treatment and Future Progress.
Topics: Antineoplastic Agents; Autophagy; Chloroquine; Humans; Hydroxychloroquine; Neoplasms | 2023 |
Hydroxychloroquine for Non-Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic | 2023 |
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; Dexamethasone; Drug Repositioning; Humans; Hydroxychloroquine; Ivermectin; Methylprednisolone; Pandemics; Reproducibility of Results; SARS-CoV-2 | 2023 |
Pharmacogenomics of chloroquine and hydroxychloroquine: current evidence and future implications.
Topics: Chloroquine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Humans; Hydroxychloroquine; Pharmacogenetics | 2023 |
16 trial(s) available for chloroquine and hydroxychloroquine
| Article | Year |
|---|---|
[Crug formulation and liberation of the active ingredient in of chloroquine phosphate].
Topics: Chloroquine; Clinical Trials as Topic; Delayed-Action Preparations; Dosage Forms; Female; Humans; Hungary; Hydroxychloroquine; Lupus Erythematosus, Systemic; Phosphates; Spectrum Analysis; Tablets, Enteric-Coated | 1975 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical Trials as Topic; Gastrointestinal Diseases; Glomerulonephritis; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Myasthenia Gravis; Myositis; Pemphigus; Penicillamine; Pyrithioxin; Sulfasalazine; Thrombocytopenia | 1986 |
Antimalarials in rheumatology: efficacy and safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Biomechanical Phenomena; Chloroquine; Clinical Trials as Topic; Drug Therapy, Combination; Eye Diseases; Humans; Hydroxychloroquine; Longitudinal Studies; Radiography; Retinitis; Rheumatic Diseases; Time Factors | 1987 |
Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine.
Topics: Adolescent; Adult; Arthritis, Juvenile; Child; Child, Preschool; Chloroquine; Clinical Trials as Topic; Cornea; Dose-Response Relationship, Drug; Eye Diseases; Female; Humans; Hydroxychloroquine; Infant; Lupus Erythematosus, Systemic; Male; Time Factors | 1974 |
The prevention of drug-induced retinopathies.
Topics: Adolescent; Adult; Aged; Chloroquine; Clinical Trials as Topic; Eye; Eye Diseases; Female; Humans; Hydroxychloroquine; Macula Lutea; Male; Middle Aged; Retina; Vision Tests | 1966 |
Antimalarial drugs for rheumatoid arthritis.
Topics: Amodiaquine; Antimalarials; Arthritis, Rheumatoid; Body Weight; Chloroquine; Clinical Trials as Topic; Gold; Humans; Hydroxychloroquine; Kinetics; Penicillamine; Tablets; Vision Disorders | 1983 |
[Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].
Topics: Adult; Aged; Algorithms; Antimalarials; Case-Control Studies; Chloroquine; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Middle Aged; Prospective Studies; Smoking; Statistics, Nonparametric; Treatment Outcome | 2004 |
Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.
Topics: Adult; Antirheumatic Agents; Chloroquine; Cross-Sectional Studies; Electroretinography; Female; Fixation, Ocular; Humans; Hydroxychloroquine; Male; Middle Aged; Retina; Retinal Diseases; Rheumatic Diseases; Visual Acuity; Visual Field Tests; Visual Fields | 2013 |
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Topics: Adamantane; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Janus Kinase 3; Male; Middle Aged; Niacinamide; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2017 |
Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Injections, Subcutaneous; Leflunomide; Male; Methotrexate; Middle Aged; Sulfasalazine; Treatment Outcome | 2019 |
An open-label cluster-randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC)-Protocol publication.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Hospitalization; Humans; Hydroxychloroquine; Long QT Syndrome; Netherlands; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2020 |
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection.
Topics: Adult; Aged; Antimalarials; Antiparasitic Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Female; Humans; Hydroxychloroquine; Inpatients; Ivermectin; Male; Middle Aged | 2021 |
An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.
Topics: Adult; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Middle Aged; SARS-CoV-2; Survival Rate; Treatment Outcome | 2021 |
A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomi
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lopinavir; Multicenter Studies as Topic; Nigeria; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2 | 2021 |
Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19.
Topics: Adult; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Hydroxychloroquine; Middle Aged; SARS-CoV-2; Treatment Outcome; Young Adult | 2021 |
Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.
Topics: Adult; Chloroquine; COVID-19; Humans; Hydroxychloroquine; Middle Aged; Nigeria; SARS-CoV-2; Treatment Outcome | 2023 |
544 other study(ies) available for chloroquine and hydroxychloroquine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
Topics: | 2015 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Antirheumatic agents.
Topics: Adrenal Cortex Hormones; Antimalarials; Aspirin; Azathioprine; Chloroquine; Cyclophosphamide; Gold; Humans; Hydroxychloroquine; Immunosuppressive Agents; Indomethacin; Penicillamine; Phenylbutazone; Phenylpropionates; Rheumatic Diseases; Salicylates; Sulindac; Tolmetin | 1979 |
[Ocular complications after treatment with antimalarial agents in dermatology].
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chloroquine; Corneal Dystrophies, Hereditary; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retrospective Studies; Skin Diseases; Time Factors | 1979 |
Long-term course of chloroquine retinopathy after cessation of medication.
Topics: Adult; Aged; Chloroquine; Color Perception Tests; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged; Ophthalmoscopy; Refraction, Ocular; Remission, Spontaneous; Retinal Diseases; Scotoma; Time Factors; Visual Acuity; Visual Fields | 1979 |
[Discoid lupus erythematosus or lichen planus?].
Topics: Chloroquine; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lichen Planus; Lupus Erythematosus, Discoid; Middle Aged; Scalp; Skin | 1978 |
[Medical treatment of rheumatoid arthritis].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chloroquine; Drug Therapy, Combination; Gold; Humans; Hydroxychloroquine; Long-Term Care; Penicillamine | 1976 |
The treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Child; Chloroquine; Female; Gold; Humans; Hydroxychloroquine; Ibuprofen; Indomethacin; Injections, Intra-Articular; Male; Penicillamine; Phenylbutazone; Physical Therapy Modalities; Pregnancy; Pregnancy Complications; Prognosis; Salicylates | 1977 |
Ocular manifestations of juvenile rheumatoid arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Arthritis, Juvenile; Atropine; Cataract; Child; Child, Preschool; Chloroquine; Dexamethasone; Endophthalmitis; Eye Diseases; Eye Manifestations; Female; Humans; Hydroxychloroquine; Infant; Infant, Newborn; Male; Retinal Diseases; Scotoma; Sex Factors; Tissue Adhesions; Uveitis; Uveitis, Anterior; Visual Acuity | 1975 |
Long-term course of antimalarial maculopathy after cessation of treatment.
Topics: Chloroquine; Follow-Up Studies; Humans; Hydroxychloroquine; Longitudinal Studies; Macula Lutea; Malaria, Falciparum; Prognosis; Retinal Diseases; Scotoma; Visual Acuity; Visual Field Tests; Visual Fields | 1992 |
Use of antimalarial drugs for the treatment of psoriatic arthritis.
Topics: Arthritis, Psoriatic; Chloroquine; Humans; Hydroxychloroquine; Retrospective Studies | 1992 |
Influence of higher rates of agitation on release patterns of immediate-release drug products.
Topics: Chloroquine; Griseofulvin; Hydroxychloroquine; Isocarboxazid; Primaquine; Quality Control; Solubility; Sulfadiazine; Tablets | 1992 |
Determination of hydroxychloroquine and its major metabolites in plasma using sequential achiral-chiral high-performance liquid chromatography.
Topics: Animals; Biological Availability; Chloroquine; Chromatography, High Pressure Liquid; Hydroxychloroquine; Male; Rabbits; Spectrophotometry, Ultraviolet; Stereoisomerism | 1992 |
Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients.
Topics: Administration, Oral; Arthritis, Rheumatoid; Chloroquine; Female; Half-Life; Humans; Hydroxychloroquine; Male | 1991 |
Chloroquine retinopathy.
Topics: Chloroquine; Color Perception; Humans; Hydroxychloroquine; Retinal Diseases; Vision Tests; Visual Acuity | 1991 |
Kinetics and thermodynamics of chloroquine and hydroxychloroquine transport across the human erythrocyte membrane.
Topics: Biological Transport; Chloroquine; Diffusion; Erythrocyte Membrane; Humans; Hydrogen Bonding; Hydroxychloroquine; Mathematics; Membrane Proteins; Solvents; Temperature; Thermodynamics | 1991 |
Pregnancy outcome following first trimester exposure to chloroquine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Arthritis, Rheumatoid; Chloroquine; Female; Fetal Death; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Malaria; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Trimester, First | 1991 |
Is corneal deposition of antimalarial any indication of retinal toxicity?
Topics: Adult; Aged; Chloroquine; Cornea; Drug Overdose; Female; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxychloroquine; Male; Pupil; Retinal Diseases | 1990 |
The blood-retinal barrier in chloroquine retinopathy.
Topics: Aged; Blood-Retinal Barrier; Chloroquine; Female; Fluorescein Angiography; Fluorometry; Humans; Hydroxychloroquine; Male; Middle Aged; Pigment Epithelium of Eye; Retinal Diseases; Vision Tests; Visual Acuity | 1989 |
Studies on the mechanism of inhibition of chemotactic tripeptide stimulated human neutrophil polymorphonuclear leucocyte superoxide production by chloroquine and hydroxychloroquine.
Topics: Chemotaxis, Leukocyte; Chloroquine; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Superoxides | 1987 |
Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release.
Topics: Cells, Cultured; Chloroquine; Fluorides; Humans; Hydroxychloroquine; Neutrophils; Receptors, Complement; Receptors, Complement 3b; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 1988 |
[Synthetic antimalarials in the therapy of rheumatoid arthritis: adverse effects and advantages].
Topics: Arthritis, Rheumatoid; Chloroquine; Drug Evaluation; Enzyme Inhibitors; Histamine H1 Antagonists; Humans; Hydroxychloroquine; Quinacrine; Time Factors | 1985 |
"Disease-modifying" drugs in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Immunosuppressive Agents; Penicillamine; Sulfasalazine | 1985 |
How reliable is ESR as a measure of disease activity in rheumatoid arthritis treated with hydroxychloroquine?
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Blood Viscosity; Chloroquine; Drug Administration Schedule; Female; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Male; Penicillamine; Sulfasalazine | 1988 |
Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes.
Topics: Arachidonic Acid; Arachidonic Acids; Calcimycin; Cell Survival; Chloroquine; Fluorides; Humans; Hydroxychloroquine; Monocytes; N-Formylmethionine Leucyl-Phenylalanine; Phospholipids; Quinacrine; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 1986 |
Ocular effects and safety of antimalarial agents.
Topics: Antimalarials; Chloroquine; Corneal Diseases; Drug Administration Schedule; Electrooculography; Electroretinography; Eye; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxychloroquine; Retinal Diseases; Vision Tests | 1988 |
A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers.
Topics: Adult; Blood Proteins; Chloroquine; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hydroxychloroquine; Infusions, Intravenous; Kidney; Male; Protein Binding | 1988 |
Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials.
Topics: Aminoquinolines; Amodiaquine; Animals; Biological Transport, Active; Chloroquine; Half-Life; Humans; Hydroxychloroquine; In Vitro Techniques; Liver; Muscles | 1988 |
Antimalarial drugs, systemic lupus erythematosus and pregnancy.
Topics: Abortion, Spontaneous; Antimalarials; Chloroquine; Female; Fetal Death; Humans; Hydroxychloroquine; Infant, Newborn; Infant, Premature; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Complications | 1988 |
Effects of chloroquine and hydroxychloroquine on the hexachlorobenzene-induced porphyria in rats.
Topics: Animals; Chlorobenzenes; Chloroquine; Female; Hexachlorobenzene; Hydroxychloroquine; Porphyrias; Rats; Rats, Inbred Strains | 1986 |
[Drug therapy of chronic juvenile arthritis].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arthritis, Juvenile; Child; Chloroquine; Gold; Humans; Hydroxychloroquine; Immunosuppressive Agents; Penicillamine | 1987 |
Dose relationships in patients with early chloroquine retinopathy.
Topics: Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases | 1987 |
The prescribing of chloroquine and hydroxychloroquine by consultant rheumatologists in the UK.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; United Kingdom | 1987 |
Cutaneous ulcers in sarcoidosis.
Topics: Adult; Chloroquine; Female; Humans; Hydroxychloroquine; Middle Aged; Prednisone; Sarcoidosis; Skin; Skin Ulcer | 1987 |
Treatment of chronic hepatic porphyria (PCT).
Topics: Bloodletting; Chloroquine; Humans; Hydroxychloroquine; Liver Diseases; Porphyrias | 1986 |
High-performance liquid chromatographic assay for hydroxychloroquine and three of its major metabolites, desethylhydroxychloroquine, desethylchloroquine and bidesethylchloroquine, in human plasma.
Topics: Chloroquine; Chromatography, High Pressure Liquid; Freezing; Humans; Hydroxychloroquine | 1986 |
Keratopathy with low dose chloroquine therapy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Chemical Phenomena; Chemistry; Chloroquine; Corneal Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Severity of Illness Index | 1986 |
Current practice in antimalarial drug prescribing in rheumatoid arthritis.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Drug Prescriptions; Humans; Hydroxychloroquine; Patient Acceptance of Health Care; Professional Practice | 1986 |
Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy.
Topics: Biopsy; Cardiomyopathies; Chloroquine; Endocardium; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Male; Middle Aged | 1987 |
Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy.
Topics: Arthritis, Rheumatoid; Cell Survival; Chloroquine; Humans; Hydroxychloroquine; In Vitro Techniques; Leukocytes | 1987 |
Chloroquine neuromyotoxicity. Clinical and pathologic perspective.
Topics: Aged; Biopsy; Cardiomyopathies; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Muscles; Muscular Diseases; Myocardium; Nervous System Diseases; Sural Nerve; Time Factors | 1987 |
The sensitivity of Amsler grid testing in early chloroquine retinopathy.
Topics: Adult; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases; Scotoma; Vision Tests | 1985 |
Cutaneous lupus erythematosus. Recognition of its many forms.
Topics: Adrenal Cortex Hormones; Adult; Chloroquine; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Male; Quinacrine; Sex Factors; Skin; Skin Diseases | 1986 |
Ocular toxicity of systemic drugs.
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Chloroquine; Contraceptives, Oral; Digitalis; Eye Diseases; Humans; Hydroxychloroquine; Phenothiazines; Plants, Medicinal; Plants, Toxic; Vision Disorders | 1985 |
Ocular side effects of systemic therapy of cutaneous diseases.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antimetabolites; Chloroquine; Eye Diseases; Humans; Hydroxychloroquine; PUVA Therapy; Retinoids; Skin Diseases; Tetracyclines | 1985 |
Antimalarial treatment of rheumatoid arthritis: 1985 status.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Drug Combinations; Gold; Humans; Hydroxychloroquine; Kidney; Penicillamine; Retinal Diseases | 1985 |
Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity.
Topics: Adult; Age Factors; Chloroquine; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Middle Aged; Prospective Studies; Retinal Diseases; Visual Acuity | 1985 |
Effect of gold salts and antimalarials on the rheumatoid factor in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Depression, Chemical; Female; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Latex Fixation Tests; Male; Rheumatoid Factor; Time Factors | 1973 |
Biochemical properties of anti-inflammatory drugs. VI. The effects of chloroquine (resochin), mepacrine (quinacrine) and some of their potential metabolites on cartilage metabolism and oxidative phosphorylation.
Topics: Animals; Cartilage; Chloroquine; Glycosaminoglycans; Gold; Hydroxychloroquine; In Vitro Techniques; Indomethacin; Oxidative Phosphorylation; Polysaccharides; Quinacrine; Quinolines; Rats; Sulfates; Sulfur Isotopes; Thiosulfates | 1965 |
The inhibition of antigen-antibody reaction by quinoline derivatives.
Topics: Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Antigen-Antibody Reactions; Arthritis, Rheumatoid; Blood Group Antigens; Cattle; Cell Nucleus; Chloroquine; Depression, Chemical; Erythrocytes; Humans; Hydroxychloroquine; Immune Sera; Isoantibodies; Liver; Lupus Erythematosus, Systemic; Mice; Quinaldines; Quinolines; Quinolinic Acids | 1974 |
Biochemical properties of anti-inflammatory drugs. VII. Inhibition of proteolytic enzymes in connective tissue by chloroquine (resochin) and related antimalarial antirheumatic drugs.
Topics: Acridines; Animals; Cartilage; Cattle; Chloroquine; Chondroitin; Connective Tissue; Hyaluronoglucosaminidase; Hydrogen-Ion Concentration; Hydroxychloroquine; Microbial Collagenase; Mucoproteins; Papain; Primaquine; Quaternary Ammonium Compounds; Quinacrine; Rabbits | 1966 |
[UV-spectrophotometry in drug control. 14. Characterization and determination of drugs with quinoline and isoquinoline chromophores].
Topics: Amodiaquine; Chloroquine; Hydroxychloroquine; Isoquinolines; Papaverine; Primaquine; Quinidine; Quinine; Quinolines; Spectrophotometry, Ultraviolet | 1974 |
Discoid lupus erythematosus.
Topics: Adult; Antimalarials; Chloroquine; Color Vision Defects; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Quinacrine; Retinal Diseases | 1972 |
[Chloroquine retinopathy].
Topics: Adult; Aged; Chloroquine; Color Vision Defects; Dark Adaptation; Electrooculography; Electroretinography; Female; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Diseases; Scotoma; Visual Acuity | 1972 |
In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine.
Topics: Animals; Carbon Radioisotopes; Cattle; Chloroquine; Cycloheximide; Epithelium; Eye Proteins; Hydroxychloroquine; In Vitro Techniques; Leucine; Lysine; Phenylalanine; Puromycin; Quinine; Retina; Tissue Extracts | 1974 |
Treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Aspirin; Chloroquine; Cyclophosphamide; Female; Gold; Humans; Hydroxychloroquine; Indomethacin; Male; Middle Aged; Phenylbutazone; Physical Therapy Modalities; Rest | 1974 |
Chloroquine-induced ocular toxicity.
Topics: Chloroquine; Color Perception; Cornea; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases; Visual Acuity; Visual Fields | 1974 |
[Chloroquine and hydroxychloroquine dosage in juvenile rheumatoid arthritis].
Topics: Administration, Oral; Adolescent; Arthritis, Juvenile; Child; Child, Preschool; Chloroquine; Corneal Opacity; Female; Humans; Hydroxychloroquine; Infant; Lupus Erythematosus, Systemic; Male | 1974 |
Ocular damage in chloroquine therapy.
Topics: Adult; Arthritis, Rheumatoid; Child; Chloroquine; Color Perception Tests; Color Vision Defects; Cornea; Electroretinography; Eye Diseases; Female; Fundus Oculi; History of Medicine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Ophthalmoscopy; Refraction, Ocular; Retina; Scotoma; Skin Diseases; Visual Field Tests | 1967 |
Immunofluorescent "band" test for lupus erythematosus. II. Employing skin lesions.
Topics: Antibodies, Antinuclear; Basement Membrane; Chloroquine; Collagen Diseases; Fluorescent Antibody Technique; Humans; Hydroxychloroquine; Immunoglobulins; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Pemphigus; Photosensitivity Disorders; Prednisone; Skin | 1970 |
Studies of the metabolism of some compounds of the 4-amino-7-chloroquinoline series.
Topics: Animals; Blood; Brain; Chloroquine; Eye; Haplorhini; Humans; Hydroxychloroquine; In Vitro Techniques; Liver; Lung; Muscles; Urine | 1966 |
Iatrogenic disease in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Glucocorticoids; Gold; Humans; Hydroxychloroquine; Iatrogenic Disease; Indomethacin; Phenylbutazone; Salicylates | 1971 |
Effects of anti-inflammatory drugs on the stability of rat liver lysosomes in vitro.
Topics: Acid Phosphatase; Animals; Anti-Inflammatory Agents; Aspirin; Chloroquine; Flufenamic Acid; Fluorine; Glucuronidase; Hydrocortisone; Hydroxychloroquine; In Vitro Techniques; Indomethacin; Liver; Lysosomes; Male; Membranes; ortho-Aminobenzoates; Oxyphenbutazone; Paramethasone; Phenylbutazone; Rats | 1971 |
Dissimilar effects of anti-inflammatory drugs on stability of lysosomes from peritoneal and circulating leukocytes and liver.
Topics: Acid Phosphatase; Animals; Anti-Inflammatory Agents; Aspirin; Chloroquine; Exudates and Transudates; Flufenamic Acid; Glucuronidase; Hydrocortisone; Hydroxychloroquine; In Vitro Techniques; Indomethacin; Leukocytes; Liver; Lysosomes; Male; Membranes; Oxyphenbutazone; Paramethasone; Peritoneal Cavity; Phenylbutazone; Rabbits; Rats | 1971 |
Cytotoxin(s) produced by human lymphocytes: inhibition by anti-inflammatory steroids and anti-malarial drugs.
Topics: Amino Acids; Animals; Anti-Inflammatory Agents; Antibody Formation; Antigen-Antibody Reactions; Antimalarials; Chloroquine; Chromium Isotopes; Complement System Proteins; Cytotoxicity Tests, Immunologic; Dexamethasone; Humans; Hydroxychloroquine; L Cells; Lymphocytes; Mice; Phenylbutazone; Prednisolone; Salicylates; Triamcinolone Acetonide | 1971 |
[Evaluation of a practical use of synthetic antimalarials in the treatment of rheumatoid polyarthritis].
Topics: Aged; Antimalarials; Arthritis, Rheumatoid; Aspirin; Chloroquine; Eye Diseases; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Indomethacin; Male; Middle Aged; Oxyphenbutazone; Prednisone | 1971 |
Arthritis and drugs. Newer steroids and drugs in clinical trial. IV.
Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Arthritis, Rheumatoid; Azoles; Chelating Agents; Chloroquine; Cyclophosphamide; Dimethyl Sulfoxide; Eye; Hydroxychloroquine; Immunosuppressive Agents; Indoles; Indomethacin; Nitrogen Mustard Compounds; Phenylacetates; Phenylbutazone; Quackery | 1969 |
Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine.
Topics: Antibodies, Antinuclear; Autoantibodies; Chloroquine; DNA; Erythema; Humans; Hydralazine; Hydroxychloroquine; Injections, Intradermal; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Methotrexate; Methylprednisolone; Prednisone; Protein Binding; Skin Manifestations; Ultraviolet Rays | 1967 |
On very short wavelength electroretinography. An original technique of diagnosis in infraclinical synthetic antimalarial retinopathies.
Topics: Adult; Aged; Antimalarials; Chloroquine; Diagnosis, Differential; Electroretinography; Eye Diseases; Female; Humans; Hydroxychloroquine; Male; Methods; Middle Aged; Retina; Ultraviolet Rays | 1969 |
Inhibition of lipolytic processes in rat adipose tissue by antimalaria drugs.
Topics: Adipose Tissue; Animals; Antimalarials; Chloroquine; Epididymis; Fatty Acids; Heparin; Hydroxychloroquine; Lipid Metabolism; Male; Primaquine; Quinacrine; Quinidine; Quinine; Rats | 1969 |
Platelet reactions and immune processes. IV. The inhibition of complement by pyrazole compounds and other inhibitors of platelet reactions.
Topics: Animals; Blood Coagulation; Blood Platelets; Chloroquine; Complement Inactivator Proteins; Erythrocytes; Guinea Pigs; Hemolysis; Hydroxychloroquine; In Vitro Techniques; Inflammation; Oxyphenbutazone; Sheep; Sulfinpyrazone; Thrombosis | 1970 |
[Eye disorders caused by chloroquine and hydroxychloroquine].
Topics: Adult; Chloroquine; Color Perception Tests; Electrooculography; Eye Manifestations; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Vision Disorders | 1970 |
[Ocular changes caused by long-lasting use of chloroquine and its derivatives in rheumatoid disease].
Topics: Adult; Antimalarials; Arthritis, Rheumatoid; Chloroquine; Color Perception; Eye; Eye Manifestations; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Time Factors; Visual Acuity | 1970 |
[Treatment of juvenile rheumatoid arthritis with chloroquine phosphate and hydroxychloroquine sulphate. Dosage of syrup and tablets with determinations of serum concentrations].
Topics: Administration, Oral; Arthritis, Juvenile; Child; Child, Preschool; Chloroquine; Female; Humans; Hydroxychloroquine; Infant; Male; Solutions; Tablets | 1971 |
Acute cardiotoxicity of chloroquine and hydroxychloroquine in dogs.
Topics: Animals; Blood Pressure; Cardiac Output; Chloroquine; Dogs; Electrocardiography; Heart; Heart Rate; Hydroxychloroquine; Time Factors | 1971 |
Erythema dyschromicum perstans.
Topics: Adolescent; Adult; Biopsy; Blood Cell Count; Blood Sedimentation; Child, Preschool; Chloroquine; Erythema; Feces; Female; Humans; Hydroquinones; Hydroxychloroquine; Male; Middle Aged; Parasitic Diseases; Prednisone; Quinacrine; Steroids; Syphilis Serodiagnosis; Triamcinolone | 1968 |
Antimalarial treatment of rheumatoid arthritis.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Eye Diseases; Humans; Hydroxychloroquine; Retina | 1968 |
[Ophthalmic side effects of chloroquine in patients with rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Chloroquine; Cornea; Eye Diseases; Female; Humans; Hydroxychloroquine; Male | 1968 |
Polymorphic light eruption and possible chloroquine retinopathy.
Topics: Chloroquine; Chorioretinitis; Dermatitis; Female; Humans; Hydroxychloroquine; Middle Aged; Photosensitivity Disorders; Sunlight | 1968 |
[Supervision of the eyes during prolonged treatment with synthetic antimalarial drugs. Results in 237 patients followed up for 4 years on the average].
Topics: Antimalarials; Chloroquine; Corneal Opacity; Drug Tolerance; Electroretinography; Eye Diseases; Hydroxychloroquine; Ophthalmoscopy; Retina; Retinitis; Scotoma; Statistics as Topic; Visual Acuity; Visual Fields | 1968 |
Ocular toxicity of antimalarial drugs. Long-term follow-up.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Electrooculography; Electroretinography; Eye Diseases; Follow-Up Studies; Fundus Oculi; Humans; Hydroxychloroquine; Light; Lupus Erythematosus, Systemic; Macula Lutea; Middle Aged; Ophthalmoscopy; Quinacrine; Retinitis; Vision Tests; Visual Fields | 1968 |
Quinoline antimalarials. Folded chloroquine.
Topics: Animals; Antimalarials; Carrageenan; Chloroquine; Edema; Hydroxychloroquine; Mice; Piperidines; Quinolines | 1969 |
Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats.
Topics: Albinism; Animals; Blood; Chloroquine; Eye; Female; Hydroxychloroquine; Kidney; Liver; Lung; Male; Muscles; Myocardium; Pigmentation; Rats; Spleen | 1965 |
Gold therapy in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Chloroquine; Gold; Humans; Hydroxychloroquine; Indomethacin; Phenylbutazone | 1965 |
Two fatal poisonings by chloroquine and by hydroxychloroquine.
Topics: Adult; Chloroquine; Female; Humans; Hydroxychloroquine; Male | 1965 |
Antimalarial therapy and early retinal changes in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Chloroquine; Electrooculography; Eye Diseases; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retina; Retinal Pigments | 1966 |
Comparative effect of antirheumatic drugs on adjuvant-induced polyarthritis in rats.
Topics: Animals; Arthritis; Aspirin; Chloroquine; Hydroxychloroquine; Indomethacin; Male; Mycobacterium; Phenylbutazone; Prednisolone; Rats | 1966 |
[Therapy of chronic lupus erythematodes].
Topics: Chloroquine; Humans; Hydroxychloroquine; Injections, Intradermal; Lupus Erythematosus, Discoid; Prednisone; Triamcinolone | 1966 |
[Electroretinography in 83 patients treated with synthetic antimalarials].
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Chloroquine; Electroretinography; Eye Diseases; Female; Humans; Hydroxychloroquine; Male; Middle Aged | 1966 |
Erythema annulare centrifugum due to hydroxychloroquine sulfate and chloroquine sulfate.
Topics: Adult; Aged; Antimalarials; Chloroquine; Erythema; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Middle Aged; Prednisolone | 1967 |
Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat.
Topics: Animals; Chloroquine; Eye; Female; Hydroxychloroquine; Kidney; Liver; Lung; Male; Muscles; Myocardium; Rats; Spleen | 1967 |
Tissue distribution of chloroquine and hydroxychloroquine in rats.
Topics: Animals; Chloroquine; Female; Hydroxychloroquine; Male; Rats; Rats, Inbred Strains; Sex Characteristics; Time Factors; Tissue Distribution | 1982 |
The interaction between aminoquinolines and presynaptically acting neurotoxins.
Topics: Aminoquinolines; Animals; Antitoxins; Botulinum Toxins; Chickens; Chloroquine; Drug Interactions; Guinea Pigs; Hydroxychloroquine; Male; Mice; Neurotoxins; Rats; Rats, Inbred Strains; Synapses; Synaptic Transmission; Temperature; Time Factors | 1982 |
Use of synthetic antimalarial drugs and other agents for rheumatoid arthritis: historic and therapeutic perspectives.
Topics: Anti-Inflammatory Agents; Antimalarials; Antimetabolites; Antineoplastic Agents; Arthritis, Rheumatoid; Chloroquine; Drug Therapy, Combination; History, 20th Century; Humans; Hydroxychloroquine | 1983 |
The use of drugs in rheumatic diseases.
Topics: Analgesics; Anti-Inflammatory Agents; Aspirin; Aurothioglucose; Chloroquine; Colchicine; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Penicillamine; Prednisone; Rheumatic Diseases; Salicylates | 1984 |
Immunosuppressive potential of antimalarials.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Immunoglobulins; Immunosuppressive Agents; Interleukin-1; Lymphocyte Activation; Monocytes; T-Lymphocytes | 1983 |
Pharmacologic actions of 4-aminoquinoline compounds.
Topics: Aminoquinolines; Cell Membrane; Chloroquine; Exocytosis; Half-Life; Hemin; Humans; Hydroxychloroquine; Intracellular Membranes; Lysosomes; Phagocytes; Pigment Epithelium of Eye; Rheumatic Diseases; Tissue Distribution | 1983 |
The EOG in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Electrooculography; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Degeneration | 1983 |
[Routine monitoring of patients treated with synthetic antimalarials].
Topics: Aged; Chloroquine; Color Perception Tests; Electroretinography; Female; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxychloroquine; Macula Lutea; Male; Middle Aged; Retinal Diseases; Visual Acuity | 1983 |
Static perimetry in chloroquine retinopathy. Perifoveal patterns of visual field depression.
Topics: Adult; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Pigment Epithelium of Eye; Retinal Diseases; Visual Acuity; Visual Field Tests; Visual Fields | 1984 |
Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy.
Topics: Adult; Arthritis, Rheumatoid; Child; Chloroquine; Ciliary Body; Cornea; Drug Administration Schedule; Humans; Hydroxychloroquine; Macula Lutea; Ophthalmoscopy; Photoreceptor Cells; Retinal Diseases; Visual Fields | 1983 |
Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials.
Topics: Arthritis, Rheumatoid; Body Weight; Chloroquine; Drug Administration Schedule; Humans; Hydroxychloroquine; Kidney; Liver; Ophthalmoscopy; Retinal Diseases; Sunlight; Tissue Distribution | 1983 |
An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of today.
Topics: Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyclophosphamide; Female; Gold; Humans; Hydroxychloroquine; Levamisole; Macular Degeneration; Male; Neoplasms; Pancytopenia; Penicillamine; Risk | 1982 |
Simple and specific reversed-phase liquid chromatographic method with diode-array detection for simultaneous determination of serum hydroxychloroquine, chloroquine and some corticosteroids.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Chloroquine; Chromatography, High Pressure Liquid; Humans; Hydroxychloroquine; Reference Standards; Spectrophotometry, Ultraviolet | 1995 |
Antimalarial drug induced decrease in creatinine clearance.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chloroquine; Creatinine; Female; Gold; Humans; Hydroxychloroquine; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Penicillamine; Regression Analysis; Retrospective Studies | 1995 |
The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Topics: Adult; Aged; Chloroquine; Drug Combinations; Drug Tolerance; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Male; Middle Aged; Quinacrine; Vision Disorders | 1994 |
Antimalarials for control of disseminated granuloma annulare in children.
Topics: Child; Child, Preschool; Chloroquine; Female; Follow-Up Studies; Granuloma Annulare; Humans; Hydroxychloroquine; Male; Remission Induction | 1994 |
Simple and rapid HPLC of quinine, hydroxychloroquine, chloroquine, and desethylchloroquine in serum, whole blood, and filter paper-adsorbed dry blood.
Topics: Adsorption; Chloroquine; Chromatography, High Pressure Liquid; Humans; Hydroxychloroquine; Quinine; Sensitivity and Specificity; Specimen Handling | 1994 |
Antimalarials for children.
Topics: Adolescent; Child; Child, Preschool; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Prurigo; Sunlight | 1994 |
Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine.
Topics: Chloroquine; Humans; Hydroxychloroquine; Male; Stereoisomerism; Time Factors | 1993 |
Mechanism of action of hydroxychloroquine as an antirheumatic drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Autoimmunity; Chloroquine; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Major Histocompatibility Complex; Peptides; T-Lymphocytes | 1993 |
Kinetics of chloroquine uptake into isolated rat hepatocytes.
Topics: Animals; Biological Transport; Cell Membrane Permeability; Cells, Cultured; Chloroquine; Cytoplasm; Hydroxychloroquine; Kinetics; Liver; Lysosomes; Male; Mathematics; Models, Biological; Rats; Rats, Wistar | 1993 |
Enantioselective determination of hydroxychloroquine and its major metabolites in urine and the observation of a reversal in the (+)/(-)-hydroxychloroquine ratio.
Topics: Chloroquine; Chromatography, High Pressure Liquid; Humans; Hydroxychloroquine; Stereoisomerism | 1993 |
Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites.
Topics: Blood Proteins; Chloroquine; Humans; Hydroxychloroquine; Protein Binding; Stereoisomerism | 1993 |
Possible mechanisms of action of antimalarials in rheumatic disease.
Topics: Cells; Chloroquine; Humans; Hydroxychloroquine; Kinetics; Rheumatic Diseases | 1993 |
Screening for antimalarial toxicity.
Topics: Chloroquine; Color Perception Tests; Corneal Diseases; Humans; Hydroxychloroquine; Retinal Diseases; Vision Screening; Visual Field Tests; Visual Fields | 1993 |
Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid.
Topics: Adult; Antigens, Differentiation, B-Lymphocyte; Chloroquine; Cyclosporine; Drug Synergism; Graft vs Host Disease; Histocompatibility Antigens Class II; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lymphocyte Activation; T-Lymphocytes; Tetanus Toxoid | 1996 |
Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.
Topics: Adult; Arthritis, Rheumatoid; Cells, Cultured; Chloroquine; Humans; Hydroxychloroquine; Interferon-gamma; Interleukin-6; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Phytohemagglutinins; Tumor Necrosis Factor-alpha | 1997 |
Neurosarcoidosis: a personal perspective based on the study of 37 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Biopsy; Central Nervous System Diseases; Child; Chloroquine; Diagnostic Imaging; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Sarcoidosis; Treatment Outcome | 1997 |
[The therapy of systemic lupus erythematosus].
Topics: Antirheumatic Agents; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Diseases; Tablets | 1997 |
Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?
Topics: Animals; Cell Survival; Cells, Cultured; Chloroquine; Concanavalin A; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Histocompatibility Antigens Class II; Hydroxychloroquine; Interferon-gamma; Interleukin-2; Kinetics; Lymphocyte Activation; Lysosomes; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Minor Histocompatibility Antigens; Spleen; T-Lymphocytes | 1997 |
Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
Topics: Adult; Antimalarials; Chloroquine; Data Collection; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Pruritus; Water | 1998 |
Current concepts in monitoring patients on antimalarials.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Monitoring, Physiologic; Practice Guidelines as Topic; Retina; Retinal Diseases; Vision Tests; Visual Acuity; Visual Fields | 1998 |
Retinitis pigmentosa inversa.
Topics: Adult; Atrophy; Blindness; Chloroquine; Diagnosis, Differential; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Photoreceptor Cells, Vertebrate; Pigment Epithelium of Eye; Retinitis Pigmentosa; Scotoma; Visual Acuity; Visual Fields | 1998 |
Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement.
Topics: Adult; Antimalarials; Brain; Chloroquine; Female; Humans; Hydroxychloroquine; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Retrospective Studies; Sarcoidosis; Treatment Outcome | 1998 |
Long-term effectiveness of antimalarial drugs in rheumatic diseases.
Topics: Adult; Antimalarials; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Chloroquine; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Retrospective Studies; Rheumatic Diseases; Time Factors; Treatment Outcome | 1998 |
The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs.
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Cholesterol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucocorticoids; Humans; Hydroxychloroquine; Hypercholesterolemia; Lupus Erythematosus, Systemic; Prednisone; Retrospective Studies | 1999 |
An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Incidence; Male; Ophthalmology; Retinal Diseases; Risk Assessment | 1999 |
Porphyria cutanea tarda affecting lower lip.
Topics: Administration, Topical; Anti-Inflammatory Agents; Cheilitis; Chloroquine; Dermatologic Agents; Diagnosis, Differential; Humans; Hydrocortisone; Hydroxychloroquine; Lip Diseases; Male; Middle Aged; Porphyria Cutanea Tarda; Sunscreening Agents | 2000 |
Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?
Topics: Aged; Aminoquinolines; ATP-Binding Cassette Transporters; Chloroquine; Genetic Predisposition to Disease; Humans; Hydroxychloroquine; Mutation, Missense; Polymorphism, Genetic; Reference Values; Retina; Retinal Diseases | 2001 |
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases.
Topics: Antirheumatic Agents; Child; Child, Preschool; Chloroquine; Female; Humans; Hydroxychloroquine; Infant; Infant, Newborn; Male; Pregnancy; Prenatal Exposure Delayed Effects; Retinitis Pigmentosa; Rheumatic Diseases; Visual Acuity | 2001 |
Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.
Topics: Aged; Antirheumatic Agents; Chloroquine; Dermatologic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Male; Middle Aged; Retina; Retinal Diseases; Retrospective Studies; Scotoma; Visual Acuity; Visual Fields | 2002 |
[Eye toxicity of antimalarial agents].
Topics: Adult; Antimalarials; Chloroquine; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2002 |
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Ophthalmology; Practice Guidelines as Topic; Retina; Retinal Diseases; United States | 2002 |
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Eye Diseases; Gastrointestinal Diseases; Humans; Hydroxychloroquine; Logistic Models; Multicenter Studies as Topic; Oxidation-Reduction; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index | 2002 |
Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells.
Topics: Animals; Cattle; Cells, Cultured; Chloroquine; Epithelial Cells; Hydroxychloroquine; Lipofuscin; Lysosomes; Pigment Epithelium of Eye; Quantitative Structure-Activity Relationship | 2002 |
[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hydroxychloroquine; Immunosuppressive Agents; Isoxazoles; Leflunomide; Methotrexate; Placebos; Prednisolone; Randomized Controlled Trials as Topic; Sulfasalazine; Time Factors | 2003 |
New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy.
Topics: Academies and Institutes; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Mass Screening; Practice Guidelines as Topic; Retina; Retinal Diseases | 2003 |
Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties.
Topics: Animals; Chemical Phenomena; Chemistry, Physical; Chloroquine; Drug Resistance; Humans; Hydroxychloroquine; Plasmodium falciparum | 2003 |
Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort.
Topics: Adult; Antimalarials; Antirheumatic Agents; Chloroquine; Cohort Studies; Drug Monitoring; Female; Guideline Adherence; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Outpatient Clinics, Hospital; Retinal Diseases | 2003 |
The treatment of acute malaria with single oral doses of amodiaquin, chloroquine, hydroxychloroquine and pyrimethamine.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Malaria; Pyrimethamine | 1954 |
Discoid lupus erythematosus treated with plaquenil.
Topics: Chloroquine; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic | 1956 |
Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report.
Topics: Chloroquine; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic | 1956 |
Plaquenil in the treatment of lupus erythematosus.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1956 |
Plaquenil sulfate in treatment of lupus erythematosus and light-sensitivity eruptions.
Topics: Chloroquine; Exanthema; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Sulfates; Sunlight | 1957 |
Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthitis.
Topics: Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine | 1957 |
Treatment of chronic lupus erythematosus: effectiveness of plaquenil and APA (Aralen 65 mg., plaquenil 50 mg., Atabrine 25 mg.) as compared with Aralen, with observations on side-reactions and toxicity; report and presentation of unusual cases.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1958 |
Plaquenil in the treatment of cutaneous lupus erythematosus.
Topics: Chloroquine; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic | 1958 |
Chloroquine and hydroxychloroquine in the treatment of cardiac arrhythmias.
Topics: Arrhythmias, Cardiac; Chloroquine; Humans; Hydroxychloroquine | 1958 |
Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1959 |
[Hydroxychloroquine sulfate in chronic lupus erythematosus (discoid)].
Topics: Chloroquine; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic | 1958 |
The burning skin syndrome: treatment with hydroxychloroquine.
Topics: Chloroquine; Dermatology; Humans; Hydroxychloroquine; Musculoskeletal Diseases; Pain; Paresthesia; Syndrome | 1960 |
[Hydroxychloroquine in the treatment of chronic erythematosus].
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1961 |
Aralen and plaquenil in treatment of the common wart.
Topics: Chloroquine; Hydroxychloroquine; Papilloma; Warts | 1961 |
Hepatic amebiasis treated with plaquenil: case report.
Topics: Amebiasis; Chloroquine; Hydroxychloroquine; Liver Abscess, Amebic; Liver Diseases; North Carolina | 1960 |
[Treatment of chronic lupus erythematosus with hydroxychloroquine].
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1961 |
Amodiaquine and hydroxychloroquine resistance in Plasmodium falciparum.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Malaria; Plasmodium falciparum | 1961 |
Hydroxychloroquine (plaquenil) in the treatment of lupus erythematosus.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1959 |
An overdose of "plaquenil".
Topics: Chloroquine; Drug Overdose; Humans; Hydroxychloroquine | 1960 |
[Plaquenil treatment of discord lupus erythematosus and polymorphous photodermatitis].
Topics: Chloroquine; Dermatitis; Hydroxychloroquine; Lupus Erythematosus, Systemic; Photosensitivity Disorders | 1960 |
[Hydroxychloroquine in intermittent claudication].
Topics: Chloroquine; Humans; Hydroxychloroquine; Intermittent Claudication | 1962 |
Hydroxychloroquine sulfate ("plaguenil") in treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine | 1962 |
Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Hydroxychloroquine | 1962 |
[Evaluation of antimalarials for rheumatoid arthritis].
Topics: Amodiaquine; Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine | 1962 |
[Chloroquine and hydroxychloroquine in the therapy of arrhythmia due to fibrillation].
Topics: Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Chloroquine; Heart Conduction System; Humans; Hydroxychloroquine | 1963 |
[Treatment of discoid lupus erythematosus, polymorphous photodermatosis and rosacea with Triquin--a combination of 3 anti-malarials].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Photosensitivity Disorders; Quinacrine; Rosacea | 1962 |
[The treatment of rheumatoid polyarthritis by synthetic antimalarials].
Topics: Amodiaquine; Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine | 1962 |
[Antimalarials in rheumatology].
Topics: Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Collagen Diseases; Humans; Hydroxychloroquine; Rheumatology | 1963 |
PIGMENTATION FROM ANTIMALARIAL THERAPY. ITS POSSIBLE RELATIONSHIP TO THE OCULAR LESIONS.
Topics: Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Cornea; Eye; Eye Manifestations; Histocytochemistry; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Photomicrography; Pigmentation; Pigmentation Disorders; Quinacrine; Retina; Toxicology | 1963 |
THE SIDE-EFFECTS OF CHLOROQUINE AND HYDROXYCHLOROQUINE: RESULTS OF A COMPARATIVE STUDY IN VIVO.
Topics: Chloroquine; Dermatology; Hydroxychloroquine; Toxicology | 1963 |
MANAGEMENT OF RHEUMATOID ARTHRITIS IN THE ELDERLY PATIENT.
Topics: Adrenal Cortex Hormones; Aged; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Gastrointestinal Hemorrhage; Geriatrics; Gold; Humans; Hydroxychloroquine; Prognosis; Rehabilitation; Rest; Social Work; Surgical Procedures, Operative; Toxicology | 1963 |
INFLAMMATORY POLYARTHRITIC DISEASE. II. THE MANAGEMENT OF RHEUMATOID ARTHRITIS.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Cortisone; Exercise Therapy; Humans; Hydroxychloroquine; Iron; Rest; Toxicology | 1963 |
[NEW CONCEPTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Chloroquine; Hydroxychloroquine; Isocarboxazid; Mechlorethamine; Monoamine Oxidase Inhibitors; Nialamide; Phenelzine; Phenylbutazone; Quinolines | 1963 |
CHEMOTHERAPY OF ARTHRITIS INDUCED IN RATS BY MYCOBACTERIAL ADJUVANT.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Aspirin; Betamethasone; Chloroquine; Cortisone; Dexamethasone; Humans; Hydroxychloroquine; Male; Mycobacterium; Paramethasone; Phenylbutazone; Prednisolone; Rats; Research; Salicylates; Sodium Salicylate | 1963 |
POLYMORPHOUS LIGHT ERUPTION. A TEN-YEAR FOLLOW-UP AND EVALUATION.
Topics: Chloroquine; Dermatitis, Phototoxic; Follow-Up Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Photosensitivity Disorders; Prurigo; Quinacrine; Seasons; Sunlight | 1963 |
ANTIMALARIAL DRUGS ON THE AUTOMATICITY OF SINO-AURICULAR AND ATRIO-VENTRICULAR NODES.
Topics: Administration, Intravenous; Amodiaquine; Animals; Anti-Arrhythmia Agents; Antimalarials; Atrioventricular Node; Atropine; Chloroquine; Dogs; Heart Conduction System; Humans; Hydroxychloroquine; Hypotension; Injections, Intravenous; Primaquine; Quinacrine; Quinidine; Research; Statistics as Topic | 1963 |
[TREATMENT OF COLLAGEN DISEASES].
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Collagen Diseases; Dermatomyositis; Dexamethasone; Edetic Acid; Gold; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Polyarteritis Nodosa; Prednisolone; Prednisone; Scleroderma, Systemic; Splenectomy; Toxicology; Triamcinolone | 1963 |
[ALBUMINURIAS].
Topics: Adolescent; Albuminuria; Chloroquine; Humans; Hydroxychloroquine | 1963 |
[CHRONIC DISCOID ERYTHEMATOSUS (REPORT ON 69 CASES OVER A PERIOD OF 6 YEARS FROM THE VIEWPOINT OF OPTIMUM THERAPY)].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1963 |
HAEMATOLOGICAL SIDE-EFFECTS OF SOME ANTI-RHEUMATIC DRUGS.
Topics: Aminopyrine; Antirheumatic Agents; Aspirin; Blood Platelets; Chloroquine; Colchicine; Complement Fixation Tests; Drug Hypersensitivity; Gold; Humans; Hydroxychloroquine; Meprobamate; Phenacetin; Phenylbutazone; Probenecid; Purpura; Purpura, Thrombocytopenic; Quinacrine; Rheumatic Diseases; Splenectomy; Toxicology | 1963 |
ANTIMALARIALS AND OTHER ANTICONVULSANT DRUGS: PREDICTIVE VALIDITY OF LABORATORY TESTS.
Topics: Animals; Anticonvulsants; Antimalarials; Chloroquine; Electric Stimulation; Hydroxychloroquine; Mice; Pentylenetetrazole; Pharmacology; Phenobarbital; Phenytoin; Quinacrine; Research; Seizures | 1964 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND.
Topics: Amodiaquine; Antimalarials; Asia, Southeastern; Biomedical Research; Chloroquine; Drug Resistance; Drug Resistance, Microbial; Humans; Hydroxychloroquine; Malaria; Malaria, Falciparum; Pharmacology; Plasmodium falciparum; Proguanil; Pyrimethamine; Quinacrine; Quinine; Thailand | 1964 |
USE OF DRUGS IN THE TREATMENT OF RHEUMATOID ARTHRITIS.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Codeine; Humans; Hydroxychloroquine; Methadone; Morphine; Oxyphenbutazone; Phenylbutazone; Toxicology | 1964 |
SYSTEMIC LUPUS ERYTHEMATOSUS: TREATMENT WITH ANTIMALARIAL DRUGS.
Topics: Antimalarials; Chloroquine; Dexamethasone; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Methylprednisolone; Prednisone; Triamcinolone | 1964 |
PAINFUL SUBCUTANEOUS HEMORRHAGES OF THE EXTREMITIES WITH UNUSUAL REACTION TO INJECTED DEOXYRIBONUCLEIC ACID.
Topics: Adolescent; Chloroquine; DNA; Drug Therapy; Hematoma; Hydroxychloroquine; Injections; Knee; Pain; Primaquine; Skin Tests; Toxicology | 1964 |
LYMPHOCYTIC INFILTRATION OF THE SKIN.
Topics: Black People; Chloroquine; Dermatology; Diagnosis, Differential; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lymphocytosis; Pathology; Penicillin V; Penicillins; Photosensitivity Disorders | 1964 |
CHILBLAIN LUPUS ERYTHEMATOSUS.
Topics: Chilblains; Chloroquine; Fluocinolone Acetonide; Frostbite; Humans; Hydroxychloroquine; Hypothyroidism; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Niacinamide; Quinacrine; Telangiectasis; Triamcinolone | 1964 |
THE VALUE AND DANGERS OF ANTIMALARIAL THERAPY IN ARTHRITIS WITH SPECIAL RELATION TO OPHTHALMIC COMPLICATIONS.
Topics: Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Corneal Opacity; Electroretinography; Eye; Eye Diseases; Gold; Humans; Hydroxychloroquine; Retina; Toxicology | 1964 |
[TREATMENT OF ANKYLOSING SPONDYLARTHRITIS].
Topics: Adrenal Cortex Hormones; Aspirin; Chloroquine; Drug Therapy; Exercise Therapy; Humans; Hydroxychloroquine; Orthopedics; Phenylbutazone; Radiotherapy; Spondylitis; Spondylitis, Ankylosing; Surgical Procedures, Operative | 1964 |
[EVALUATION OF LONG-TERM THERAPY WITH CHLOROQUINE AND HYDROXYCHLOROQUINE IN RHEUMATOLOGY].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Drug Therapy; Humans; Hydrarthrosis; Hydroxychloroquine; Lupus Erythematosus, Systemic; Multiple Sclerosis; Myositis; Rheumatology; Spondylitis; Spondylitis, Ankylosing | 1964 |
[RESEARCH ON THE ANTIFUNGAL ACTION IN VITRO OF HYDROXYCHLOROQUINE SULFATE].
Topics: Antifungal Agents; Chloroquine; Fungi; Gentisates; Hydroxychloroquine; In Vitro Techniques; Pharmacology; Phosphates; Research; Sulfates | 1964 |
[OUR PRESENT EXPERIENCE IN DIAGNOSIS AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS].
Topics: Adolescent; Adrenocorticotropic Hormone; Aspirin; Chloroquine; Cortisone; Diagnosis; Drug Therapy; Hydroxychloroquine; Lupus Erythematosus, Systemic; Neutrophils | 1964 |
DISCOID LUPUS ERYTHEMATOSUS. IS SYSTEMIC TREATMENT NECESSARY?
Topics: Bandages; Chloroquine; Drug Therapy; Fluocinolone Acetonide; Humans; Hydrocortisone; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Toxicology; Triamcinolone Acetonide | 1965 |
The treatment of malaria with hydroxychloroquine.
Topics: Chloroquine; Hydroxychloroquine; Malaria | 1955 |
Amodiaquine and hydroxychloroquine in rheumatoid arthritis.
Topics: Amodiaquine; Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine | 1959 |
[The treatment of inflammatory rheumatism by antimalarials (chloroquine and hydroxychloroquine)].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Rheumatic Diseases; Rheumatic Fever | 1960 |
Mass suppression of hyperendemic vivax malaria with hydroxychloroquine.
Topics: Chloroquine; Humans; Hydroxychloroquine; Malaria; Malaria, Vivax | 1960 |
[Studies on bronchial asthma therapy using quinoline derivatives. On results of orotic acid-chloroquine therapy].
Topics: Anti-Infective Agents, Local; Asthma; Chloroquine; Dermatologic Agents; Hydroxychloroquine; Hydroxyquinolines; Orotic Acid; Proguanil | 1961 |
Chloroquine-induced retinal toxicity.
Topics: Antimalarials; Blindness; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases; South Africa | 2004 |
[Analysis of 925 patients on long-term hydroxychloroquine or chloroquine treatment: results of ophthalmological screening].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Sarcoidosis; Vision Tests | 2004 |
[Systemic lupus erythematosus therapy. Antimalarials in inflammatory diseases].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Quinacrine | 2004 |
Chloroquine-induced retinal toxicity.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases | 2005 |
[Ophthalmologic prevention of chloroquine and hydroxychloroquine induced retinopathy].
Topics: Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Diseases; Retrospective Studies | 2005 |
Blue-yellow perimetry can be an early detector of hydroxychloroquine and chloroquine retinopathy.
Topics: Antimalarials; Chloroquine; Color Vision Defects; Humans; Hydroxychloroquine; Retina; Visual Field Tests | 2005 |
Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.
Topics: Adult; Aged; Antimalarials; Antirheumatic Agents; Biopsy; Chloroquine; Clinical Enzyme Tests; Electromyography; Enzymes; Epidemiologic Methods; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Rheumatic Diseases | 2006 |
New insights into the antiviral effects of chloroquine.
Topics: Anti-HIV Agents; Antimalarials; Antiviral Agents; Chloroquine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; HIV Infections; HIV-1; Humans; Hydroxychloroquine; Severe Acute Respiratory Syndrome; Treatment Outcome; Viral Load; Virus Replication | 2006 |
Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease.
Topics: Acute Disease; Adult; Antirheumatic Agents; Chemical and Drug Induced Liver Injury; Chloroquine; Female; Humans; Hydroxychloroquine; Mixed Connective Tissue Disease | 2007 |
[Beneficial effects of antimalarials in the treatment of generalized granuloma annular in children].
Topics: Antimalarials; Child; Chloroquine; Female; Granuloma Annulare; Humans; Hydroxychloroquine; Male | 2006 |
[Long-term results of treatment and prediction in patients with sarcoidosis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Indomethacin; Male; Middle Aged; Prospective Studies; Sarcoidosis, Pulmonary; Severity of Illness Index; Time Factors | 2006 |
Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Diagnostic Imaging; Electroretinography; Female; Fluorescein Angiography; Fluorescence; Fundus Oculi; Humans; Hydroxychloroquine; Male; Middle Aged; Ophthalmoscopy; Retinal Diseases | 2006 |
[Severe chloroquine- and hydroxychloroquine-induced retinopathy].
Topics: Aged; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Diseases; Severity of Illness Index | 2006 |
Chloroquine/hydroxychloroquine-induced pemphigus.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Middle Aged; Pemphigus | 2006 |
[Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Azathioprine; Child; Chloroquine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroretinography; Female; Fundus Oculi; Humans; Hydroxychloroquine; Long-Term Care; Lupus Erythematosus, Systemic; Macula Lutea; Male; Middle Aged; Ophthalmoscopy; Prednisolone; Retina; Retinal Diseases; Visual Fields | 2007 |
Stereoselective determination of hydroxychloro-quine and its major metabolites in human urine by solid-phase microextraction and HPLC.
Topics: Calibration; Chemistry Techniques, Analytical; Chloroquine; Chromatography; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Methanol; Models, Chemical; Reproducibility of Results; Solid Phase Extraction; Stereoisomerism; Temperature; Time Factors | 2007 |
Severe, reversible dysphagia from chloroquine and hydroxychloroquine myopathy.
Topics: Aged, 80 and over; Antirheumatic Agents; Chloroquine; Deglutition Disorders; Humans; Hydroxychloroquine; Laryngeal Muscles; Male; Muscle, Skeletal; Muscular Diseases; Pharynx; Scleroderma, Localized; Tongue Diseases | 2007 |
Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases.
Topics: Adult; Antirheumatic Agents; Chloroquine; Connective Tissue Diseases; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Smoking | 2007 |
The treatment of amoebic liver abscess with chloroquine.
Topics: Amebiasis; Chloroquine; Humans; Hydroxychloroquine; Liver; Liver Abscess, Amebic; Quinolines | 1949 |
Mass suppression with chloroquine; chloroquine and pentaquine; and neopremaline.
Topics: Aminoquinolines; Chloroquine; Humans; Hydroxychloroquine; Quinolines | 1949 |
Successful treatment of necrobiosis lipoidica with antimalarial agents.
Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Middle Aged; Necrobiosis Lipoidica; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2008 |
Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
Topics: Adolescent; Adult; Aged; Antimalarials; Biopsy; Child; Chloroquine; Disease Progression; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Lupus Nephritis; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Spain | 2008 |
Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Inflammation; Informed Consent; Lupus Erythematosus, Systemic; Retinal Diseases; Risk Assessment; Risk Factors; Skin Diseases | 2007 |
Chloroquine psychosis masquerading as PCP: a case report.
Topics: Adolescent; Antimalarials; Catatonia; Chloroquine; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Medication Errors; Phencyclidine; Phencyclidine Abuse; Psychoses, Substance-Induced; Substance Abuse Detection | 2008 |
Lysosomotropic drugs inhibit maturation of transforming growth factor-beta.
Topics: Amodiaquine; Animals; Azithromycin; Blotting, Western; Bronchoalveolar Lavage Fluid; Cell Line; Cell Line, Tumor; Chloroquine; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Furin; Humans; Hydroxychloroquine; Kinetics; Lysosomes; Mice; Mice, Inbred C57BL; Phosphorylation; Stem Cells; Transforming Growth Factor beta | 2008 |
Chloroquine.
Topics: Chloroquine; Dermatologic Agents; Hydroxychloroquine; Hydroxyquinolines | 1948 |
On the antimalarial activity of nivaquine C.
Topics: Antimalarials; Chloroquine; Hydroxychloroquine; Quinolines | 1947 |
Growth inhibitory and differentiation effects of chloroquine and its analogue on human leukemic cells potentiate fetal hemoglobin production by targeting the polyamine pathway.
Topics: Arginase; Cell Differentiation; Chloroquine; Drug Delivery Systems; Drug Synergism; Fetal Hemoglobin; Growth Inhibitors; Humans; Hydroxychloroquine; K562 Cells; Leukemia, Erythroblastic, Acute; Polyamines; Signal Transduction | 2009 |
[Antimalarial's retinopaty remains a current threat].
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Cohort Studies; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Hydroxychloroquine; Long-Term Care; Lupus Erythematosus, Systemic; Macula Lutea; Malaria; Middle Aged; Retinal Diseases; Retrospective Studies; Vision Disorders | 2009 |
The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine.
Topics: Antimalarials; Chloroquine; Drug Interactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Proton Pump Inhibitors | 2009 |
Short report: chloroquine-resistant Plasmodium vivax in the Republic of Korea.
Topics: Adult; Aged; Animals; Antimalarials; Chloroquine; Drug Resistance; Female; Humans; Hydroxychloroquine; Korea; Malaria, Vivax; Male; Plasmodium vivax; Treatment Failure | 2009 |
Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR.
Topics: Antimalarials; Chloroquine; Chromatography, High Pressure Liquid; Drug Contamination; Hydroxychloroquine; Indicators and Reagents; Magnetic Resonance Spectroscopy; Mass Spectrometry; Spectrometry, Mass, Electrospray Ionization | 2009 |
Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
Topics: Adult; Aged; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Smoking; Treatment Outcome | 2009 |
Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Macula Lutea; Male; Middle Aged; Nerve Fibers; Retinal Diseases; Retinal Ganglion Cells; Tomography, Optical Coherence | 2010 |
Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
Topics: Acetylation; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Cellular Senescence; Chloroquine; Enzyme Inhibitors; Female; HeLa Cells; Histone Acetyltransferases; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Hydroxychloroquine; Ki-67 Antigen; Mass Spectrometry; Tretinoin; Tumor Stem Cell Assay | 2009 |
Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Hydroxychloroquine; Korea; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaquine; Young Adult | 2009 |
Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study.
Topics: Adolescent; Adult; Aged; Antimalarials; Arthritis, Rheumatoid; Chi-Square Distribution; Chloroquine; Connective Tissue Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Malaria; Male; Middle Aged; Ophthalmoscopy; Retinal Diseases; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Sjogren's Syndrome; Time Factors; Turkey; Vision, Ocular; Visual Field Tests; Young Adult | 2010 |
[The ERG contribution in early diagnosis of chloroquine and hydroxychloroquine maculopathy].
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Macula Lutea; Middle Aged; Retinal Diseases | 2010 |
Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Dose-Response Relationship, Drug; Electroretinography; Female; Humans; Hydroxychloroquine; Long-Term Care; Male; Middle Aged; Retina; Retinal Diseases; Retrospective Studies; Risk Factors; Visual Fields; Young Adult | 2010 |
Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Disease Progression; Drug Therapy, Combination; Electroretinography; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Middle Aged; Retina; Retinal Diseases; Risk Factors; Tomography, Optical Coherence; Vision Disorders; Visual Field Tests; Visual Fields | 2011 |
Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.
Topics: Academies and Institutes; Age Factors; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological; Electroretinography; Fluorescein Angiography; Humans; Hydroxychloroquine; Ophthalmology; Retina; Retinal Diseases; Risk Assessment; Tomography, Optical Coherence; United States | 2011 |
Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis.
Topics: Antimalarials; Chloroquine; Drug Resistance; Humans; Hydroxychloroquine; Malaria, Vivax; Multidrug Resistance-Associated Proteins; Plasmodium vivax; Polymorphism, Genetic; Primaquine; Protozoan Proteins; Republic of Korea | 2011 |
Chloroquine and hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Vision Disorders | 2011 |
Prophylactic use of antimalarials during pregnancy.
Topics: Antimalarials; Atovaquone; Chemoprevention; Chloroquine; Doxycycline; Drug Combinations; Female; Humans; Hydroxychloroquine; Malaria; Mefloquine; Pregnancy; Pregnancy Complications, Parasitic; Primaquine; Proguanil; Travel | 2011 |
Targeting autophagy addiction in cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Chloroquine; Genes, ras; Humans; Hydroxychloroquine; Mice; Neoplasms; Signal Transduction | 2011 |
Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Color Perception Tests; Diagnostic Techniques, Ophthalmological; Early Diagnosis; Electroretinography; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Middle Aged; Ophthalmoscopy; Retina; Retinal Diseases; Rheumatic Diseases; Visual Acuity; Visual Field Tests | 2012 |
Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells.
Topics: Antimalarials; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chloroquine; Drug Discovery; Humans; Hydroxychloroquine; Pancreatic Neoplasms; Receptors, CXCR4 | 2012 |
Fatal antimalarial-induced cardiomyopathy: report of 2 cases.
Topics: Adult; Antimalarials; Arthritis, Rheumatoid; Cardiomyopathies; Chloroquine; Fatal Outcome; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged | 2012 |
Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Cohort Studies; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Diseases; Risk Factors; Turkey; Young Adult | 2013 |
LC3 and p62 as diagnostic markers of drug-induced autophagic vacuolar cardiomyopathy: a study of 3 cases.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antimalarials; Autophagy; Biomarkers; Cardiomyopathies; Chloroquine; Diagnostic Errors; Fatal Outcome; Female; Humans; Hydroxychloroquine; Microtubule-Associated Proteins; Middle Aged; Sequestosome-1 Protein; Vacuoles | 2013 |
Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide.
Topics: 6-Aminonicotinamide; Animals; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Caspase 1; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cellular Reprogramming; Chloroquine; Enzyme Inhibitors; Glucose; Hydroxychloroquine; Lysosomal-Associated Membrane Protein 2; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred A; Mice, Transgenic; Microtubule-Associated Proteins; Mitochondria; Multiprotein Complexes; NF-kappa B; Oxygen Consumption; Pentose Phosphate Pathway; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction; Teratogens; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2014 |
Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report.
Topics: Adult; Antimalarials; Bipolar Disorder; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Male | 2014 |
The treatment of Plasmodium falciparum malaria with a single dose antimalarial; a preliminary report of the use of hydroxychloroquine, 7-chloro-4(4-(N-ethyl-N-B-hydroxyethylamino)-1-methylbutylamino)-quinoline diphosphate.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Malaria; Malaria, Falciparum; Quinolines | 1952 |
RE: Microperimetry and the diagnosis of antimalarial maculopathy.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retina; Retinal Diseases; Visual Field Tests; Visual Fields | 2014 |
RE: Author reply:.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retina; Retinal Diseases; Visual Field Tests; Visual Fields | 2014 |
Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.
Topics: Aged; Ambulatory Care; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Color Perception Tests; Diagnostic Techniques, Ophthalmological; Electroretinography; Female; Fluorescein Angiography; Guideline Adherence; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Physical Examination; Practice Guidelines as Topic; Retinal Diseases; Visual Fields | 2014 |
The effects of chloroquine and hydroxychloroquine on nitric oxide production in RAW 264.7 and bone marrow-derived macrophages.
Topics: Animals; Bone Marrow Cells; Cell Survival; Chloroquine; Hydroxychloroquine; Macrophages; Mice; Nitric Oxide; Nitrites | 2014 |
Hydroxychloroquine and the retina.
Topics: Ambulatory Care; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases | 2015 |
Chloroquine and Hydroxychloroquine Increase Retinal Pigment Epithelial Layer Permeability.
Topics: Antimalarials; Blood-Retinal Barrier; Chloroquine; Claudin-1; Gene Expression Regulation; Humans; Hydroxychloroquine; Occludin; Permeability; Retinal Pigment Epithelium; RNA, Messenger; Tight Junctions | 2015 |
Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Smoking | 2015 |
Smoking enhances Toll-like receptor-9 responsiveness and type I interferon production in plasmacytoid dendritic cells in patients with cutaneous lupus erythematosus.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Smoking | 2015 |
Chloroquine and Hydroxychloroquine Are Novel Inhibitors of Human Organic Anion Transporting Polypeptide 1A2.
Topics: Adult; Aged; Cells, Cultured; Chloroquine; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Hydroxychloroquine; Middle Aged; Organic Anion Transporters | 2016 |
Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Chloroquine; Drug Eruptions; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retrospective Studies; Risk Assessment; Skin Tests; Young Adult | 2015 |
Evaluation of a follow-up protocol for patients on chloroquine and hydroxychloroquine treatment.
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Middle Aged; Retina; Retinal Diseases; Retrospective Studies; Tomography, Optical Coherence; Visual Fields | 2016 |
[Multimodal imaging of hydroxychloroquine and chloroquine retinopathy].
Topics: Adult; Atrophy; Chloroquine; Diagnostic Techniques, Ophthalmological; Drug Substitution; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Macula Lutea; Multimodal Imaging; Radiography; Retinal Diseases | 2016 |
Unilateral unique Lupus tumidus: pathogenetic mystery and diagnostic problem.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Biopsy; Chloroquine; Combined Modality Therapy; Dapsone; Diagnosis, Differential; Humans; Hydroxychloroquine; Lasers, Dye; Lupus Erythematosus, Discoid; Male; Ointments; Quinacrine; Skin; Sunscreening Agents; Tacrolimus | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinography; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Maximum Allowable Concentration; Middle Aged; Ophthalmology; Retinal Diseases; Risk Factors; Tomography, Optical Coherence; United States; Vision Disorders; Visual Acuity; Visual Field Tests; Visual Fields | 2016 |
Lysosomotropic cationic drugs induce cytostatic and cytotoxic effects: Role of liposolubility and autophagic flux and antagonism by cholesterol ablation.
Topics: Amiodarone; Anticholesteremic Agents; Autophagy; beta-Cyclodextrins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chloroquine; Cholesterol; Cytostatic Agents; Cytotoxins; Human Umbilical Vein Endothelial Cells; Humans; Hydroxychloroquine; Lidocaine; Lovastatin; Lysosomes; Microtubule-Associated Proteins; Poly (ADP-Ribose) Polymerase-1; Procainamide; Quinacrine | 2016 |
Cross-Reactivity of Chloroquine and Hydroxychloroquine With DRI Amphetamine Immunoassay.
Topics: Adolescent; Amphetamine; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Cross Reactions; Female; Humans; Hydroxychloroquine; Immunoassay; Substance Abuse Detection | 2017 |
Re: Marmor et al.: American Academy of Ophthalmology Statement: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). (Ophthalmology 2016;123:1386-1394).
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Ophthalmology; Retinal Diseases; United States | 2017 |
Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; DNA Fragmentation; Humans; Hydroxychloroquine; MCF-7 Cells; Poly(ADP-ribose) Polymerases; Urinary Bladder Neoplasms | 2017 |
Antimalarial drug retinopathy: A typical « Bull's eyes » appearance of fundus.
Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Monitoring, Physiologic; Prognosis; Retinal Diseases; Risk Assessment; Time Factors | 2018 |
Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
Topics: Adult; Antirheumatic Agents; Chloroquine; Female; Health Status; Humans; Hydroxychloroquine; Immunosuppressive Agents; Italy; Lupus Erythematosus, Systemic; Male; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Risk Factors; Self-Assessment; Severity of Illness Index; Treatment Adherence and Compliance | 2018 |
ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Autophagy; Cell Line, Tumor; Chloroquine; DNA Damage; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Hydroxychloroquine; Lysosomes; Mice, Nude; Reactive Oxygen Species; Reproducibility of Results; Retinal Dehydrogenase; Transcription Factors | 2017 |
Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Topics: Adult; Age Factors; Antimalarials; Chloroquine; Cohort Studies; Databases, Factual; Dermatomyositis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Incidence; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Sex Factors; Treatment Outcome | 2018 |
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Chloroquine; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; France; Hospitals, University; Humans; Hydroxychloroquine; Kaplan-Meier Estimate; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Failure; Young Adult | 2018 |
Chloroquine Autophagic Inhibition Rebalances Th17/Treg-Mediated Immunity and Ameliorates Systemic Lupus Erythematosus.
Topics: Adult; Animals; Antimalarials; Autophagy; Cells, Cultured; Chloroquine; Female; Humans; Hydroxychloroquine; Interferon-gamma; Interleukin-17; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred MRL lpr; Microtubule-Associated Proteins; T-Lymphocytes, Regulatory; Th17 Cells; Transforming Growth Factor beta; Young Adult | 2017 |
More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.
Topics: Adult; Antimalarials; Chi-Square Distribution; Chloroquine; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Linear Models; Logistic Models; Longitudinal Studies; Lupus Erythematosus, Systemic; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Poisson Distribution; Prognosis; Prospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2018 |
Requirement for retinal screening in patients taking hydroxychloroquine and chloroquine.
Topics: Adolescent; Antirheumatic Agents; Chloroquine; Humans; Hydroxychloroquine; Mass Screening; Retinal Diseases | 2018 |
[Antimalarial drug retinopathy].
Topics: Adult; Antimalarials; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Retinal Diseases; Tomography, Optical Coherence; Vision Disorders | 2018 |
Monitoring for retinal toxicity in patients taking hydroxychloroquine and chloroquine.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Mass Screening; Practice Guidelines as Topic; Retinal Diseases; Rheumatology | 2019 |
[Variability of chloroquine and hydroxychloroquine retinopathy among various ethnicities].
Topics: Antirheumatic Agents; Asian People; Chloroquine; Delayed Diagnosis; Early Diagnosis; Electroretinography; Ethnicity; Genetic Predisposition to Disease; Humans; Hydroxychloroquine; Macula Lutea; Optical Imaging; Retina; Retinal Diseases; Tomography, Optical Coherence; Visual Field Tests; Visual Fields; White People | 2018 |
Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps.
Topics: Adenocarcinoma; Animals; Chloroquine; DNA; Extracellular Traps; Female; Humans; Hydrolases; Hydroxychloroquine; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Platelet Aggregation; Protein-Arginine Deiminase Type 4; Receptor for Advanced Glycation End Products; Thrombelastography; Thrombophilia; Thromboplastin; Venous Thromboembolism | 2018 |
Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion.
Topics: Animals; Autophagosomes; Autophagy; Cell Line, Tumor; Chloroquine; Endocytosis; Endosomes; ErbB Receptors; Female; Golgi Apparatus; Humans; Hydroxychloroquine; Lysosomes; Macrolides; Membrane Fusion; Mice, Inbred C57BL; Proteolysis; Sequestosome-1 Protein | 2018 |
Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
Topics: Adult; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Longitudinal Studies; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Male; Middle Aged; Retrospective Studies; Rome; Time Factors; Treatment Outcome | 2018 |
Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer's disease: a population-based cohort study.
Topics: Alzheimer Disease; Antirheumatic Agents; Chloroquine; Chronic Disease; Connective Tissue Diseases; Databases, Factual; Humans; Hydroxychloroquine; Prospective Studies; United Kingdom | 2019 |
Type IV allergy to antimalarials can mimic cutaneous manifestations of lupus erythematosus.
Topics: Adult; Antimanic Agents; Chloroquine; Drug Eruptions; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2019 |
Response to: 'Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer's disease' by Lee.
Topics: Alzheimer Disease; Chloroquine; Cohort Studies; Connective Tissue Diseases; Humans; Hydroxychloroquine | 2019 |
Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer's disease.
Topics: Alzheimer Disease; Chloroquine; Cohort Studies; Connective Tissue Diseases; Humans; Hydroxychloroquine | 2019 |
Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells.
Topics: Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Cell Line; Chloroquine; Dexamethasone; Endothelial Cells; Humans; Hydroxychloroquine; Interferon-Induced Helicase, IFIH1; Interleukin-6; Kidney Glomerulus; Plasminogen Activator Inhibitor 1; Poly I-C; Receptors, Retinoic Acid; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tissue Plasminogen Activator; Toll-Like Receptor 3 | 2019 |
[Spectral Domain Optical Coherence Tomographic Findings in Systemic Lupus erythematosus in Patients Treated with Chloroquine].
Topics: Chloroquine; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Diseases; Tomography, Optical Coherence | 2019 |
[Chloroquine retinopathy].
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Macular Degeneration; Middle Aged | 2018 |
Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine.
Topics: Antimalarials; Chloroquine; Drug Eruptions; Humans; Hydroxychloroquine; Retrospective Studies | 2019 |
Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus.
Topics: Antirheumatic Agents; Calibration; Chloroquine; Chromatography, High Pressure Liquid; Drug Monitoring; Fluorescence; Humans; Hydroxychloroquine; Indicators and Reagents; Lupus Erythematosus, Systemic; Reproducibility of Results | 2019 |
Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment.
Topics: Adult; Antimalarials; Arthritis, Rheumatoid; Chloroquine; Cross-Sectional Studies; Female; Headache; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Medication Adherence; Middle Aged; Surveys and Questionnaires; Young Adult | 2020 |
The Diagnostic Utility of Multifocal Electroretinography in Detecting Chloroquine and Hydroxychloroquine Retinal Toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Electroretinography; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Hydroxychloroquine; Male; Middle Aged; Reproducibility of Results; Retina; Retinal Diseases; Retrospective Studies; Tomography, Optical Coherence; Visual Acuity; Visual Fields | 2019 |
Hydroxychloroquine and Antimalarials.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine | 2019 |
Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs.
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2020 |
Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
Topics: Abatacept; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Biological Products; British Columbia; Chloroquine; Cohort Studies; Cyclophosphamide; Cyclosporine; Deprescriptions; Female; Glucocorticoids; Gold Compounds; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Leflunomide; Logistic Models; Maternal Age; Methotrexate; Mycophenolic Acid; Odds Ratio; Preconception Care; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Trimester, First; Rheumatology; Rituximab; Sulfasalazine; Tumor Necrosis Factor Inhibitors | 2020 |
Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI.
Topics: Adult; Aged; Antimalarials; Biopsy; Cardiomyopathies; Cardiotoxicity; Chloroquine; Diagnosis, Differential; Fabry Disease; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardium; Predictive Value of Tests; Retrospective Studies | 2020 |
A metal organic framework-functionalized monolithic column for enantioseparation of six basic chiral drugs by capillary electrochromatography.
Topics: Amlodipine; Capillary Electrochromatography; Chloroquine; Clenbuterol; Ethylene Glycols; Hydroxychloroquine; Hydroxyzine; Metal-Organic Frameworks; Methacrylates; Molecular Structure; Nefopam; Particle Size; Stereoisomerism; Surface Properties | 2019 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hydroxychloroquine; Lung; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Vero Cells | 2020 |
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Insights from nanomedicine into chloroquine efficacy against COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Endocytosis; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Inflammation; Nanomedicine; Nanoparticles; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Virion; Virus Replication | 2020 |
Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Hydroxychloroquine and Chloroquine.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; World Health Organization | 2020 |
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Rheumatic Diseases; SARS-CoV-2 | 2020 |
Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2020 |
COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Ophthalmology; Pandemics; Pneumonia, Viral; Retina | 2020 |
Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts.
Topics: Adipogenesis; Adult; Aged; Antimalarials; Autophagy; Case-Control Studies; Cell Differentiation; Cells, Cultured; Chloroquine; Female; Fibroblasts; Graves Ophthalmopathy; Humans; Hyaluronic Acid; Hydroxychloroquine; Male; Middle Aged; Orbit; Oxidative Stress; Prognosis | 2020 |
What is the role of rheumatologists in the era of COVID-19?
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimalarials; Azetidines; Betacoronavirus; Chloroquine; Comorbidity; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Interleukin-1; Middle Aged; Pandemics; Physician's Role; Pneumonia, Viral; Purines; Pyrazoles; Respiratory Distress Syndrome; Rheumatic Diseases; Rheumatologists; SARS-CoV-2; Sulfonamides | 2020 |
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
Topics: Amino Acid Sequence; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Models, Molecular; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Structure, Quaternary; Protein Structure, Tertiary; SARS-CoV-2; Sequence Analysis, Protein; Spike Glycoprotein, Coronavirus | 2020 |
Chloroquine and hydroxychloroquine in covid-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Endpoint Determination; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Research Design; SARS-CoV-2 | 2020 |
Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fear; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Can prophylactic drugs keep fragile health systems running?
Topics: Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; India; Pandemics; Pneumonia, Viral; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Spain | 2020 |
Regulators split on antimalarials for COVID-19.
Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Approval; European Union; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States | 2020 |
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2020 |
Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity.
Topics: Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Risk Factors; SARS-CoV-2; Torsades de Pointes | 2020 |
Drug Evaluation during the Covid-19 Pandemic.
Topics: Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Evaluation; Drugs, Investigational; Humans; Hydroxychloroquine; Off-Label Use; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States; United States Food and Drug Administration | 2020 |
Chloroquine as a prophylactic agent against COVID-19?
Topics: Animals; Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Chlorocebus aethiops; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Pre-Exposure Prophylaxis; SARS-CoV-2; Vero Cells | 2020 |
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cytokines; Humans; Hydroxychloroquine; Immunomodulation; Immunotherapy; Interleukin-6; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Pre-Exposure Prophylaxis; SARS-CoV-2 | 2020 |
Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
Topics: Betacoronavirus; Chloroquine; Contact Tracing; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Family Characteristics; Humans; Hydroxychloroquine; India; Pandemics; Pneumonia, Viral; Pre-Exposure Prophylaxis; SARS-CoV-2 | 2020 |
COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
Topics: Antimalarials; Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Stereoisomerism | 2020 |
Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2 | 2021 |
Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).
Topics: Aged; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; COVID-19; Delivery of Health Care; Female; Glucocorticoids; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Metabolic Diseases; Middle Aged; Pandemics; SARS-CoV-2; Uncertainty | 2020 |
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
Topics: Antimalarials; Antirheumatic Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Repositioning; Humans; Hydroxychloroquine; Off-Label Use; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sample Size; SARS-CoV-2; Treatment Outcome; United States | 2020 |
Some drugs for COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Neuraminidase; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Aquatic Organisms; Biological Products; Chloroquine; Coronavirus Infections; COVID-19; Drug Compounding; Humans; Hydroxychloroquine; Models, Molecular; Pandemics; Pneumonia, Viral; Volatilization | 2020 |
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxychloroquine; Long QT Syndrome; Pharmacovigilance; Torsades de Pointes; United States | 2021 |
Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019.
Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus | 2020 |
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
Topics: Azithromycin; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Torsades de Pointes | 2020 |
COVID-19: an update on diagnostic and therapeutic approaches.
Topics: Betacoronavirus; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Testing; Drug Repositioning; Humans; Hydroxychloroquine; Immunization, Passive; Pandemics; Pneumonia, Viral; Reagent Kits, Diagnostic; SARS-CoV-2; Specimen Handling | 2020 |
Thoughts on COVID-19 and autoimmune diseases.
Topics: Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Humans; Hydroxychloroquine; Immunomodulation; Immunosuppression Therapy; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Rheumatology; SARS-CoV-2; Sulfonamides | 2020 |
Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
Topics: Africa South of the Sahara; Anti-Inflammatory Agents; Antigen Presentation; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviridae; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Utilization; Humans; Hydroxychloroquine; Immunologic Factors; Macrophages; Malaria, Falciparum; Pandemics; Pneumonia, Viral; SARS-CoV-2; Virus Replication | 2020 |
Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev
Topics: Antiviral Agents; Chloroquine; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Topics: Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Humans; Hydroxychloroquine; Incidence; Pandemics; Pneumonia, Viral; Prospective Studies; Risk Factors; SARS-CoV-2; United States | 2020 |
Internet Searches for Unproven COVID-19 Therapies in the United States.
Topics: Betacoronavirus; Chloroquine; Consumer Health Information; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fraud; Humans; Hydroxychloroquine; Information Seeking Behavior; Internet; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States | 2020 |
Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
Topics: Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Hydroxychloroquine; Long QT Syndrome; Mental Disorders; Pandemics; Pneumonia, Viral; Risk Factors | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Dehydration; Drug Interactions; Electrocardiography; Humans; Hydroxychloroquine; Long QT Syndrome; Pandemics; Pneumonia, Viral; Risk Assessment; Water-Electrolyte Imbalance | 2020 |
Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Systemic; Male; Middle Aged; Mouth Mucosa; Retinal Diseases; Risk Factors; Venezuela; Young Adult | 2020 |
COVID-19 and Depression.
Topics: Anxiety; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Depression; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Unemployment | 2020 |
[Potential harms associated with 4-aminoquinoline treatment].
Topics: Aminoquinolines; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
The COVID-19 Pandemic and Mayo Clinic Proceedings.
Topics: Adrenal Cortex Hormones; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Periodicals as Topic; Pneumonia, Viral; Risk Assessment; SARS-CoV-2 | 2020 |
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Stereoisomerism | 2020 |
COVID-19: an unexpected indication for anti-rheumatic therapies?
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Repositioning; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides | 2020 |
COVID-19 and toxicity from potential treatments: Panacea or poison.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome | 2020 |
Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Emergencies; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Chloroquine and hydroxychloroquine for COVID-19: A word of caution.
Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
[The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Bioethical Issues; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Editorial Policies; Humans; Hydroxychloroquine; International Cooperation; Lopinavir; Pandemics; Pneumonia, Viral; Research Design; Ritonavir; SARS-CoV-2; World Health Organization | 2020 |
In Vitro Data of Current Therapies for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Emetine; Homoharringtonine; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; SARS-CoV-2; Teicoplanin; Thiazoles | 2020 |
Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
Topics: Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Health Policy; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
Topics: Aged; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dietary Supplements; Drug Synergism; Female; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Length of Stay; Lysosomes; Male; Models, Theoretical; Pandemics; Patient Safety; Pneumonia, Viral; SARS-CoV-2; Zinc | 2020 |
An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.
Topics: Adolescent; Adult; Aged; Azithromycin; Chloroquine; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Heart Diseases; Humans; Hydroxychloroquine; Male; Middle Aged; Pharmacoepidemiology; Retrospective Studies; Risk Factors; Young Adult | 2021 |
Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1).
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2; United States | 2020 |
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2020 |
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Decision-Making; Clinical Trials as Topic; Coronavirus Infections; Cost-Benefit Analysis; COVID-19; Drug Combinations; Empiricism; Humans; Hydroxychloroquine; Information Dissemination; Lopinavir; Pandemics; Pneumonia, Viral; Reproducibility of Results; Ritonavir; SARS-CoV-2; Viral Load | 2020 |
Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
Topics: Access to Information; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; Evidence-Based Medicine; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Prior Authorization; SARS-CoV-2 | 2020 |
Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19.
Topics: Acute Kidney Injury; Autophagy; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Critical Illness; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Retina; Retinal Diseases; SARS-CoV-2 | 2020 |
The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
Topics: Adrenal Cortex Hormones; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Immunologic Factors; Long QT Syndrome; Mental Disorders; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Navigating COVID-19 in the developing world.
Topics: Antirheumatic Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Delivery of Health Care; Developing Countries; Humans; Hydroxychloroquine; Immunocompromised Host; Pandemics; Pneumonia, Viral; Rheumatic Diseases; SARS-CoV-2; Telemedicine | 2020 |
Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.
Topics: Antihypertensive Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Utilization; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pandemics; Pneumonia, Viral; Prescription Drugs; SARS-CoV-2; United States | 2020 |
A Sensitive and Optimized HPLC-FLD Method for the Simultaneous Quantification of Hydroxychloroquine and Its Two Metabolites in Blood of Systemic Lupus Erythematosus Patients.
Topics: Adult; Chloroquine; Chromatography, High Pressure Liquid; Female; Humans; Hydroxychloroquine; Linear Models; Lupus Erythematosus, Systemic; Male; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Young Adult | 2020 |
Safety fears over drug hyped to treat the coronavirus spark global confusion.
Topics: Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Global Health; Humans; Hydroxychloroquine; Observational Studies as Topic; Pandemics; Patient Safety; Pneumonia, Viral; Uncertainty; World Health Organization | 2020 |
Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Resistance; Humans; Hydroxychloroquine; Malaria; Pandemics; Plasmodium; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
Topics: Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Eradication; Drug Repositioning; Drug-Related Side Effects and Adverse Reactions; Ebolavirus; History, 21st Century; HIV; Humans; Hydroxychloroquine; Malaria; Pandemics; Plasmodium malariae; SARS-CoV-2; Signal Transduction | 2020 |
Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
Topics: Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatment; Endosomes; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Immunity, Innate; Lysosomes; Molecular Targeted Therapy; SARS-CoV-2; Severity of Illness Index | 2020 |
Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral | 2020 |
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous.
Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Culture; Endpoint Determination; Humans; Hydroxychloroquine; Pandemics; Patient Education as Topic; Pneumonia, Viral; Randomized Controlled Trials as Topic | 2020 |
Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Developing Countries; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Primary Health Care; SARS-CoV-2 | 2020 |
Living evidence in response to controversies about the use of antimalarials in COVID-19.
Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Treatment Outcome | 2020 |
Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States | 2020 |
The parent drugs chloroquine and hydroxychloroquine do not inhibit human CYP3A activity in vitro.
Topics: Antirheumatic Agents; Chloroquine; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Hydroxychloroquine; In Vitro Techniques | 2020 |
Clearance of chloroquine and hydroxychloroquine by the Seraph® 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients.
Topics: Chloroquine; Chromatography, High Pressure Liquid; COVID-19 Drug Treatment; Hemofiltration; Hemoperfusion; Humans; Hydroxychloroquine; In Vitro Techniques | 2021 |
Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy.
Topics: Adolescent; Adult; Aged; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Epilepsy; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2; Seizures; Young Adult | 2020 |
Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Delivery Systems; Humans; Hydroxychloroquine; Lung; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19.
Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; Data Mining; Humans; Hydroxychloroquine; Journal Impact Factor; Pandemics; Periodicals as Topic; Pneumonia, Viral; Registries; Research Design; SARS-CoV-2 | 2020 |
Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Molecular Docking Simulation; Pandemics; Pharmaceutical Preparations; SARS-CoV-2 | 2021 |
Chloroquine and COVID-19: A western medical and scientific drift?
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question.
Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral | 2020 |
Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients.
Topics: Acoustic Impedance Tests; Adult; Antimalarials; Audiometry, Pure-Tone; Chloroquine; Cross-Sectional Studies; Female; Hearing Loss, Sensorineural; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Prevalence | 2021 |
Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Databases, Pharmaceutical; Drug Prescriptions; Humans; Hydroxychloroquine; Outpatients; Pandemics; Pneumonia, Viral; Practice Patterns, Physicians'; Pre-Exposure Prophylaxis; Prescription Drug Monitoring Programs; SARS-CoV-2; United States | 2020 |
Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cytokines; Endocytosis; Endosomes; Golgi Apparatus; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Lysosomes; Malaria; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Topics: Antimalarials; Betacoronavirus; Chloroquine; Contraindications, Drug; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Risk Assessment; SARS-CoV-2 | 2020 |
Concentration-dependent mortality of chloroquine in overdose.
Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Drug Overdose; Drug Repositioning; Electrocardiography; Female; Heart Diseases; Humans; Hydroxychloroquine; Long QT Syndrome; Malaria; Male; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Risk Assessment; Suicide; Suicide, Attempted | 2020 |
Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?
Topics: Antimalarials; Chloroquine; COVID-19; Fear; Humans; Hydroxychloroquine | 2022 |
Response to: 'Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?' by Santos-Moreno
Topics: Antimalarials; Chloroquine; COVID-19; Fear; Humans; Hydroxychloroquine | 2022 |
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
Topics: Age Distribution; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Electrocardiography; Female; Follow-Up Studies; Hospitalization; Humans; Hydroxychloroquine; Incidence; Long QT Syndrome; Male; Middle Aged; Pandemics; Pneumonia, Viral; Risk Assessment; Sex Distribution; Urban Population | 2020 |
Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.
Topics: Aging; Antiviral Agents; BCG Vaccine; Chemoprevention; Chloroquine; Coronavirus Infections; COVID-19; Disease Susceptibility; Female; Geographic Mapping; Humans; Hydroxychloroquine; Infant; Internationality; Male; Pandemics; Pneumonia, Viral; Sex Characteristics | 2020 |
Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2020 |
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
COVID-19 and hydroxychloroquine: Let the available data speak for themselves.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Drug Interactions; Humans; Hydrogen Bonding; Hydroxychloroquine; Ligands; Molecular Docking Simulation; Nanotechnology; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Static Electricity; Viral Nonstructural Proteins | 2020 |
Chloroquine in fighting COVID-19: good, bad, or both?
Topics: Autophagy; Cardiovascular Diseases; China; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; France; Humans; Hydroxychloroquine; Italy; Pandemics; SARS-CoV-2; Severity of Illness Index | 2020 |
Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States | 2020 |
In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Topics: Amino Acid Motifs; Angiotensin-Converting Enzyme 2; Antiviral Agents; Azithromycin; Betacoronavirus; Binding Sites; Cathepsin L; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Molecular Docking Simulation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Thermodynamics; Viral Nonstructural Proteins; Virus Attachment | 2020 |
[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
Topics: Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Enzyme Inhibitors; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; COVID-19; Disease Susceptibility; Female; Humans; Hydroxychloroquine; Italy; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Male; Middle Aged; Odds Ratio; SARS-CoV-2 | 2021 |
Chloroquine kills hair cells in zebrafish lateral line and murine cochlear cultures: Implications for ototoxicity.
Topics: Animals; Antiviral Agents; Cell Survival; Cells, Cultured; Chloroquine; Hair Cells, Auditory; Hydroxychloroquine; Larva; Lateral Line System; Mice; Models, Animal; Ototoxicity; Zebrafish | 2020 |
Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunity, Cellular; Models, Theoretical; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Patient Safety | 2021 |
SDRIFE-like rash associated with COVID-19, clinicopathological correlation.
Topics: Aged; Antiviral Agents; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Drug Eruptions; Exanthema; Female; Humans; Hydroxychloroquine | 2021 |
Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Envelope Proteins; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Exoribonucleases; Humans; Hydroxychloroquine; Methyltransferases; Molecular Docking Simulation; Pandemics; Pneumonia, Viral; RNA, Viral; SARS-CoV-2; Viral Envelope Proteins; Viral Nonstructural Proteins; Virus Replication | 2020 |
No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency.
Topics: Antimalarials; Chloroquine; COVID-19 Drug Treatment; Enzyme Inhibitors; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Hydroxychloroquine; Malaria | 2020 |
Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; France; Hospitalization; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV-2 | 2023 |
Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.
Topics: Antimalarials; Brazil; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Nephrology; Pandemics; Pneumonia, Viral; Renal Insufficiency; Societies, Medical | 2020 |
Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.
Topics: Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Practice Patterns, Physicians'; Specialization; Treatment Outcome; United States | 2020 |
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19?
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Forecasting; Humans; Hydroxychloroquine; Mental Disorders | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychloroquine; Long QT Syndrome; Pandemics; Pneumonia, Viral; Prognosis; Risk Assessment; Treatment Outcome | 2020 |
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Data Mining; Databases, Genetic; Drug Therapy, Combination; Gene Regulatory Networks; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Toxicogenetics | 2020 |
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Autophagy; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; HEK293 Cells; Humans; Hydroxychloroquine; Molecular Docking Simulation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
Topics: Anti-Infective Agents; Betacoronavirus; Chloroquine; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Humans; Hydroxychloroquine; Hypoglycemic Agents; Meta-Analysis as Topic; Pandemics; Pneumonia, Viral; Research Design; SARS-CoV-2; Systematic Reviews as Topic; Treatment Outcome | 2020 |
Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Palliative Care; Polypharmacy; Treatment Outcome | 2021 |
Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy.
Topics: Adult; Animals; Antirheumatic Agents; Chloroquine; Cross-Sectional Studies; Fluorescein Angiography; Humans; Hydroxychloroquine; Middle Aged; Prospective Studies; Young Adult | 2020 |
Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Double-Blind Method; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Registries; Ritonavir; SARS-CoV-2; Single-Blind Method; Stem Cell Transplantation | 2020 |
Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach.
Topics: Aminoquinolines; Binding Sites; Chloroquine; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Hydroxychloroquine; Imidazoles; Molecular Docking Simulation; Molecular Structure; Pandemics; Protease Inhibitors; SARS-CoV-2 | 2020 |
Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
Topics: Betacoronavirus; Catalytic Domain; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Humans; Hydroxychloroquine; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Pneumonia, Viral; Protease Inhibitors; Protein Binding; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Topics: Adult; Aged; Antimalarials; Cardiovascular Diseases; Chloroquine; COVID-19; COVID-19 Drug Treatment; Databases, Factual; Drug Overdose; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Odds Ratio; Pharmacovigilance; Treatment Outcome | 2021 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Chemical and Drug Induced Liver Injury; Chloroquine; COVID-19 Drug Treatment; Databases, Pharmaceutical; Diarrhea; Drug Combinations; Drug Eruptions; Drug Repositioning; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Male; Nausea; Oseltamivir; Ritonavir; Sex Distribution; Sex Factors; Vomiting | 2020 |
Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Hydroxychloroquine; Intensive Care Units; Male; Middle Aged; Netherlands; Patient Admission; Prospective Studies; SARS-CoV-2; Treatment Outcome | 2020 |
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Dipyridamole; Drug Repositioning; Humans; Hydroxychloroquine; Molecular Docking Simulation; Molecular Structure; Pandemics; Pneumonia, Viral; Protease Inhibitors; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |
Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine.
Topics: Aged; Aged, 80 and over; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Hospital Mortality; Hospitals; Humans; Hydroxychloroquine; Male; Middle Aged; Netherlands; SARS-CoV-2; Standard of Care | 2021 |
Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ototoxicity; Pandemics; Risk Assessment; SARS-CoV-2 | 2020 |
Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
Topics: Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Flow Cytometry; Heart Diseases; Humans; Hydroxychloroquine; Microscopy, Fluorescence; Myocytes, Cardiac; Pluripotent Stem Cells; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Vero Cells; Viral Plaque Assay | 2020 |
Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
Topics: Adult; Antimalarials; China; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Renal Insufficiency; Retrospective Studies; Young Adult | 2021 |
Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study.
Topics: Adenosine Monophosphate; Alanine; Azithromycin; Chloroquine; Communication; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Federal Government; Fraud; Humans; Hydroxychloroquine; Internet; Language; Mass Media; Pandemics; Pneumonia, Viral; Public Health; United States | 2020 |
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
Topics: Chloroquine; Cohort Studies; Coronavirus Infections; COVID-19; Female; Heart; Humans; Hydroxychloroquine; Male; Middle Aged; Pandemics; Pneumonia, Viral; Product Surveillance, Postmarketing; Safety | 2020 |
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude to Health; Biological Products; Chloroquine; Connective Tissue Diseases; COVID-19; Cross-Sectional Studies; Female; Glucocorticoids; Humans; Hydroxychloroquine; Ireland; Janus Kinase Inhibitors; Male; Medication Adherence; Middle Aged; Rheumatic Diseases; SARS-CoV-2; Spondylarthropathies; Telemedicine; Vasculitis | 2021 |
Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M
Topics: Amides; Antiviral Agents; Benzaldehydes; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus 3C Proteases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Hydroxychloroquine; Laurates; Microbial Sensitivity Tests; Models, Molecular; Monoglycerides; Pyrazines; SARS-CoV-2; Structure-Activity Relationship; Tetrodotoxin; Viral Nonstructural Proteins | 2020 |
Hydroxychloroquine and COVID-19: a tale of populism and obscurantism.
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.
Topics: Antiviral Agents; Chloroquine; Coronavirus Papain-Like Proteases; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Molecular Docking Simulation; Molecular Dynamics Simulation; Papain; SARS-CoV-2 | 2022 |
Knowing more about chloroquine/hydroxycloroquine in COVID-19 patients.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunomodulation; Randomized Controlled Trials as Topic | 2020 |
Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science.
Topics: Acquired Immunodeficiency Syndrome; Anthropology, Medical; Antimalarials; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Political Activism; SARS-CoV-2; Social Media | 2020 |
Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Cohort Studies; Denmark; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy Outcome; Premature Birth; Prenatal Care; Prevalence; Risk; Young Adult | 2021 |
Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion.
Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Expert Testimony; Humans; Hydroxychloroquine; Pandemics; Pharmacovigilance; Pneumonia, Viral; Projection; SARS-CoV-2 | 2020 |
COVID-19 and Cardiac Concerns for Psychiatric Patients.
Topics: Antidepressive Agents; Antiviral Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Block; Bundle-Branch Block; Chloroquine; COVID-19; COVID-19 Drug Treatment; Depressive Disorder; Heart Diseases; Humans; Hydroxychloroquine; Long QT Syndrome; Torsades de Pointes | 2020 |
Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19.
Topics: Autophagy; Cachexia; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Humans; Hydroxychloroquine; Immunologic Factors; Models, Biological; Neoplasms; Pandemics; SARS-CoV-2 | 2021 |
Comparison of hospital treatment strategy or of treatment actually received in COVID-19?: Commenting on: Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, et al. Early hydroxychloroquine but not chloroquine use reduces ICU admission
Topics: Chloroquine; COVID-19 Drug Treatment; Hospitals; Humans; Hydroxychloroquine; Intensive Care Units; SARS-CoV-2 | 2021 |
More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine.
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Intensive Care Units; SARS-CoV-2 | 2021 |
Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Intensive Care Units; SARS-CoV-2 | 2021 |
Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Intensive Care Units; SARS-CoV-2 | 2021 |
Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.
Topics: Angiotensin-Converting Enzyme 2; Antimalarials; Binding, Competitive; Cell Membrane; Chloroquine; Chromatography; COVID-19; Humans; Hydroxychloroquine; Models, Molecular; Molecular Docking Simulation | 2021 |
Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study.
Topics: Adult; Aged; Blood Coagulation; Chloroquine; Coinfection; Comorbidity; Cough; COVID-19; COVID-19 Drug Treatment; Democratic Republic of the Congo; Female; Fever; Hospitalization; Hospitals, Public; Humans; Hydroxychloroquine; Inflammation; Liver Function Tests; Malaria; Male; Middle Aged; Regression Analysis; Retrospective Studies; Risk Factors; Social Class; Tachycardia | 2020 |
Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Chloroquine; Humans; Hydroxychloroquine; Mice | 2021 |
The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary.
Topics: Chloroquine; Humans; Hydroxychloroquine; Ophthalmologists; Retinal Diseases; United Kingdom | 2021 |
Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pneumonia; SARS-CoV-2 | 2021 |
Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Myocytes, Cardiac; Risk Assessment; SARS-CoV-2; United States | 2021 |
Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic.
Topics: Chloroquine; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; Male; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States; United States Food and Drug Administration | 2021 |
[Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients].
Topics: Aged, 80 and over; Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Hydroxychloroquine; Male; Physical Functional Performance; Polypharmacy; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism.
Topics: Angiotensin-Converting Enzyme 2; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Molecular Docking Simulation; Polymorphism, Genetic; Protein Domains; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2021 |
Lipid emulsion treatment as an antidote for chloroquine and hydroxychloroquine toxicity.
Topics: Antidotes; Chloroquine; Drug Overdose; Fat Emulsions, Intravenous; Humans; Hydroxychloroquine | 2021 |
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum
Topics: Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Chloroquine; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Furans; Humans; Hydroxychloroquine; Isotopes; Lopinavir; Pandemics; Pyrazines; Pyrroles; Ritonavir; SARS-CoV-2; Tandem Mass Spectrometry; Triazines | 2021 |
Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
Topics: Angiotensin-Converting Enzyme 2; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Cardiovascular Diseases; Chloroquine; Comorbidity; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Humans; Hydroxychloroquine; Long QT Syndrome; Myocytes, Cardiac; Receptors, Coronavirus; SARS-CoV-2; Torsades de Pointes | 2021 |
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19.
Topics: Animals; Antimalarials; Arrhythmias, Cardiac; Chloroquine; CHO Cells; COVID-19 Drug Treatment; Cricetulus; Dose-Response Relationship, Drug; Electrocardiography; Humans; Hydroxychloroquine; Ion Channels; Off-Label Use; SARS-CoV-2 | 2021 |
Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Outcome Assessment, Health Care; Pandemics; Registries; SARS-CoV-2 | 2021 |
Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020.
Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Incidence; Male; Prospective Studies; SARS-CoV-2; Spain | 2021 |
Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma.
Topics: Anti-Bacterial Agents; Antimalarials; Azithromycin; Blood Specimen Collection; Chloroquine; Chromatography, High Pressure Liquid; Drug Monitoring; Edetic Acid; Humans; Hydroxychloroquine; Limit of Detection; Tandem Mass Spectrometry | 2021 |
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; ERG1 Potassium Channel; HEK293 Cells; Humans; Hydroxychloroquine; Potassium Channel Blockers | 2021 |
Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Chloroquine; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Odds Ratio; Registries; Sulfasalazine; Sweden; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2021 |
Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19.
Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; France; Humans; Hydroxychloroquine; Mass Media; Politics; Publishing; United States; United States Food and Drug Administration | 2021 |
Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; COVID-19 Drug Treatment; Eye; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Rheumatic Diseases | 2021 |
Prophylaxis Against COVID-19 With Hydroxychloroquine and Chloroquine: Comment on the Article by Putman et al.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Management of Chloroquine and Hydroxychloroquine Poisoning: Do Not Miss the Time of Tracheal Intubation and Mechanical Ventilation.
Topics: Chloroquine; COVID-19; Humans; Hydroxychloroquine; Intubation, Intratracheal; Respiration, Artificial | 2021 |
Response to: "Management of Chloroquine and Hydroxychloroquine Poisoning: Do Not Miss the Time of Tracheal Intubation and Mechanical Ventilation".
Topics: Chloroquine; COVID-19; Humans; Hydroxychloroquine; Intubation, Intratracheal; Respiration, Artificial | 2021 |
Binding of hydroxychloroquine and chloroquine dimers to palmitoyl-protein thioesterase 1 (PPT1) and its glycosylated forms: a computational approach.
Topics: Asparagine; Child; Chloroquine; Fatty Acids; Humans; Hydroxychloroquine; Membrane Proteins; Neoplasms; Neuronal Ceroid-Lipofuscinoses; Palmitates; Thiolester Hydrolases | 2022 |
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Darunavir; Disease Progression; Drug Combinations; Female; Hospitals; Hospitals, University; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pyrazines; Referral and Consultation; Retrospective Studies; Ritonavir; Thailand; Treatment Outcome; Young Adult | 2021 |
Reply to the Letter to Editor by Lacout and colleagues: Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2.
Topics: A549 Cells; Animals; Caco-2 Cells; Cell Line; Cell Survival; Chlorocebus aethiops; Chloroquine; Colon; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lung; Middle Aged; Quinine; SARS-CoV-2; Vero Cells | 2021 |
Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Topics: Adult; Aged; Azithromycin; Chloroquine; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pharmacovigilance; Retrospective Studies; Torsades de Pointes | 2021 |
Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.
Topics: Antimalarials; Cells, Cultured; Chloroquine; Down-Regulation; Fibroblasts; Humans; Hydroxychloroquine; Matrix Metalloproteinase 1; Neurofibromatosis 1; Transfection | 2021 |
Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Toward a Coronavirus Knowledge Graph.
Topics: Chloroquine; Computer Graphics; COVID-19; Databases, Factual; Hemorrhagic Fever, Ebola; Humans; Hydroxychloroquine; Knowledge Bases; Pattern Recognition, Automated; Peptidyl-Dipeptidase A; PubMed; Receptors, Interleukin-6; SARS-CoV-2; STAT1 Transcription Factor | 2021 |
Opinion and uptake of chloroquine for treatment of COVID-19 during the mandatory lockdown in the sub-Saharan African region.
Topics: Adolescent; Adult; Africa South of the Sahara; Chloroquine; Communicable Disease Control; COVID-19 Drug Treatment; Female; Health Knowledge, Attitudes, Practice; Humans; Hydroxychloroquine; Male; Middle Aged; Pandemics; Public Opinion; SARS-CoV-2; Surveys and Questionnaires; Young Adult | 2021 |
Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
Topics: Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; Coronavirus; Coronavirus 229E, Human; Coronavirus Infections; Coronavirus OC43, Human; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Quinolines; SARS-CoV-2; Vero Cells; Virus Internalization; Virus Replication | 2021 |
Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Chloroquine; Clathrin; COVID-19; COVID-19 Drug Treatment; Drug Synergism; Endocytosis; Endosomes; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Macrolides; Niclosamide; Protein Binding; Protein Domains; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vero Cells; Virus Internalization | 2021 |
Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Drugs, Chinese Herbal; Electrocardiography; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Indoles; Interferons; Long QT Syndrome; Lopinavir; Male; Middle Aged; Odds Ratio; Quinolones; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index | 2021 |
Attenuation of chloroquine and hydroxychloroquine on the invasive potential of bladder cancer through targeting matrix metalloproteinase 2 expression.
Topics: Autophagy; Chloroquine; Humans; Hydroxychloroquine; Male; Matrix Metalloproteinase 2; Urinary Bladder Neoplasms | 2021 |
Reply Letter - Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Letter to editor on the paper entitled "Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19".
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19.
Topics: Africa South of the Sahara; Chloroquine; COVID-19; COVID-19 Drug Treatment; Databases, Genetic; Genetic Variation; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Hydroxychloroquine; Mutation, Missense; Risk Factors | 2021 |
Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis - Authors reply.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2021 |
Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study.
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Retrospective Studies; RNA, Viral; SARS-CoV-2 | 2021 |
Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Gene Expression Regulation, Leukemic; Human T-lymphotropic virus 1; Humans; Hydroxychloroquine; Immunologic Factors; Leukemia-Lymphoma, Adult T-Cell; Male; Mice; Mice, SCID; NF-kappa B; Primary Cell Culture; Signal Transduction; Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins; Survival Analysis; Xenograft Model Antitumor Assays | 2021 |
Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database.
Topics: Adverse Drug Reaction Reporting Systems; Chloroquine; Confidence Intervals; COVID-19 Drug Treatment; Databases, Factual; Humans; Hydroxychloroquine; Male; Middle Aged; Odds Ratio; Pharmacovigilance; Suicide; United States; United States Food and Drug Administration | 2021 |
American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
Topics: Antimalarials; Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine | 2021 |
Investigating interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Cell Membrane; Chloroquine; Chromatography, High Pressure Liquid; COVID-19; COVID-19 Drug Treatment; HEK293 Cells; Humans; Hydroxychloroquine; In Vitro Techniques; Molecular Docking Simulation; Receptors, Virus; SARS-CoV-2; Solvents; Stereoisomerism; Viral Pseudotyping; Virus Internalization | 2022 |
Enantioselective analyses of chloroquine and hydroxychloroquine in rat liver microsomes through chiral liquid chromatography-tandem mass spectrometry.
Topics: Animals; Chloroquine; Chromatography, High Pressure Liquid; Chromatography, Liquid; Hydroxychloroquine; Microsomes, Liver; Rats; Stereoisomerism; Tandem Mass Spectrometry | 2022 |
Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept.
Topics: Action Potentials; Antiviral Agents; Arrhythmias, Cardiac; Biological Assay; Chloroquine; Computer Simulation; Correlation of Data; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; ERG1 Potassium Channel; HEK293 Cells; Humans; Hydroxychloroquine; Inhibitory Concentration 50; KCNQ1 Potassium Channel; Kinetics; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Potassium Channels, Voltage-Gated; Risk Assessment; SARS-CoV-2 | 2021 |
Chloroquine Induces ROS-mediated Macrophage Migration Inhibitory Factor Secretion and Epithelial to Mesenchymal Transition in ER-positive Breast Cancer Cell Lines.
Topics: Breast Neoplasms; Cadherins; Cell Line; Cell Line, Tumor; Chloroquine; Epithelial-Mesenchymal Transition; Female; Humans; Hydroxychloroquine; Macrophage Migration-Inhibitory Factors; Reactive Oxygen Species | 2021 |
Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation.
Topics: Acidosis; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Hypokalemia; Induced Pluripotent Stem Cells; SARS-CoV-2 | 2022 |
Letter to the editor: The effect of hydroxychloroquine on COVID-19.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2022 |
Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.
Topics: Administration, Inhalation; Aerosols; Algorithms; Cell Line; Chloroquine; COVID-19; Cytosol; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Lysosomes; Primary Cell Culture; Respiratory Tract Infections; Virus Diseases | 2022 |
Interventions for Cutaneous Disease in Systemic Lupus Erythematosus: Summary of a Cochrane Review.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Skin Diseases | 2022 |
Pulmonary Delivery of Aerosolized Chloroquine and Hydroxychloroquine to Treat COVID-19: In Vitro Experimentation to Human Dosing Predictions.
Topics: Administration, Inhalation; Animals; Antimalarials; Cells, Cultured; Chloroquine; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Humans; Hydroxychloroquine; Male; Mice; Middle Aged; Models, Chemical; Rats | 2022 |
Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.
Topics: Antiviral Agents; Azithromycin; Burkina Faso; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Inpatients; Outpatients; SARS-CoV-2 | 2022 |
Chloroquine and COVID-19-A systems biology model uncovers the drug's detrimental effect on autophagy and explains its failure.
Topics: Autophagy; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2; Systems Biology | 2022 |
Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; Humans; Hydroxychloroquine; Male; Prevalence; SARS-CoV-2; Tertiary Care Centers | 2022 |
Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.
Topics: Animals; Chloroquine; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Hydroxychloroquine; Rats; SARS-CoV-2 | 2022 |
Hydroxychloroquine and Chloroquine Toxicity as Reported by Medical Toxicologists to the Toxicology Investigators Consortium (ToxIC) Registry.
Topics: Chloroquine; Drug Overdose; Humans; Hydroxychloroquine; Registries; Research Personnel | 2022 |
Effect of hydroxychloroquine or chloroquine and short wavelength light on
Topics: Animals; Chloroquine; Electroretinography; Hydroxychloroquine; Mice; Mice, Inbred C57BL; Retina | 2023 |
Computational study on the affinity of potential drugs to SARS-CoV-2 main protease.
Topics: Amino Acids; Betamethasone; Chloroquine; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Dexamethasone; Humans; Hydroxychloroquine; Molecular Docking Simulation; Molecular Dynamics Simulation; Protease Inhibitors; SARS-CoV-2 | 2022 |
New Insights into the Mechanism of Action of the Drug Chloroquine: Direct Interaction with DNA and Cytotoxicity.
Topics: Chloroquine; DNA; Humans; Hydroxychloroquine; Optical Tweezers | 2022 |
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; DNA-Binding Proteins; Electrocardiography; Healthy Volunteers; Humans; Hydroxychloroquine; Long QT Syndrome; Pandemics; Pneumonia, Viral; Torsades de Pointes | 2022 |
Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Neoplasm Recurrence, Local; Signal Transduction; Tumor Microenvironment | 2023 |
Redox aspects of cytotoxicity and anti-neuroinflammatory profile of chloroquine and hydroxychloroquine in serum-starved BV-2 microglia.
Topics: Animals; Chloroquine; Humans; Hydroxychloroquine; Mice; Microglia; Oxidation-Reduction; Signal Transduction | 2022 |
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2022 |
Chloroquine drops against SARS-CoV-2 infection.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2 | 2022 |
Effect of hydroxychloroquine and chloroquine on syncytial differentiation and autophagy in primary human trophoblasts.
Topics: Autophagy; Cell Differentiation; Chloroquine; Female; Glypicans; Humans; Hydroxychloroquine; Pregnancy; Trophoblasts | 2022 |
Chloroquine disrupts zinc storage granules in primary Malpighian tubule cells of Drosophila melanogaster.
Topics: Animals; Chloroquine; Dogs; Drosophila melanogaster; Hydroxychloroquine; Ionophores; Malpighian Tubules; Potassium; Zinc | 2022 |
[CHLOROQUINE AND HYDROXYCHLOROQUINE TOXICITY].
Topics: Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases | 2022 |
Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chloroquine; Hydroxychloroquine; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2023 |
Polymeric Chloroquine as an Effective Antimigration Agent in the Treatment of Pancreatic Cancer.
Topics: Antineoplastic Agents; Chloroquine; Humans; Hydroxychloroquine; Pancreatic Neoplasms; Polymers | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Retinal Diseases | 2022 |
"En Face" Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening.
Topics: Chloroquine; Cohort Studies; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; Retinal Diseases; Tomography, Optical Coherence | 2023 |
Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4).
Topics: Chloroquine; Extracellular Traps; Humans; Hydroxychloroquine; Neutrophils; Protein-Arginine Deiminase Type 4 | 2023 |
MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.
Topics: Carcinoma, Pancreatic Ductal; Chloroquine; Cyclin-Dependent Kinase 4; Humans; Hydroxychloroquine; Lysosomes; Pancreatic Neoplasms | 2023 |
Affinity binding of COVID-19 drug candidates (chloroquine/hydroxychloroquine) and serum albumin: Based on photochemistry and molecular docking.
Topics: Antiviral Agents; Chloroquine; Computer Simulation; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Molecular Docking Simulation; Photochemistry; SARS-CoV-2 | 2023 |
Salivary gland LAMP3 mRNA expression is a possible predictive marker in the response to hydroxychloroquine in Sjögren's disease.
Topics: Animals; Chloroquine; Hydroxychloroquine; Lysosomal Membrane Proteins; Mice; Retrospective Studies; RNA, Messenger; Salivary Glands; Sjogren's Syndrome | 2023 |
Novel Tetrahydroisoquinoline-Based Heterocyclic Compounds Efficiently Inhibit SARS-CoV-2 Infection
Topics: Antiviral Agents; Chloroquine; COVID-19; Heterocyclic Compounds; Humans; Hydroxychloroquine; Pandemics; SARS-CoV-2; Tetrahydroisoquinolines | 2023 |
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer.
Topics: Antifungal Agents; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chloroquine; Drug Repositioning; Female; Homeostasis; Humans; Hydroxychloroquine; Itraconazole; Lysosomes; Ovarian Neoplasms | 2022 |
Lysosomal lipid peroxidation mediates immunogenic cell death.
Topics: Chloroquine; Humans; Hydroxychloroquine; Immunogenic Cell Death; Lipid Peroxidation; Lysosomes; Neoplasms | 2023 |
Cardiotoxicity of chloroquine and hydroxychloroquine through mitochondrial pathway.
Topics: Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochromes c; Humans; Hydroxychloroquine; Mitochondria; Reactive Oxygen Species | 2023 |
Chloroquine inhibits vasodilation induced by ATP-sensitive potassium channels in isolated rat aorta.
Topics: Animals; Aorta; Chloroquine; Cromakalim; Emulsions; Glyburide; Hydroxychloroquine; KATP Channels; Lipids; Potassium Channels; Rats; Reactive Oxygen Species; Vasodilation; Vasodilator Agents | 2023 |
Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Morocco; Pharmacovigilance | 2023 |
Retinal alterations in evaluation of rheumatoid arthritis with chloroquine treatment: A new approach.
Topics: Arthritis, Rheumatoid; Chloroquine; Fluorescein Angiography; Humans; Hydroxychloroquine; Retinal Vessels; Tomography, Optical Coherence | 2023 |
Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress.
Topics: Animals; Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hydroxychloroquine; Mice; Oxidative Stress; SARS-CoV-2 | 2023 |
Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy: One Year Follow-Up.
Topics: Antirheumatic Agents; Chloroquine; Follow-Up Studies; Humans; Hydroxychloroquine; Infant; Infant, Newborn | 2023 |
Real-Life Data on Hydroxychloroquine or Chloroquine with or Without Azithromycin in COVID-19 Patients: A Retrospective Analysis in Brazil.
Topics: Aged; Arrhythmias, Cardiac; Azithromycin; Brazil; Chloroquine; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retrospective Studies; SARS-CoV-2 | 2023 |